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As the volume of transcriptomic data continues to increase, so too does its potential to deepen 
our understanding of disease; for example, by revealing gene expression patterns shared 
between diseases.  However, key questions remain around the strength of the transcriptomic 
signal of disease and the identification of meaningful commonalities between datasets, which 
are addressed in this thesis as follows. 
The first chapter, Concordance of Microarray Studies of Parkinson’s Disease, examines the 
agreement between differential expression signatures across 33 studies of Parkinson’s disease.  
Comparison of these studies, which cover a range of microarray platforms, tissues, and disease 
models, reveals a characteristic pattern of differential expression in the most highly-affected 
tissues in human patients.  Using correlation and clustering analyses to measure the 
representativeness of different study designs to human disease, the work described acts as a 
guideline for the comparison of microarray studies in the following chapters. 
In the next chapter, Using Dysregulated Signalling Paths to Understand Disease, gene 
expression changes are linked on the human signalling network, enabling identification of 
network regions dysregulated in disease.  Applying this method across a large dataset of 141 
common and rare diseases identifies dysregulated processes shared between diverse conditions, 
which relate to known disease- and drug-sharing-relationships.  
The final chapter, Understanding and Predicting Disease Relationships Through Similarity 
Fusion, explores the integration of gene expression with other data types – in this case, 
ontological, phenotypic, literature co-occurrence, genetic, and drug data – to understand 
relationships between diseases.  A similarity fusion approach is proposed to overcome the 
differences in data type properties between each space, resulting in the identification of novel 
disease relationships spanning multiple bioinformatic levels.  The similarity of disease 
relationships between each data type is considered, revealing that relationships in differential 
expression space are distinct from those in other molecular and clinical spaces. 
In summary, the work described in this thesis sets out a framework for the comparative analysis 
of transcriptomic data in disease, including the integration of biological networks and other 
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1.1 UNDERSTANDING DISEASE 
1.1.1  Defining disease 
Disease can be defined as the dysfunction of one or more of the systems in our body, resulting 
in the signs and symptoms which characterize a particular condition.  Diseases may result from 
heritable genetic factors, lifestyle and environmental factors, external causes such as infection, 
or a mixture of these factors: the chance of developing disease may be determined by the 
combination of inherited genetic risk factors with risk modifiers such as age and lifestyle.  
Advances in molecular biology have deepened our understanding of the origins of disease, 
illuminating the flow of dysfunction from the molecular level through successive biological 
‘layers’ (including cells, tissues, organs, systems, and the communications between them) that 
eventually give rise to the observable phenotype of a disease. 
Recent advances in our understanding of disease have introduced several issues in the 
definition and classification of disease.  One example is a blurring of the boundaries between 
health and disease.  It has long been known that certain diseases, such as infectious and/or 
chronic diseases, have dormant or ‘asymptomatic’ states during which affected individuals do 
not display symptoms but still carry the disease, which may recur at any time.  In recent years, 
however, advances in genetics and medical imaging have revealed the existence of what could 
be called a ‘pre-symptomatic’ state in certain diseases.  In autosomal dominant hereditary 
disorders such as Huntington’s disease, genetic testing can confirm the eventual development 
of the disease in at-risk individuals1; in Alzheimer’s disease, accumulation of amyloid proteins 
in the brain begins years before the associated memory impairment2.  In the pre-symptomatic 
state, an individual does not experience any of the physical effects of the disease, yet may not 
be fully classified as healthy3, calling into question how disease can be defined in the absence 
of its symptoms. 
A second issue relates to the specificity with which disease is defined.  One example of this is 
the definition of cancer: a broad term referring to disruption of cellular proliferation leading to 
uncontrolled cell growth, which has the potential to spread throughout the body4.  However, 
cancer also refers to a collection of diseases affecting different anatomical locations (lung 
cancer, breast cancer); different locations within an organ (small cell lung cancer, non-small 
 10 
cell lung cancer); different tissue types (carcinoma, sarcoma); and different cell types 
(adenocarcinoma, squamous cell carcinoma).  A specific cancer is usually defined according 
to all of these classifiers (e.g. non-small cell lung adenocarcinoma).  Within these subtypes, 
however, cancer can now be further defined according to its molecular features, such as the 
estrogen receptor status in breast cancer, which determines which type of treatment is most 
likely to be effective5.  Genomic features of tumours may also be an important determinant of 
drug response6, leading to the development of ‘personalised medicine’ approaches to cancer 
treatment based on exploiting particular mutations.  Whilst these molecular features may not 
affect the symptoms or histopathological appearance of cancer, they are therefore of great 
importance in defining appropriate treatment strategies for each patient. 
These two examples illustrate the difficulty of defining disease by its clinical features alone.  
One solution to this, which has been made possible by recent developments in molecular 
biology and bioinformatics, is to understand disease through its molecular features (such as 
genetic factors) rather than through its symptoms or clinical presentation.  By altering our 
understanding of how a disease is defined, these developments have the potential to 
revolutionise disease biology, changing the way that disease is prevented, managed and treated. 
 
1.1.2  Using disease relationships to understand disease 
Disease classifications describe disease by establishing the relationships between them, which 
may be based on clinical presentation, aetiology7, or a combination of these factors.  Existing 
classification systems, which are used by medics, health researchers, and economists7, include 
the International Classification of Diseases (ICD)8, the Systematized Nomenclature of 
Medicine (SNOMED)9, the Disease Ontology (DO)10, and Medical Subject Headings 
(MeSH)11.  There are also specialized disease classification systems for particular disease areas, 
such as the Diagnostic and Statistical Manual of Mental Disorders (DSM)12 which classifies 
mental disorders, or Online Mendelian Inheritance In Man (OMIM)13 for genetic disorders.  
Although each system is developed for a specific purpose, in general disease classification 
systems provide a shared computer-readable vocabulary to describe disease, and have a 
hierarchical structure which groups related diseases together under ‘is-a’ relationships (e.g. 
lung cancer is-a cancer).  
These traditional classification systems are based on established disease relationships, and as 
such do not incorporate new evidence arising from recently developed bioinformatic data 
 11 
types.  At one end of the scale, the advent of large-scale electronic health record data (such as 
that held by insurance companies) allows the identification of disease comorbidities14, or links 
between disease and particular lifestyle or environmental factors.  At the other end of the scale, 
the development of ‘-omics’ techniques, such as genomics, transcriptomics, and proteomics, 
allows diseases to be related at a molecular level, e.g. through shared genes15.   
These ‘molecular-level’ relationships between diseases are an important new way of 
understanding disease relationships, both to identify the shared features underlying known 
disease relationships and to identify unexpected connections between diseases.  Two diseases 
which appear to be highly related may have very different molecular mechanisms: to adapt an 
example from Dudley et al.16, hereditary pattern baldness and alopecia both result in the 
symptom ‘hair loss’, but result from different underlying causes (hormonal vs. immune-
related).  Conversely, two diseases which appear unrelated symptomatically may in fact be 
very similar at the cellular or molecular level – for instance, a particular type of cancer may 
produce different symptoms depending on which organ is affected, but the underlying process 
of uncontrolled cell growth and division is the same.   
The identification of molecular commonalities between apparently unrelated diseases could 
not only shed new light on the pathogenesis of disease, but could help to identify potential 
treatments.  A direct consequence of this would be the ability to reposition or repurpose drugs 
between related conditions.  Drug repurposing (or drug repositioning), defined as the use of a 
drug in a new indication for which the drug was not originally developed17, is a promising 
strategy in the identification of new treatments for diseases, dramatically reducing the cost and 
time taken to get a drug to market compared to de novo drug development18.    Historically, 
drug repurposing opportunities have arisen through chance discoveries17, but our deepening 
understanding of the molecular basis of diseases and disease relationships could enable the 
identification of novel repurposing opportunities in a more systematic way.   
The comparison of diseases at a molecular level is therefore an invaluable tool for improving 
our understanding of diseases and their treatment.  Current research into the molecular basis of 
disease is focused primarily on genomics and gene expression, as the technology for both data 
types is now mature and relatively cost-effective, with well-established methods and software 
for analysis and large amounts of publicly available data (compared to other -omics 
technologies such as proteomics and metabolomics).  However, whilst DNA generally remains 
static over the course of an individual’s lifespan, gene expression provides a dynamic 
‘snapshot’ of cellular state at a particular point in time, and as such is a key molecular read-out 
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of disease.  In the following sections, I will discuss gene expression data, its analysis, and its 
use in the comparison of diseases. 
 
1.2 INTRODUCTION TO GENE EXPRESSION DATA  
1.2.1  Gene expression and its regulation 
 
Figure 1.1 Formation of a protein from the ‘recipe’ encoded by the DNA 
DNA	 is	 transcribed	 into	 RNA	 through	 complementary	 base	 pairing,	 catalysed	 by	 RNA	
polymerase	under	the	control	of	an	assembly	of	transcription	factors	(not	shown).	 	The	RNA	
molecule	initially	contains	non-coding	sequences	called	introns,	which	are	removed	in	a	process	








Gene expression is the process by which a gene encoded as DNA is converted into a functional 
gene product, such as a protein19.  An overview of this process is given in Figure 1.1.  The 
process begins with transcription: the synthesis of an RNA molecule from the ‘recipe’ 
contained in the DNA.  To begin the process of transcription, molecules called transcription 
factors must assemble at specific regulatory binding sites situated upstream of the gene.  The 
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transcription factors help to recruit and bind an enzyme, RNA polymerase, which catalyses the 
process of transcription.  RNA polymerase unwinds the double-stranded DNA helix and works 
along a single DNA strand, base pairing the deoxyribonucleic acids of the DNA code with 
complementary free ribonucleic acids (RNAs) in the cell.  This process continues until a 
termination site is reached, and RNA polymerase releases a single-stranded RNA molecule.  
Various processing is carried out on the RNA molecule before it leaves the nucleus of the cell, 
including splicing (the removal of sequences of intervening RNA called introns) and the 
addition of an RNA cap at the 5’ end and a poly-adenylated tail at the other, marking the RNA 
as complete and intact. 
The next step in the expression of protein-coding genes is the translation of messenger RNA 
(mRNA) into protein, which takes place on cellular structures called ribosomes.  Beginning 
from a specific ‘start’ codon (a sequence of three nucleotide bases), mRNA is threaded through 
the ribosomes, where it binds to complementary transfer RNA (tRNA), which carries an amino 
acid corresponding to each codon.  The amino acids are therefore joined in the sequence 
specified by the mRNA, continuing until the ‘stop’ codon is reached, at which point the 
completed polypeptide formed by the chain of amino acids is released and can fold into its 
three-dimensional structure.  Protein-coding mRNA comprises only 3-5% of total RNA20; other 
RNA types are not translated but remain as RNA molecules in the cell.  These include 
ribosomal RNAs, which form the core of the ribosomes; microRNAs, which play a role in the 
regulation of gene expression; and long non-coding RNAs, whose function is not completely 
understood but which may regulate diverse cell processes20.  
Although each cell contains all the DNA code required to make every protein in the human 
body, only a certain fraction (estimated at around 30-60%) of genes are expressed at any one 
time20.  Control of gene expression underlies the differentiation of cell types, and allows cells 
to respond to environmental conditions and extracellular signals.  Gene expression regulation 
is therefore absolutely crucial to development and homeostasis.  Although gene expression can 
be regulated post-transcriptionally (for example, through complementary binding by 
microRNAs), the dominant mechanism of gene expression regulation is through transcriptional 
control20.  Transcriptional control is mediated through transcription factors, which activate or 
repress transcription through gene-specific mechanisms, such as enhancing the binding of RNA 
polymerase (activation) or blocking the promoter (repression).  Transcription factors can be 
activated in response to changing conditions in the cell: for example, the binding of a molecule 
to a specific transcription factor (which takes place when the molecule is present in sufficient 
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concentrations) changes the three-dimensional conformation of the transcription factor in such 
a manner that it can then bind to a repressor site on the DNA, blocking transcription20.  Gene 
expression levels can therefore be seen as a response to the cellular context, providing a 
measurement of the cell’s response to different conditions. 
   
1.2.2 Motivation for studying gene expression 
Improving our understanding of the cellular state in diseased tissue could provide increased 
insight into the pathogenesis of, and cellular response to, disease.  One approach to measuring 
cellular state is proteomics, or the quantification of proteins.  Proteomics is an appealing 
approach for the study of disease, because it is a direct measure of the ‘final’ product of gene 
expression; proteins associated with a disease could therefore function as biomarkers, or even 
new targets for drugs.  However, the proteome is extremely complex, containing some 100,000 
proteins according to some estimates21; it is also challenging to measure due to the need for 
quantification of the complex three-dimensional structure of proteins, which may also be post-
translationally modified by phosphorylation, ubiquitination, or other processes.   
A simpler way to measure gene expression is via RNA molecules, rather than proteins.  Each 
RNA species can be uniquely described by its nucleotide sequence, so quantifying RNA is far 
less complex than quantifying proteins.  In the last two decades, high-throughput methods 
(such as microarray or RNA-sequencing technologies, which will be discussed in more detail 
in Methods) have been developed which can measure the expression levels of tens of thousands 
of genes relatively cheaply and quickly22.  Studies of this type, which enable gene expression 
to be studied at a large scale, are referred to as transcriptomics.  Transcriptomic experiments 
generally focus on protein-coding mRNA, which can be interpreted as a proxy or rough 
estimate of the levels of protein present in the cell (although the correlation between the two is 
far from perfect, due to numerous factors including post-transcriptional regulation and post-
translational modifications23; these are reviewed in in Maier et al.24).  Measurement of other 
RNA types, such as miRNA, provide additional information about what is taking place inside 
the cell; indeed, these molecules may play a key part in disease25.  However, these technologies 
are still developing and are less widely adopted.  In this thesis, therefore, the terms 
‘transcriptomics’ and (less precisely) ‘gene expression data’ will be used to refer to the 
quantification of mRNA levels in a high-throughput manner. 
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The suffix ‘-ome’ in molecular biology is generally understood to indicate a global viewpoint 
– the transcriptome therefore refers to the mRNA expression levels of (close to) all genes in a 
cell.  In contrast to classical molecular biology, where individual features may be studied in 
great detail, -omics approaches are most suited to drive hypothesis generation – for instance, 
indicating potential biomarkers or altered pathway activity – which may then be confirmed in 
a more focused manner.  A very brief overview of the wide variety of applications of 
transcriptomics includes uses in developmental biology to study early embryonic 
development26; in agricultural and environmental biology to profile response to environmental 
stressors27,28; in drug development to study drug mechanism of action29 and toxicity30,31, and 
in microbiology to study antibiotic resistance32 and host-pathogen interactions33,34 (a more 
detailed review of these various applications is available in Lowe et al.22).  In the study of 
disease, transcriptomics is used to understand more about disease biology, such as to identify 
perturbed biological pathways35,36, discover disease subtypes37 and predict prognosis38; 
transcriptomics is also used in drug discovery to predict drug sensitivity in cancer39 and to 
identify drug repurposing opportunities40,41.  Some of these applications will be discussed 
further in the following sections. 
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1.2.3 Measurement of gene expression  
 












Older techniques to measure gene expression, such as Northern blotting and reverse-
transcriptase quantitative polymerase chain reaction (rt-qPCR), are low-throughput, measuring 
only a few individual transcripts at a time.  True transcriptomic methods able to measure the 
expression of thousands of transcripts at a time were introduced with the advent of microarrays 
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in the mid-1990s, followed by RNA-Seq a decade later.  Both methods aim to quantify the 
amount of mRNA present in a sample and share similar initial steps: extraction of the RNA 
from the sample; purification to remove unwanted molecular fragments; enrichment for mRNA 
(this process involves removing the ribosomal RNA which can account for up to 98% of total 
RNA content in a cell42); and finally generation of stable cDNA via reverse transcriptase, which 
may be further amplified by PCR.  The difference between microarrays and RNA-Seq lies in 
the method of quantification of the generated cDNA. 
Microarrays consist of a specific arrangement of oligonucleotide sequences (or ‘probes’) on a 
solid surface, each probe being designed to match a particular transcript.  In a microarray 
experiment, the generated cDNA is fluorescently labelled and, when washed over the 
microarray, will hybridize to complementary probes matching specific RNA sequences (Figure 
1.2).  Once the unbound cDNA is washed off, the amount of fluorescence at each probe gives 
an indication of the abundance of each mRNA species in the original sample (relative to other 
samples).  In older ‘dual-channel’ microarray designs, test and control samples are labelled 
with different fluorophores (e.g. red and green dyes) and hybridized on the same array, and it 
is the ratio between the two colours which determines the relative amount of mRNA present in 
each condition. 
RNA-Seq, by contrast, works by sequencing fragments of the cDNA.  Each sequenced 
fragment is aligned to a reference transcriptome (which may be assembled from the genome or 
generated de novo), and the count of each fragment at each transcript location indicates the 
abundance of each mRNA species in the original sample.  RNA-Seq has a number of 
advantages over microarrays: firstly, its dynamic range is substantially higher, allowing 
detection of very highly or lowly expressed transcripts (over five orders of magnitude22), 
whereas microarrays suffer from the limits of detection of fluorescence.  A further advantage 
of RNA-Seq is that it doesn’t use pre-designed probes, allowing identification of novel 
transcripts.  For these reasons, RNA-Seq is now the dominant technique in transcriptomics, 
overtaking microarrays (in terms of number of publications referring to the technique) in 
201522.  However, due to the popularity of microarrays in the preceding two decades, 
microarray datasets still far outnumber RNA-Seq in public repositories (discussed below); a 
further advantage is that during this time, techniques for pre-processing and analysis of 
microarray data have become highly developed and standardized.  These techniques will be 
discussed further in Methods. 
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1.2.4 Obtaining gene expression data from public repositories 
Since the advent of high-throughput technologies in the mid-1990s, the volume of gene 
expression data stored in public repositories has been increasing rapidly43.  Developments in 
technology have enabled transcriptomic studies to be carried out more cheaply and easily than 
ever before; at the same time, requirements for data sharing put in place by funders and journals 
mean that this data is increasingly being made publicly available.  The largest public gene 
expression repositories, Gene Expression Omnibus44 (GEO) and ArrayExpress, contain tens of 
thousands of studies: at the time of writing, GEO contained 73,388 expression profiling studies, 
(of which 53,691 were microarray studies and 18,126 were high-throughput RNA sequencing 
studies45), and ArrayExpress contained 70,894 experiments46 (ArrayExpress imports data from 
GEO, so there is substantial overlap between the two).  These cover many study types, from 
early microarray studies to cutting-edge single-cell RNA-Seq experiments, and span diverse 
research areas including toxicology, pharmacology, ageing, and development.  In particular, 
available studies cover hundreds of different diseases, from common, well-studied diseases to 
extremely rare conditions. 
In addition to these general-purpose repositories, several application-specific gene expression 
databases are available.  These include DrugMatrix47 and Open TG-Gates48 for toxicity, and 
the Connectivity Map (CMap)49 and the Library of Interconnected Cellular Signatures L1000 
dataset (LINCS)50, which record gene expression in human cell lines in response to 
perturbation by drugs.  There are also disease- and organ-specific databases such as the 
Oncomine database of gene expression in cancer51 and the Allen Human Brain Atlas52.  These 
databases generally have better annotation, curation, and integration than their general-purpose 
counterparts; the trade-off, however, is that they may not be as comprehensive, i.e. they are 
unlikely to include all studies related to a particular condition. 
 
1.3  USING GENE EXPRESSION DATA TO UNDERSTAND DISEASE 
1.3.1 Differential expression analysis 
1.3.1.1 Calculating differential expression  
After the appropriate pre-processing steps (discussed in Methods, as these are platform-
specific), a transcriptomic experiment results in a matrix containing the measured abundance 
of i genes in each of j samples.  Whilst this ‘baseline’ gene expression can be informative (for 
instance, to assess the expression of a particular gene in a specific tissue or cell type, or to 
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examine the change in gene expression over a time series experiment), the measured abundance 
can be strongly affected by technical and laboratory-specific factors (discussed below).  In 
many applications, it is more helpful to give gene expression as a ratio of expression between 
conditions, known as ‘differential expression’.  In differential expression analysis, genes are 
interpreted in terms of the expression difference between one group (the condition under study, 
e.g. patient or tumour samples) and another (the control group, e.g. healthy individuals or non-
cancerous tissue).  Differential expression has become a popular means of working with gene 
expression data, as it accounts for the fact that (unless special ‘spike-in’ controls are used) gene 
expression measurements are relative, rather than absolute.  The magnitude of differential 
expression is expressed as a fold change (e.g. if a gene is twice as highly expressed in one 
group than the other, this would be a two-fold change), usually in log2-transformed space in 
order to provide a symmetric scale around zero.   
Due to the noise inherent to gene expression data, the magnitude of fold change values should 
be considered in conjunction with a measure of significance – i.e., given the variance observed 
across samples, how likely is it that the observed difference in means could occur under the 
null hypothesis (that values in the two groups are drawn from the same distribution)?  This is 
essentially a t-test; however, because of the particular properties of gene expression data 
(noisiness, gene- and sample-specific variance, low ratio of observations to features), several 
methods have been developed to estimate a ‘moderated’ t-statistic more suited to the analysis 
of transcriptomic data.  Numerous packages exist to calculate these quantities including 
limma53 (LInear Models for MicroArrays) and SAM54 (Significance Analysis of Microarrays) 
for microarrays; and EdgeR55 and DESeq56/DESeq257 for RNA-Seq data.   
The basic outline of a limma analysis (limma being the most popular analysis package for 
microarray data) is as follows: 
1. Specify the design matrix indicating which samples are to be compared against each 
other (in a simple case-vs-control differential expression analysis this simply requires 
assigning samples to case and control groups; additional steps are required for more 
complicated analyses). 
2. Fit a linear model ! = #$ + 	' to each probe, where ! are the observed expression 
values in each sample, # is the design matrix, $ are the co-efficients, and ' is an error 
term (limma function lmFit). 
3. Use an empirical Bayes procedure (limma function eBayes) to smooth the probe-wise 
variances by borrowing information from other probes.  The reasoning behind this is 
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that given the small sample sizes usually used in microarray experiments, the true 
variance will be difficult to estimate, so the eBayes call adjusts the observed variance 
towards the expected variance computed from the average of all variances.  The 
smoothed variances are used to calculate a moderated t-statistic for each probe. 
4. Summarize the fold changes, significance values, and other statistics (e.g. average 
expression) for each probe (limma function topTable). 
An important consideration here is the correction of the obtained significance values for 
multiple testing.  The traditional concept of hypothesis testing was designed to be used in the 
context of single experiments, but with an individual p-value for each gene, tens of thousands 
of hypotheses are effectively being tested at once.  On a 10,000-gene microarray, an average 
of 500 genes would meet a significance threshold of p<0.05, whether or not any genes were 
truly differentially expressed. One way to address this problem is to use multiple testing 
correction to select a more stringent significance threshold, such as the Bonferroni method 
(which simply divides the chosen significance threshold by the number of hypotheses tested) 
or less stringent False Discovery Rate methods which specify an acceptable proportion of false 
discoveries, such as the widely-used Benjamini-Hochberg method. 
Probes may then be mapped to their corresponding genes (discussed in Section 2.1.3).  Once 
fold change and (multiple-testing corrected) significance values have been obtained for each 
gene, ‘interesting’ genes can be selected based on some combination of fold change magnitude 
and statistical significance. It is important to note that the fold change and significance 
threshold used to determine what counts as ‘significant differential expression’ are essentially 
arbitrary, and so hundreds or even thousands of genes may be classed as differentially 
expressed in a particular experiment depending on the selected threshold.  The selection of an 
appropriate threshold is dependent on the context (what question is being answered with the 
analysis?) and the type of analysis carried out. 
 
1.3.1.2 Using differential expression to understand disease 
Classical differential expression analysis aims to understand DEG lists through the functions 
of individual dysregulated genes, identifying those which could form a compelling hypothesis 
for the changes underlying the development of or response to disease.  An example of this type 
of analysis is the work of Trigueros-Motos et al.58, who analysed differential expression in 
vascular regions prone to atherosclerosis compared to those resistant to atherosclerosis.  They 
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found overexpression of a set of four homeobox genes (involved in anatomical specification in 
embryonic development), Hox6-Hox10, in murine athero-resistant aorta.  The athero-prone 
regions in murine aorta and human smooth muscle cells showed higher activity of 
inflammatory mediators normally inhibited by homeobox genes, suggesting that the interplay 
between homeobox and inflammatory gene expression patterns could create an environment 
which allows the development of atherosclerosis.   
The advantage of this type of analysis is that it can provide a mechanistic understanding of the 
observed gene expression patterns, which can then be followed up in detail by e.g. confirmation 
of high-throughput measurements using techniques such as qPCR.  However, this relies on 
human interpretation of potentially tens of thousands of data points, necessitating the use of 
strict thresholds to reduce DEG lists to a reasonably interpretable size.  This leads to a focus 
on only on the most strongly dysregulated genes, risking the exclusion of less strongly 
dysregulated genes which could nevertheless be relevant to the studied condition.  Further, 
human interpretation is subject to bias, as investigators will naturally focus on the most 
recognised and well-studied genes, potentially overlooking important but less well-
characterized genes.  Other methods which have been developed for the analysis of gene 
expression data therefore aim to provide an interpretable summary of large gene lists by 




1.3.2 Analysis against known gene sets 
1.3.2.1 Performing gene set analysis 
 










Given a selection of genes of interest, gene set analysis methods aim to associate (subsets of) 
these genes with known biological processes. This can be thought of as a ‘translation’ of the 
observed gene expression patterns to a higher biological level, reducing complexity and aiding 
interpretation.   Typically, gene set methods calculate enrichment against biological pathways, 
including: 
• Metabolic pathways, which describe a sequence of reactions taking place in the cell 
that transform (metabolise) substrates into new products59.  Examples include 
glycolysis and the citric acid cycle. 
• Gene regulatory pathways, which describe the interaction of genes, RNA, proteins, 
and other cofactors to regulate gene expression and protein production in the cell. 
• Signalling pathways, which are involved in cellular communication and the 
transmission of cellular signals to and from the cell.  Examples include pathways 
involved in homeostasis, such as the insulin signalling pathway. 
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• Some collections also define disease pathways, which detail perturbations to the 
healthy biological system which are associated with disease.  Disease pathways are 
available for several well-studied diseases such as cancer, diabetes, and cystic fibrosis, 
but for many diseases pathways are not known; and where pathways are known these 
may be incomplete. 
In the last two decades, numerous collections have been developed which relate genes to 
biological pathways.  Popular resources include primary pathway databases such as KEGG 
Pathways60, Reactome61, and Panther62 as well as commercial pathway databases.  Aside from 
biological pathways, other ways to group genes include functional or local grouping – a well-
known gene set collection of this type of is Gene Ontology63, which annotates genes with 
lower-level biological processes (which can be considered the ‘building blocks’ of biological 
pathways), molecular functions, and cellular components.  Other gene set collections include 
collated resources such as WikiPathways64 and MSigDB65, which bring together multiple 
collections into a single database. 
The identification of gene sets relevant to the condition under study can be achieved through 
various methods which can be divided into two broad classes: overrepresentation and 
enrichment.  Overrepresentation methods take a gene list as input, and test for a significant 
difference in the representation of the input list compared to the background or ‘reference’ list 
in each gene set.  By contrast, enrichment analysis uses the whole measured expression profile, 
removing the need to define a DEG list using an (arbitrary) cut-off.  The most widely-used 
enrichment method is gene set enrichment analysis (GSEA)66, which uses a Kolgomorov-
Smirnov-like statistic to test for the distribution of each gene set within the measured gene 
expression profile, which is rank-ordered by e.g. fold change or significance (Figure 1.3).  
Numerous tools exist to perform either type of gene set analysis, including online tools such as 
DAVID67, ToppGene Suite68, WebGestalt69, and GOrilla70, as well as R packages such as 
ReactomePA71 and TopGO72, and standalone software for GSEA.  Whilst in theory the choice 
of method is independent of the gene set used, in practice, the tools are generally integrated 
with particular datasets – for instance, the aforementioned Panther includes a web tool to 
perform both overrepresentation and enrichment analysis on Panther pathways, although recent 
updates have added GO and Reactome annotations as well.  
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1.3.2.2 Using gene set analysis to understand disease 
One example of the use of gene set analysis to understand diseases is the meta-analysis of 17 
Parkinson’s disease (PD) studies carried out by Zheng et al.73, covering studies ranging from 
early subclinical to severe disease stages.  The authors used GSEA to identify 10 MSigDB gene 
sets associated with PD across multiple studies, including ‘electron transport chain’, ‘oxidative 
phosphorylation’, and ‘pyruvate metabolism’.  The ten gene sets covered four distinct 
biological areas related to neuronal energy metabolism: electron transport, mitochondrial 
biogenesis, and glucose utilization and sensing.  These findings suggested the intriguing 
hypothesis of Parkinson’s disease as an alteration of normal cellular energetics to which 
dopaminergic neurons ‘may be intrinsically more susceptible than other cells’73.   
Whilst gene set enrichment methods provide a high-level description of altered gene expression 
in terms of the biological functions affected, they hide information about the roles of individual 
genes.  Analysis against known gene sets is also limited by the fact that our knowledge of 
biological pathways and processes is incomplete and incompletely accurate74.   Recently, de 
novo gene set identification methods have been proposed as an intermediate, providing insight 
as to how genes work together (e.g. along signalling pathways) whilst retaining information on 
the activity of individual genes. 
 
1.3.3 Gene network analysis 
Rather than analysing gene expression against predefined gene sets, more recently developed 
methods of interpreting gene expression data are based on the identification of de novo gene 
groupings by linking genes whose expression is altered in the condition under study, forming 
condition-specific gene networks.  Current network-based methods fall into one of two 
categories according to what the gene links (edges of the network) represent: the first is co-
expression methods, which link genes whose expression varies similarly across a series of 
samples.  Co-expression methods are based on the hypothesis that groups of genes whose 
expression varies together are associated with similar biological or regulatory processes75; they 
do not try to describe the causality or directionality of interactions between genes76.   
Conversely, methods in the second category (which can be termed interaction-based methods) 
link genes via known interactions between them (or between their products).  These may 
include physical binding interactions and/or (indirect) functional (e.g. regulatory, metabolic, 
or signalling) interactions; all of these different interaction types can collectively be termed the 
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‘interactome’77.  Many databases are available which cover interactions of different types; 
some of the best-known are String78, IntAct79, ConsensusPathDB80, and SignalLink81, as well 
as more recent integrative efforts such as OmniPath82 and HIPPIE83.  Just as with gene set data, 
our knowledge of the interactome is incomplete84; however, the interactome can be treated as 
a ‘scaffold’ of prior knowledge to aid gene expression analysis.  For example, Rakshit et al.85 
constructed a protein-protein interaction (PPI) network from differentially expressed genes in 
Parkinson’s disease (PD).  The authors suggested that genes which were topologically 
significant in the constructed PPI network (hub or bottleneck nodes) may represent possible 
therapeutic targets in PD.  However, by focusing only on the most topologically significant 
nodes, key genes involved in disease – which tend not to be ‘hub’ genes15 – may be missed. 
An alternative method to analyse gene networks is to group the network into ‘modules’, 
representing sets of interlinked genes that may be related to a particular biological function.  
Module identification methods include clustering methods like MCODE86 or GLay87, which 
are based on network topology and are therefore independent of network type.  Other 
approaches have been developed which are specific to either co-expression- or interaction-
based networks, such as Weighted Gene Co-expression Network Analysis (WGCNA)88 for co-
expression networks, which performs co-expression analysis, network construction, and 
module identification.  
An example of module-based analysis of gene networks is the work of Ray et al.89, who 
investigated co-expression patterns across six brain regions in Alzheimer’s disease.  For each 
pair of brain regions, genes showing dysregulation in both regions were used to construct co-
expression modules.  Each module was analysed for preservation or perturbation between the 
two regions: the varying co-expression patterns of commonly differentially expressed genes in 
perturbed modules suggest regulatory variation between the two regions.  A limitation of 
module-based network analysis is that the resulting modules may be large, necessitating further 
analysis in order to be interpretable – in this study, the authors used pathway analysis to explore 
the functions of the genes in each co-expression module.  A key challenge for network-based 
analysis is therefore to highlight small ‘active’ network regions, forming a middle ground 
between analysis of individual topologically significant nodes and analysis of large modules. 
Developments in this area will be described in more detail in Chapter 4. 
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1.3.4 Integration of other data types 
Gene expression represents only one dimension of the molecular changes associated with 
disease, and as the volume of bioinformatic data of all types continues to grow, methods which 
combine gene expression with other data types are becoming increasingly popular.  A common 
choice is to integrate gene expression data with genetic variant data (heritable variants, e.g. 
SNPs, or somatic mutations) in order to explore potential relationships between genetic 
alterations and gene expression90.  Integration approaches can be extended to different -omics 
data types including proteomics and metabolomics. In the last few years, large-scale datasets 
such as The Cancer Genome Atlas91 which contain genomic, epigenomic, transcriptomic, and 
proteomic data relating to each sample92, have enabled ‘multi-omics’ approaches which have 
the potential to provide a comprehensive molecular-level characterization of disease.   
Molecular-level data can then be combined with data at the clinical level – such as survival, 
comorbidity, phenotype, and drug prescription – to identify links between molecular-level 
changes and clinical outcomes in disease.  For example, Orozco et al.93 used a ‘systems 
genetics’ approach to study the association between methylation data and clinical (including 
blood, fat, and insulin-related) and molecular (including metabolites and proteins as well as 
gene expression) traits in mice, finding that many associations could be identified by the 
methylation data (‘epigenome-wide association’) which were not identified using traditional 
genome-wide association methods.  Methods for data integration are currently an active area 
of research, particularly for methods which integrate data types other than -omics data (such as 
electronic health record or co-morbidity data), as it is not yet clear how associations can best 
be modelled across diverse data types.  This issue will be discussed further in Chapter 5. 
 
1.4 USING GENE EXPRESSION AND OTHER BIOINFORMATIC DATA 
FOR THE COMPARATIVE ANALYSIS OF DISEASES 
1.4.1 Using comparative analysis to deepen our understanding of disease 
The reuse and reanalysis of existing studies reduces duplication of effort and enables multiple 
researchers to analyse the same data, ensuring reproducibility.  Further, previous studies can 
be combined to increase statistical power, enabling us to address existing biological questions 
with greater insight, and even to pose new questions motivated by greater data availability.  A 
2012 review of reuse of gene expression data found that a quarter of studies citing 
 27 
ArrayExpress used it to address a biological question without generating any new experimental 
data94; a further quarter used public data to complement their own newly generated data (e.g. 
as a validation dataset).  However, the high dimensionality of gene expression data, and its 
susceptibility to noise resulting from multiple biological95 and technical96 factors, means that 
comparison across gene expression datasets is challenging.  In this section I will discuss how 
the comparative analysis of multiple studies can inform us about disease, including some of 
the potential pitfalls that must be considered. 
 
1.4.1.1 Meta-analysis reveals commonalities across studies of the same condition 
A common type of comparative analysis is meta-analysis: the integration of multiple studies of 
the same condition to effectively form a much larger study which is more generalizable 
(drawing results across different experimental designs and sample populations)97 and has 
increased statistical power compared to any one individual study98.  Meta-analysis approaches 
are particularly useful in the context of gene expression studies, where the high dimensionality 
and non-standardized (pre-)processing and analysis methods mean that there may be little 
agreement between individual differentially expressed gene lists99 of the type discussed in 
Section 1.3.1.2.  In a meta-analysis of 21 thyroid cancer studies100, for example, only 107 of 
755 genes in published gene lists showed consistent differential expression in more than one 
study.  Those genes which are consistently differentially expressed across multiple studies, 
however, are then more likely to be associated with the condition under study rather than 
technical or experimental factors (discussed below).   
Given the low agreement between gene expression studies of the same condition, a key issue 
in conducting a meta-analysis is how to define which studies are comparable, i.e. how to 
determine the best balance between study inclusion vs exclusion: the greater the number of 
studies that can be included in a meta-analysis, the greater the statistical power that can be 
achieved, but including too wide a range of studies risks diluting the detected signal due to 
‘noise’ from studies which do not accurately reflect the condition under study.   
 
1.4.1.2 Comparing gene expression reveals links between different conditions 
The comparison of clinically related diseases can reveal common molecular mechanisms 
underpinning shared pathogenesis or phenotypes.  Studies of gene expression patterns have 
illustrated the similarities between inflammatory bowel diseases101, systemic autoimmune 
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diseases102, neurodegenerative diseases103, and mental health diseases104 to name just a few 
examples.  As well as identifying similarities between related diseases, this approach can also 
be applied to phenotypically diverse diseases to uncover similar mechanisms of dysregulation 
that may lead to distinct phenotypes due to e.g. differences in cellular context105.  A 2009 
study40 compared 74 diseases using both 1) the correlation between their gene expression 
profiles and 2) the enrichment of genes significantly differentially expressed in one disease in 
the profile of another (analogous to gene set enrichment analysis).  This approach revealed 
unexpected connections between diseases, such as between Crohn’s disease and malaria, as 
well as known or emerging connections between diseases in the same ontological category, 
such as between actinic keratosis (‘sun spots’, which may be pre-cancerous) and multiple 
cancers.  This illustrates how large-scale exploratory comparisons of gene expression profiles 
from clinically unrelated diseases can highlight unexpected similarities between diseases. 
The genes and pathways shared between diseases can be used to generate new hypotheses about 
the molecular mechanisms of disease: for instance, Yang et al.106 compared gene co-expression 
across 108 diseases, finding overlap of co-expressed genes between allergic asthma, type 2 
diabetes, and chronic kidney disease.  Many of the shared genes were involved in Wnt 
signalling, suggesting the possible involvement of a common pathway in these phenotypically 
distinct diseases.  In the network as a whole, more than half (57%) of the 1326 disease-disease 
links are novel links according to traditional disease classifications, with 82% of these sharing 
disease-related genes or drugs, illustrating a relevant biological basis for the connection.  This 
study provides an example of the use of co-expression network analysis to compare diseases; 
surprisingly, however, few approaches have compared diseases based on gene expression in an 
interaction network (the other type of network-based analysis discussed above), despite the 
potential utility of identifying shared network regions active in disease.  This will be discussed 
further in Chapter 4. 
Shifting focus from diseases to genes, other approaches have used large-scale disease 
comparisons to identify genes which are frequently dysregulated in different conditions.  This 
analysis helps us to better understand observed gene expression patterns by identifying which 
patterns may reflect a general ‘disease response’ such as inflammation or immune system 
activation, and which appear specific to the disease.  Suthram et al.107 identified ‘disease 
modules’ by mapping differential gene expression in 54 diseases to pre-computed ‘functional 
modules’ (describing e.g. protein complexes in the human protein-protein interaction network).  
They found that 59 of the 4,620 functional modules were enriched in at least half of diseases 
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in the network, which the authors suggested form a ‘common disease-state signature’.  Further, 
these frequently dysregulated modules were found to be enriched for known drug targets, 
illustrating that these modules could form a useful basis for therapeutic options targeting 
common disease symptoms.  Unfortunately, this study (which was carried out in 2009) is 
somewhat limited due to the restricted number of diseases studied, as well as the use of generic 
pre-computed modules, rather than disease-specific modules.  A similar analysis over a wider 
range of diseases would therefore be of great interest for the analysis of gene expression 
profiles and how they reflect common disease responses. 
 
1.4.1.3 Cross-condition comparison of gene expression signatures can be used for 
drug repurposing 
Comparative analysis of gene expression signatures is a popular approach in transcriptomic 
drug repurposing, based on the idea that drugs inducing gene expression profiles which are 
‘opposite’ to a disease-induced differential expression profile may be able to reverse the 
dysregulation associated with the disease40,41.  A study comparing gene expression profiles in 
100 diseases and 164 drugs (using drug-induced gene expression profiles from the CMap 
resource introduced in Section 1.2.4)41 used the ‘connectivity’ between diseases and drugs (a 
concept similar to gene set enrichment, in which the top differentially expressed genes in 
disease form the ‘gene set’ against which the drug expression profile is tested) to identify 
potential candidates for drug repurposing.  If a disease is strongly negatively enriched for a 
particular drug, this suggests that the drug may potentially be therapeutic against the disease.  
As well as known drug-disease connections, such as the corticosteroid prednisolone for 
inflammatory bowel diseases, the authors identified novel connections such as the anti-ulcer 
drug cimetidine for lung cancer, which experimental validation showed to be effective in a 
mouse model.  Following the success of this study, many other approaches have been 
developed based on similar concepts108–110. 
Despite the potential of these approaches for the identification of drug repurposing hypotheses, 
comparisons between drug and disease signatures suffer from the same limitations as 
comparisons across disease signatures, including incomplete understanding of issues such as 
how cell line models of disease (which are used to record drug response) can be compared to 
disease gene expression profiles from patients.  Our understanding of potential repurposed 
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treatments for disease would greatly benefit from improved insight into the comparative 
analysis of gene expression profiles.  
 




Figure 1.4 Types of comparative analysis of gene expression profiles of disease and 








Sources of variation between gene expression experiments can be roughly divided into two 
categories: variation arising from the noise inherent to gene expression measurement, which is 
pervasive and difficult to control; and variation arising from choices made in the design of the 
experiment, which is controlled according to the aims of the study.   
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Figure 1.4 summarises these types of variation, which will be discussed further in this section.  
Although this figure illustrates the comparison of differential gene expression profiles, which 
is the focus of this thesis, these factors also apply to the comparison of base gene expression.  
However, comparison of base expression profiles is further complicated by differences in e.g. 
average measured intensity, which are cancelled out (due to being reported as a ratio) in 
differential expression analysis. 
	
1.4.2.1 Experimental factors affecting comparison of gene expression studies 
The first source of variation can be described as noise – unintentional variation resulting from 
factors other than the condition under study – and can be further divided into biological and 
technical noise.  Biological noise is an inherent property of gene expression, and includes noise 
resulting from the dynamic nature of transcription, including transcriptional bursting112 and 
differences in transcription at different stages of the cell cycle95; these are of more concern in 
recently developed single-cell transcriptomics methods, as they should even out over RNA 
sampled from whole tissue.  Another source of biological noise is variation in gene expression 
patterns between individuals113, although these differences should also even out over an 
adequate number of samples.   
Technical noise is noise resulting from experimental and measurement factors, such as sample 
preparation (RNA extraction, labelling and amplification114), probe hybridization115 and array 
scanning116.  This type of noise appears even between repeat measurements of the same sample.  
Numerous studies, most notably the large-scale studies co-ordinated by the Microarray Quality 
Control Consortium117 and the Sequencing Quality Control Consortium118, have found good 
agreement for relative (differential) gene expression measurements of the same sample, 
suggesting that repeats of an experiment should be highly concordant.  Outside of these 
controlled large-scale studies, however, a further source of technical variation between gene 
expression studies arises from laboratory-specific differences in sample handling and the 
protocols and platform type used.  
 
1.4.2.2 Study design factors affecting comparison of gene expression studies 
The second group of factors that must be taken into account when comparing experiments 
relates to the design choices made for a given study.  A key consideration in the study of disease 
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is the choice of tissue from which to sample: investigators may choose to sample gene 
expression in the tissue most relevant to the disease, or they may choose to use tissues that are 
more easily accessible, such as blood samples.  This is particularly important in cases where 
sampling the actual tissue is invasive (e.g. colonic tissue) or where tissue cannot be sampled 
until post-mortem (e.g. brain tissue).  In the case of progressive diseases such as 
neurodegenerative disease, different sub-tissues may be sampled to follow the progression of 
the disease.  Patterns of tissue-specific baseline gene expression exist across healthy tissue119, 
and it is reasonable to assume that the gene expression response to disease may also differ 
between tissues.  A study by Dudley et al.111 addressed the subject of whether the disease-
specific signal across tissues is stronger than the tissue-specific response to disease.  Across 
microarray studies representing 238 diseases and 122 tissues, under 84 combinations of 
workflow parameters (normalization, merging, and quantification methods), the authors 
concluded that although comparison across different tissues reduced the concordance between 
studies, ‘the molecular signature of disease across tissues is overall more prominent than the 
signature of tissue expression across diseases’111.  However, the question remains to what 
extent an experiment carried out in a ‘surrogate’ tissue is reflective of the gene expression 
changes that would be observed in the most directly affected tissue.   
A further issue is the selection of patients (and equivalent healthy controls).  Distinct from 
biological noise as discussed above, which would be found even in a controlled population 
(e.g. of genetically identical laboratory animals raised in identical conditions), human studies 
involve genetically diverse populations of patients of different ages and genders.  These factors 
may affect both baseline gene expression120 and the gene expression response to disease.  A 
further consideration particular to the study of disease is the drug treatment history of patients: 
patients may follow many different drug treatment regimes, which will affect the observed 
expression patterns by diluting the ‘disease signal’ with the ‘drug signal’.  Complicating these 
issues further is the fact that this demographic information is often not supplied in the sample 
meta-data stored in public repositories.   
A final issue in sample selection concerns the choice of disease model.  The ‘gold standard’ 
for gene expression experiments in disease is samples directly from patients; however, some 
studies of disease use animal models or cell lines in order to perform experiments which would 
not be possible in human patients.  The question of how well gene expression in e.g. cell lines 
taken from patients reflects gene expression sampled directly from the patient has not yet been 
answered definitively.  The issues raised here will be addressed further in Chapter 3. 
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1.4.2.3 Factors specific to cross-condition comparison of gene expression studies 
As well as the general issues in comparing gene expression data discussed above, there are 
further issues specific to comparing gene expression between different diseases.  An initial 
consideration is that diseases affect different anatomical locations – their effects may be 
systemic, such as autoimmune or metabolic disorders, or they may be localized to a particular 
tissue or organ, such as skin diseases or cancers.  As discussed above, gene expression 
responses to disease differ depending on the sampled tissue; one solution is simply to assume 
that the strongest and most ‘representative’ signal of disease is found in the most highly 
affected tissue, and to compare disease signatures in the most affected tissue for each.  Given 
the availability of enough studies (which is not currently the case), diseases could be compared 
across studies in a single tissue such as blood.  However, the strength of the transcriptomic 
signal of disease in e.g. blood compared to the affected tissue is not yet established. 
A further consideration is that different diseases have different drug treatment programs, which 
will affect observed gene expression to different extents.  The alternative is to limit the dataset 
to the few studies which state that they have been carried out in drug-naïve patients, but 
currently there are not enough transcriptomic studies available in explicitly drug-naïve patients 
for this to be practical.  Despite these limitations, previous studies, such as those discussed in 
the preceding sections, have illustrated that comparing gene expression data across diseases 
can yield valuable insights into disease and its potential treatment.   
 
1.5 PROPOSED RESEARCH 
In the Introduction so far, I have discussed issues relating to the analysis of gene expression 
data, and explored the advantages and limitations relating specifically to the comparison of 
multiple gene expression data sets.  In particular, I have focused on the use of gene expression 
data to compare different diseases.  Despite the potential of this type of analysis to deepen our 
knowledge of diseases (and their possible treatments), there are key questions remaining to be 
answered in order to fully exploit the potential of this approach.  I will now provide a more 
detailed summary of how these will be addressed in this thesis. 
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1.5.1 How do experimental factors affect measured gene expression in 
disease? 
This question concerns the comparability of microarray data across different tissues and 
organisms.  As discussed above, factors such as the choice of microarray platform and disease 
model in a transcriptomic experiment all affect the measured signal of a disease.  Several 
studies have addressed these factors individually, but it remains unclear how these factors 
affect the ‘representativeness’ of the measured gene expression to the condition under study.  
This in turn affects the ability to compare gene expression from different studies – if the choice 
of e.g. microarray platform strongly influences the measured gene expression, is it meaningful 
to compare studies from different microarray platforms? 
As an initial study in the comparison of transcriptomic data, I examine the concordance of 
microarray studies across different tissues, microarray platforms, and disease models, as well 
as the effect of sample sizes, using the neurodegenerative condition Parkinson’s disease as a 
case study.  After establishing the similarity of different study types to the ‘gold-standard’ 
studies of human brain tissue, I further examine the specificity of the measured signals through 
comparison with other brain diseases: Alzheimer’s disease and cancer.  As well as being the 
largest meta-analysis of gene expression in Parkinson’s disease to date, this work provides 
guidelines for study selection e.g. in a meta-analysis context.  This chapter forms a basis for 
the following work, helping to define the criteria for study inclusion in the larger disease dataset 
used in the following chapter. 
 
1.5.2 How can shared gene expression patterns across different diseases 
be identified? 
Previous sections of the Introduction discussed methods to aid the interpretation of gene 
expression data, including enrichment of differentially expressed genes against functional gene 
sets (e.g. biological pathways) and grouping into functional or co-expression networks.  Whilst 
these methods can be invaluable for the analysis of individual gene expression datasets, they 
have several limitations for comparison of diseases.  Biological pathways are a high-level 
description of a biological process, and comparison of diseases at this level discards the gene-
level information that could help to identify more specific processes.  Further, methods reliant 
on known biological pathways are restricted only to the identification of known processes, and 
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are thus incapable of identifying novel disease-associated processes. By contrast, methods 
based on interaction networks not only retain the gene-level information, but (depending on 
the interaction type) can also illustrate the potential flow of disease-related perturbation 
through the network.  However, network-based methods tend to produce large modules that 
may include many genes solely on the basis of topology, which are not ideal for making 
comparisons between diseases.  
In this chapter, I introduce a weighted shortest-paths method (based on the work of Sambarey 
et al.121) which identifies the most highly perturbed signalling paths in a disease.  Each edge in 
the path links two differentially expressed genes, allowing comparison of diseases based on 
individual shared edges.  Connecting the shared edges forms shared dysregulated networks, 
enabling the identification of processes showing altered expression in both diseases.  I first 
confirm the biological relevance of the identified paths by showing their enrichment for 
disease-associated genes and drug-interacting genes compared to the use of simple (non-
network based) differentially expressed gene lists.  I then examine the properties of genes 
which are frequently in dysregulated paths across multiple diseases, identifying commonly 
dysregulated genes which may represent ‘pressure points’ in the human signalling network.  
Finally, I apply the method to the pairwise comparison of 141 studies of common and rare 
diseases, identifying disease pairs with significant similarity (i.e., a significant number of 
shared interacting gene pairs) and illustrating how shared dysregulated paths might be used to 
identify potential opportunities for drug repurposing. 
 
1.5.3 How can gene expression data be integrated with other 
bioinformatic data types to make connections between diseases? 
Previous sections of the Introduction outlined how the integration of other bioinformatic data 
types can aid the interpretation of gene expression in disease.  However, gene expression 
represents just one possible information ‘layer’ at which diseases may be compared: diseases 
may share drug treatments, for instance, or a genetic variation conferring risk for the disease.   
Defining relationships between diseases across multiple biological layers could form a new 
bioinformatic classification of disease, incorporating new molecular data types as well as 
traditional disease relationships.  Such multi-layer links between diseases could improve our 
understanding of disease biology and potentially identify opportunities for drug-sharing.   
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However, relatively few methods have been developed for the comparison of diseases across 
diverse data types.  One reason for this may be that differences in data type properties (e.g. 
information content) make it difficult to directly compare disease relationships across 
spaces122.  In the final section, I explore the use of additional data types in the comparison of 
diseases, developing a method based on the integration of pairwise disease similarities in an 
unbiased manner which accounts for differences in data type properties.  The proposed method 
is used to integrate gene expression data with five other data types – ontology, phenotype, 
literature co-occurrence, genetic variation, and drug prescription – and is designed to easily 
incorporate additional data types.  The integrated similarities reveal how links between diseases 
at the gene expression level relate to links at other levels, and are used to explore disease 
relationships that exist across multiple levels, particularly in relation to drug-sharing. 
 
1.6 SUMMARY 
In this thesis, I will use comparative analysis of gene expression data to understand diseases 
and the relationships between them, addressing issues including the comparability and 
interpretation of transcriptomic data, as well as the integration of other data types to aid 
identification of disease relationships.  The remainder of the thesis is structured as follows: 
In Methods, I discuss methodological aspects related to the selection, pre-processing, and 
analysis of gene expression studies. 
In Concordance of Microarray Studies of Parkinson’s Disease, I describe work investigating 
the comparability of microarray studies across different species, tissues, and microarray 
platforms. 
In Using Dysregulated Signalling Paths to Understand Disease, I describe the integration of 
gene expression data with a signalling network to aid the interpretation and comparison of gene 
expression datasets across diseases. 
In Understanding and Predicting Disease Relationships Through Similarity Fusion, I introduce 
a method for the integration of multiple bioinformatic data types, and apply it to reveal disease 
relationships spanning gene expression and other spaces. 
Finally, in Conclusions I describe the significance and possible future directions of the research 




2.1 ANALYSIS OF MICROARRAY DATA 
2.1.1 Motivation for using microarray data in this project 
In the Introduction, I discussed the advantages and disadvantages of microarray and RNA-Seq 
technology.  Despite the many advantages of RNA-Seq, in this work I have chosen to focus 
exclusively on the analysis of gene expression data from microarrays.  This is the most suitable 
data type for this project, which involves the analysis of hundreds of transcriptomic datasets, 
for two reasons. The first reason is the greater ease of analysis of microarray data: the large 
volumes of data required by this project necessitate a semi-automated analysis workflow that 
can be applied in a standardized manner across multiple datasets, which would be much more 
complex without the greater homogeneity and standardization amongst microarrays (at least 
within a platform type).  The second reason is the greater number of microarray datasets: as 
detailed in the Introduction, microarray experiments make up much of the data stored in public 
repositories due to their longer history of use compared to RNA-Seq.  As this project relies on 
the use of public datasets, focusing on microarray data then allows a greater number and variety 
of datasets to be included in the comparative analysis setting.   
The other possibility is to analyse both data types together, with the bulk of the datasets coming 
from microarray experiments, supplemented with RNA-Seq experiments where necessary for 
greater coverage.  However, given that the reported concordance between the two technologies 
is moderate123 and dependent on transcript abundance124, the risk is that the use of different 
technologies might introduce an extra confounding factor in the comparison of measured gene 
expression.  Therefore, only microarray studies were used in this project. 
 
2.1.2 Retrieval and pre-processing of microarray data 
A broad range of microarray platforms are in use for the measurement of gene expression data.  
By far the most common microarray type in the datasets used by this project is the Affymetrix 
range of microarrays (see Appendices A, B, and C), in particular the Human Genome U133A 
and Human Genome U133A Plus 2.0 arrays; other platform types represented in the dataset 
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include Illumina BeadChip and Agilent SurePrint arrays.  While there should be general 
consistency amongst these different platform types (as evidenced by e.g. the work of the 
Microarray Quality Control Consortium117), platform effects may still be detectable between 
the different technologies125,126.  This is investigated further in Chapter 3.  No matter the 
platform, differential expression analysis of microarray data follows the same basic steps: data 
retrieval; pre-processing and normalization; and determination of significantly differentially 
expressed genes.   
As discussed in the Introduction, microarray data can be retrieved from public repositories such 
as Gene Expression Omnibus44 or ArrayExpress127.  The datasets used in this project were 
obtained from GEO, which has a number of associated R tools and also contains much of the 
data in ArrayExpress.  GEO records often contain both raw and pre-processed data.  Several 
different algorithms are available for pre-processing (which is required to convert the measured 
fluorescent intensities from each chip into comparable expression values), and in a comparative 
analysis setting it is therefore advisable to download the raw rather than submitter-supplied 
pre-processed data in order to exclude the possibility of bias resulting from different pre-
processing methods.   
Pre-processing methods are specific to each platform type: for Affymetrix data, the different 
pre-processing algorithms available include MAS-5.0, RMA, and gc-RMA.  RMA has several 
advantages over the older MAS-5.0 algorithm, namely less noise and variance at lower 
expression levels, and is the currently the most widely-used approach128, so I have used RMA 
for processing Affymetrix data.  The three steps of RMA are: background correction, which 
models the observed expression as a function of signal and noise; quantile normalization, which 
fits the expression values on the chip to the same distribution; and finally summarization of the 
log-transformed values using a median polish algorithm, which iteratively subtracts chip- and 
probe-level medians to estimate chip- and probe-specific errors.  Following this step, the 
measurements from each chip are comparable to each other, and further analysis can be 
undertaken. 
 
2.1.3 Generating a differential expression profile  
In the Introduction, I discussed differential expression analysis: the comparison of gene 
expression values between case and control samples, and the calculation of the magnitude and 
significance of the fold change value for each probe on the microarray.  The next step in 
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generating a differential expression profile is mapping of probes to their corresponding gene(s) 
using the platform-specific annotation files supplied by the manufacturer, which can be 
obtained from repositories such as GEO.  The relationship between probes and genes is not 
one-to-one.  There are several methods to resolve this relationship (which are detailed in a 
review by Ramasamy et al.129); a straightforward method adopted for this project is to retain 
the probes with the highest p-value in the case of multiple probes mapping to a gene, and to 
duplicate the probe information in the case of probes mapping to multiple genes.   
The final stage of differential expression analysis is to determine which genes are considered 
meaningfully differentially expressed.  This requires the choice of an appropriate threshold of 
fold change and/or significance; as mentioned in the Introduction, the use of these thresholds 
will vary depending on the particular experiment and the goals of the analysis.  Multiple testing 
correction is generally advisable in differential expression analysis of a single experiment, 
where a list of high-confidence differentially expressed genes with few false positives is the 
desired outcome.   
By contrast, this project involves the comparative analysis of many datasets, with highly 
variable profiles of significance.  For some of the studies used in this work, no genes remain 
significantly differentially expressed after Benjamini-Hochberg multiple testing correction (the 
default in limma) is applied: this is the case for 24 of 42 studies used in Chapter 3, 35 of 141 
studies used in Chapter 4, and 17 of 84 studies used in Chapter 5.  Rather than remove these 
studies from consideration entirely, I have applied a non-conservative significance cut-off of 
raw p < 0.05 to call differentially expressed genes throughout the dataset.  In the comparative 
analysis setting, it is the genes that are shared between datasets that are of interest, rather than 
each individual gene in a gene list.  The proportion of false positives is therefore less of a 
concern than in the analysis of a single experiment: a study which does not record any truly 
differentially expressed genes will likely not appear similar to any other experiment, and can 
be excluded from further consideration at this point.  
Following the approach recommended by the Microarray Quality Control consortium (which 
found that combining a non-stringent significance cut-off with log-fold change ranking 
generates gene lists of higher reproducibility compared to methods such as p-value based 
ranking130–132), this significance cut-off is combined with further gene selection based on log-
fold change magnitude.  In Chapters 3 and 5, the top e.g. 100 most significantly differentially 
expressed genes are considered; in Chapter 4, a combination of log-fold change magnitude and 
signalling network interactions is used to select ‘interesting’ genes.   
 40 
2.2 IDENTIFICATION OF SUITABLE MICROARRAY EXPERIMENTS 
This work relies entirely on the re-use of publicly available microarray data.  I used three main 
criteria for selecting suitable experiments from the Gene Expression Omnibus (GEO) 
repository: 
• The study must include (healthy) controls, in order to calculate differential expression.  
The definition of a control varies from study to study: in many studies, the control 
samples are from different individuals, but there are also studies where the control 
samples are non-affected tissues from the same individual (e.g. acne-affected skin vs 
non-acne-affected skin); in some studies, both contrasts are provided (e.g. lobular breast 
tumour samples vs non-affected lobular tissue from lobular breast carcinoma patients 
or vs non-affected lobular tissue from ductal breast carcinoma patients).  In the latter 
case samples from different individuals were used rather than ‘non-affected’ samples 
from the same patient, in order to avoid bias resulting from non-phenotypic gene 
expression changes that might be present even in apparently unaffected tissue. 
• There must be at least two samples per condition.  Whilst larger sample sizes are 
desirable for increased statistical power and reduction of biological noise, in the setting 
of large-scale comparative analysis the inclusion of a greater number of possibly noisy 
studies is preferable to fewer, more reliable studies, in order to increase the coverage 
of diseases in the dataset. 
• There must not be another study in the dataset submitted by the same investigator, in 
order to minimize the chance of overlap between datasets resulting from technical 
factors.  For Chapter 3 this criterion was relaxed to include only those studies submitted 
within a year of each other, in order to include as many Parkinson’s disease studies as 
possible.  This criterion was not applied to the drug response datasets used in Chapter 
4, as they are not compared against other studies. 
• Following the work described in Chapter 3, an additional condition in building the 
datasets used in the subsequent chapters was that the diseases must be recorded in 
human patients, rather than in animal models, and where possible they must be from 
whole tissues, rather than from cell lines.  A few cell line studies were included where 
no patient tissue studies were available, i.e. in rare disease studies. 
The Parkinson’s disease dataset used for Chapter 3 is detailed in Appendix A. 
The large dataset of common and rare diseases used for Chapter 4 is detailed in Appendix B. 
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A smaller dataset containing common diseases was used in Chapter 5, this is detailed in 
Appendix C. 
Metadata recorded from each experiment included the disease, the submitter and institution 
name, the microarray platform, the tissue sampled, the number of cases and controls, and the 
samples which were included/excluded.  Sample selection is necessary for studies which cover 
a number of different conditions, such as comparing two different types of arthritis to healthy 
controls; in this case only the relevant conditions were retained, and the other samples excluded 
from the analysis. 
An early version of the disease dataset was based on the work of Yasaman Kalantar Motamedi 
on text-mining of GEO records to identify suitable experiments.  However, as many of these 
experiments did not pass the above inclusion criteria, I chose instead to base my dataset on 
manual searching, which enabled me to find a higher number of datasets whilst applying strict 
quality control.  Those datasets discovered by her text mining approach that did pass the quality 
criteria after manual checks were retained. 
 
2.3 DEVELOPMENT OF AN AUTOMATED WORKFLOW FOR 
PROCESSING OF RAW MICROARRAY DATA 
The processing of large numbers of datasets requires a standardized system to convert raw CEL 
files from GEO into differential expression profiles with minimal manual input.  Given the 
large variety of microarray types (some of which occur only once in the dataset) and the need 
to specify e.g. the correct case-control designation of samples, a fully automated system for 
microarray data processing is not possible.  With these limitations in mind, I constructed a 
workflow that requires minimal input for most cases.   
The first part of the workflow (steps 1-4) takes the raw CEL files and calculates log-fold change 
and significance metrics for every probe on the microarray.  The second part of the workflow 
(steps 5-6) maps the probe-level data to their corresponding genes, in order to compare data 
across different microarray platforms.  All analyses were carried out in R version 3.3.2 running 
under OS X 10.11.6 (El Capitan)133.  
The protocol is as follows: 
1. Download the raw CEL files from GEO.  Delete any files that correspond to samples 
to be excluded. 
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2. Specify the design matrix corresponding to that particular experiment.  This indicates 
(in order of filename) which files are cases, i.e. disease samples, and which are controls, 
i.e. healthy samples.  The controls are designated as the reference (represented by 0), 
so that a positive log fold change indicates a gene that is more highly expressed in cases 
(represented by 1) than in controls. 
3. Read in the CEL files and rma-normalize them using functions ReadAffy and rma from 
the package affy134 (version 1.52.0).  
4. Determine probe-level statistics (including log-fold change, p-value, adjusted p-value) 
using the functions lmFit, eBayes, and topTable from the package limma53 (versions 
3.26.7-3.30.13 depending on when the analysis was carried out).  Statistics for all 
probes are retained by setting the parameter number = “LNF” (equivalent to setting to 
Inf). 
5. Retrieve the appropriate platform annotation file from GEO using the getGEO function 
from the GEOQuery package135 (version 2.40.0).  Match the probe IDs to their 
corresponding gene ID and symbol (using code from the online differential expression 
service integrated with GEO, GEO2R136). 
6. Where more than one probe maps to a gene, retain the probe with the smallest p-
value129.  Where a probe maps to more than one gene, duplicate the probe record, 
matching its information to both genes.  Remove any probes that do not map to a gene, 
as these are non-informative for cross-platform comparison. 
This describes the basic workflow constructed for Affymetrix arrays, which were the most 
common array type encountered in my dataset.  Variations of the workflow for other 
microarray types include the following: 
• Certain Affymetrix ST arrays cannot be processed by the affy package, in which cases 
the oligo package137 (version 1.38.0) was used in step 3.  
• For experiments that used Illumina platforms, the submitter-supplied non-normalized 
data was obtained from GEO, and step 3 was replaced by log-transformation and 
quantile-normalization (for consistency with the steps used in the Affymetrix-specific 
RMA normalization method).   
• For the few experiments which used other platforms such as Agilent arrays, or where 
raw data was not provided, submitter-supplied normalized data was processed using 
GEO’s web service GEO2R136 in place of steps 1-5.   
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Additional processing steps that can be applied to further reduce noise in microarray data 
include array quality-checking to remove aberrant or outlier arrays; variance filtering to 
exclude those genes which show low variance across all experiments; and batch correction to 
account for the effects of sample handling and processing across different experimental 
batches.  Batch correction was not considered for this analysis, as GEO records do not generally 
supply experimental batch information.  It is possible to use the microarray scan date as a 
potential source of batch effects, but given the potential for sample clustering across these 
batches (e.g. all disease samples scanned on one date, all controls scanned on another), batch 
correction risks normalizing out biological signal and is therefore not appropriate in this setting. 
Variance filtering and array quality checking methods were tested on the dataset described in 
Chapter 3, as this was the first piece of work undertaken and provided a simple metric with 
which to test the utility of various methods in the comparative analysis setting: a ‘useful’ 
method should increase the concordance between two studies of the same disease.  Variance 
filtering was carried out using the package genefilter138 (version 1.56.0) and array quality 
checking was carried out using the package ArrayQualityMetrics139, version 3.30.0.  These 
were found to make almost no difference to the observed concordance between studies of 
Parkinson’s disease.  Variance filtering was therefore not applied, in order to retain the 
maximum number of genes for comparison between experiments; the results of array quality 
checking were retained for the Parkinson’s disease dataset (see description in Section 3.2.2) 
but were not applied to the larger dataset, as with such a large volume of datasets to process 
this would involve a significant amount of manual work for potentially very little benefit.  
Whilst these steps may be valuable for the analysis of individual datasets, for these reasons I 






3 CONCORDANCE OF MICROARRAY STUDIES 
OF PARKINSON’S DISEASE 
 
This work was previously published as Oerton E, Bender A. Concordance analysis of microarray studies identifies 
representative gene expression changes in Parkinson’s disease: a comparison of 33 human and animal studies. 
BMC Neurol. 2017;17(1):58. doi:10.1186/s12883-017-0838-x. 
 All analyses, text, and figures were produced by the author, incorporating comments from co-authors. 
 
SUMMARY 
The reported lack of concordance between transcriptomic studies of the same condition raises 
questions about the representativeness of different study types, such as studies of surrogate 
tissues or animal models, to gene expression in the human disease.  In a comparison of 33 
microarray studies of Parkinson’s disease, correlation and clustering analyses were used to 
investigate concordance between studies, including agreement between different tissue types, 
different microarray platforms, and between disease models and human Parkinson’s disease.   
Concordance over all studies is low, with correlation of only 0.05 between differential gene 
expression signatures on average, but increases within human patients and studies of the same 
tissue type, rising to 0.38 for studies of the substantia nigra region of the human brain.  Studies 
of the substantia nigra in Parkinson’s disease patients form a distinct group, showing patterns 
of differential gene expression noticeably different from that in non-brain tissues and animal 
models of Parkinson’s disease.  A meta-analysis of these 33 microarray studies demonstrates 
the greater ability of studies in humans and highly-affected tissues to identify expression 
changes in genes previously known to be associated with Parkinson’s disease.  
The observed clustering and concordance results suggest the existence of a ‘characteristic’ 
signal of Parkinson’s disease found in significantly affected tissues in humans.  These results 
help to account for the consistency (or lack thereof) so far observed in microarray studies of 
Parkinson’s disease, and act as a guide to the selection of transcriptomic studies most 
representative of the underlying gene expression changes in the human disease. 
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3.1 INTRODUCTION 
Parkinson’s disease (PD) – a neurodegenerative disorder which causes the death of 
dopaminergic neurons in the substantia nigra, causing tremors and postural instability – has 
been well-studied at the level of gene expression, with numerous microarray studies available 
in public repositories.  However, the concordance of differential gene expression between these 
studies has been reported to be low, even when standardized analysis is applied140–143.  The 
observed discordance may result from multiple factors, including differences in the progression 
of the disease at time of post-mortem142 and differing amounts of neuronal loss between the 
substantia nigra (SN) and other regions of the brain.  Several meta-analyses of PD gene 
expression in human patients have been carried out73,140,143 on datasets of up to 14 unique 
studies.  Although meta-analyses generally focus on the commonalities between studies (in 
order to identify the genes most relevant to the condition under study), meta-analysis 
approaches can also be used to shed light on inconsistencies between studies.  For instance, 
one such analysis of 11 human PD microarray studies highlighted tissue-specific differences 
between studies, demonstrating increased convergence within studies using samples from the 
SN140.  
Also demonstrated by an early microarray study of PD144 is the difference between animal 
models of PD (reviewed in Blesa et al.145) and the human condition, which is of much practical 
relevance for therapeutic research.  These models were developed to mimic the clinical 
symptoms of Parkinson’s disease, and it is unclear to what extent the underlying patterns of 
gene expression will reflect those that take place in human PD.  Studies comparing disease 
models to human patients have reported conflicting results: one study examined the consistency 
of gene expression between a mouse model of colorectal liver metastasis and human 
specimens, and found an overlap of 35% of differentially expressed genes, as opposed to 44% 
in normal liver tissue146.  Another study of mouse models of inflammation found little 
transcriptomic agreement between human inflammatory conditions and their murine 
counterparts147, although a re-analysis of this data using different statistical methods questioned 
this conclusion148.  As the use of transcriptomics becomes more prevalent in medicine and drug 
development, it is important to establish whether gene expression in a model system can be 
treated as a proxy for gene expression in the human condition.  
Choice of microarray platform is another factor that can affect concordance between studies.  
Notably, although some studies have reported good cross-platform reproducibility117,149, an 
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early study of a mouse model of PD found very little concordance between Affymetrix and 
CodeLink platforms150.  More recent studies in psoriasis151 and in healthy tissues119 still found 
detectable platform biases, indicating that this issue will not necessarily be resolved by the use 
of newer microarray technologies.  The effect of sample size on study concordance should also 
be considered.  Multiple studies have found that larger sample sizes in microarray experiments 
allow greater confidence in calling differentially expressed genes and produce more robust 
differentially expressed gene lists130,152,153, but the effect of sample size in the context of 
average concordance across different datasets – i.e., the likelihood of being an unrepresentative 
‘outlier’ study – has not been examined directly.   This question is particularly important in the 
study of neurodegenerative diseases such as PD, given that large numbers of high-quality brain 
tissue samples are not always easy to obtain154,155.  
The concordance between different studies of the same condition will act as a measure of 
‘representativeness’ of the recorded gene expression to true human PD, helping to establish 
whether animal models of disease are representative of the human condition at the 
transcriptomic level, and whether gene expression in more easily accessible surrogate tissues 
could be useful in PD research or diagnostics156.  In this chapter, the effects of four factors – 
species, tissue, platform, and sample size – are analysed in relation to the observed 
inconsistency between microarray studies of PD.  As well as the specific findings related to 
PD, the general findings from this work will serve as a basis for study selection in the datasets 




3.2.1 Obtaining Parkinson’s disease microarray studies 
GEO was searched for suitable case-control studies of Parkinson’s disease using combinations 
of PD keywords, i.e. "Parkinson's"/"Rotenone"/"MPTP" [rotenone and MPTP are neurotoxins 
used to model PD in animal studies] AND "homo sapiens"/"mammals"/"primate", using 
studies submitted up to February 2017.   
Inclusion/exclusion criteria were as follows: 
• Studies must be designed specifically for the investigation of PD or PD drug treatment. 
• At least two Parkinson’s disease (or equivalent model) samples and two healthy (wild-
type/vehicle injected) control samples must be available for each condition. 
• Gene expression must be measured using microarray technology, as too few studies are 
currently available on GEO using other methods of expression profiling (e.g. RNA-
Seq) to be able to draw any conclusions about their use in PD.   
• Human stem cell studies must be derived from PD patients and not just modelled by 
PD-associated mutations, in order to be comparable with human PD; equivalently, stem 
cells derived from PD patients compared to mutation corrected controls were excluded. 
In order to minimise the impact of possible laboratory effects on concordance results, where 
multiple datasets were contributed by the same investigator and less than a year apart, only one 
of the two was retained (with the exception of two studies submitted as part of a meta-analysis 
that did not state whether the studies originated from the same experimental group, see 
Appendix A).  Similarly, if a single study analysed multiple tissues, only one tissue was 
retained for analysis.  In both cases, the retained study was chosen in order to provide the most 
balanced dataset; i.e. the most even split between tissues. 
This gave a total of 33 PD studies.  Four studies of Alzheimer’s disease and five studies of 
brain tumours (glia- and astrocyte-derived) were included as disease controls, giving a total of 
42 studies (see Appendix A).  These studies were analysed in Section 3.3.6.   
 
3.2.2 Processing of datasets 
Following pre-processing and generation of a differential gene expression profile as described 
in Section 2.3, array quality was assessed using the ArrayQualityMetrics package139, version 
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3.30.0; any samples which failed more than one of the three outlier tests (distances between 
arrays; boxplots; MA plots) were removed.   
In order to make comparisons between gene expression in different species, all non-human 
studies were mapped to orthologous human genes using annotationTools 1.44.0157.  As stated 
in Section 2.3, where a probe was associated with multiple genes, the probe information was 
retained for both genes in order to maximise the number of genes available for comparisons 
between different platforms, and it should be noted that this could artificially inflate 
concordance between studies, especially for those using the same platform.  
 
3.2.3 Biological pathway enrichment 
Biological pathway enrichment profiles were calculated from the differential gene expression 
profiles (generated above) against the Reactome pathway database with the GSEA function of 
the Bioconductor package ReactomePA 1.14.471, using the default settings of 1000 
permutations to calculate significance and a minimum geneset size of 10.   For mouse and rat 
studies, the original (animal) genes were used to calculate enrichment profiles using species-
specific pathways provided by Reactome.   
 
3.2.4 Calculation of pairwise concordance of differential gene expression 
The ‘agreement’ between two microarray studies can be measured in many different ways, 
including comparison of lists of genes which are differentially expressed according to some 
cut-off (which can be published lists, or lists created by standardized analysis of published 
data)140,141,144, comparison of ranked expression values (e.g. Spearman correlation)111,158, and 
agreement of sign and/or magnitude of measured gene expression (e.g. Pearson 
correlation)151,159, either over all measured genes, or over those defined as significant by some 
cut-off.  These are reviewed in a 2009 paper by Lu et al.160. 
In this analysis, concordance between studies is defined as the Pearson correlation (as 
calculated by R’s cor function161) of their differential gene expression signatures: an 
expression signature is here defined as the 50 genes showing the highest absolute log-fold 
change at a significance of p<0.05 in each study, from the set of 2,372 genes recorded by all 
33 PD studies, or 2,310 over all 42 studies of brain disease.  Similar concordance results were 
obtained when the expression signature was defined over 20, 100, or 250 genes for each study; 
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a value of 50 was chosen in order to capture the most relevant information while keeping the 
dimensionality relatively low (important in the following analyses).  If correlation was 
calculated over the sign of the log-fold changes (i.e. considering only the direction and not the 
magnitude of fold changes), similar results were obtained; concordance in the SN was 
somewhat reduced from 0.3 to 0.22, but was still the highest-concordance tissue type, and so 
the measured log-fold change magnitudes were used in order to retain information.   
 
3.2.5 Calculation of pairwise concordance of biological pathway 
enrichment 
At the biological pathway enrichment level, pairwise concordance cij between two studies was 
defined as the Pearson correlation of the normalized enrichment scores (NES) of pathways that 
are significantly up- or down-regulated (at an FDR <0.25, as recommended by the Broad 
Institute’s GSEA page162) in either experiment.  In the case where a pathway is significant in 
one experiment but there is no score reported in the other, a NES of 0 was assigned for the 
missing pathway.  If no significantly enriched pathways were reported for either experiment, 
the correlation was set to 0.  The Pearson correlation is the most appropriate correlation 
measure to use given the high proportion of zeros amongst the normalized enrichment 
scores163. 
 
3.2.6 Calculation of average concordances within subsets of studies 
The mean of the pairwise concordances cij of a study i with every other study j in a set of studies 
S gives a measure Ai of how well this study agrees with other studies in S.  From the average 
agreement of each individual study, the average agreement AS in a set can be measured (i.e. AS 
is the average of each Ai).  In this case, S is a subset of studies chosen to represent a particular 
factor of experimental design, such as the subset of studies using human specimens or the 
subset of studies run on a particular microarray platform, and the basis of this analysis is the 
comparison of AS between these different subsets, specifically for subsets in which three or 
more studies share one of the experimental factors tissue, species, platform, or sample size.  
These four factors were chosen to analyse as they are nearly always specified in study meta-
data, and such can be quickly determined in a meta-analysis context. 
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Note that smaller subsets may have larger numbers of shared genes, (e.g. due to sharing a 
platform which measures the same genes).  Concordance over smaller subsets was calculated 
on the same expression signatures as for the set of all studies, i.e. expression signatures selected 
from the shared 2,372 genes, in order to ensure that AS was not biased by the size of shared 
gene-sets in different subsets.   If concordance was calculated over the full set of genes shared 
by each subset, results were not substantially different (see Appendix F). 
Significance of average subgroup concordances was tested against the average concordances 
over randomly sampled subgroups of the 33 PD studies (to a maximum of 100,000) of each 
size.  An observed average correlation is defined as significant if it is greater than the 95th 
percentile value.  The smaller the subgroup size, the more likely that randomly chosen 
subgroups show high concordance by chance alone (the distribution of observed correlations 
is wider), and so the confidence threshold is higher for smaller subgroups (see Appendix E).  
 
3.2.7 Principal component analysis and hierarchical clustering 
Hierarchical clustering was performed using R’s hclust function164 using correlation distance.  
Correlation distance was chosen over the default Euclidean distance because it is not affected 
by scale (e.g., differences in average log fold change magnitude across experiments)165. 
Significance of the observed clusters was calculated using the R package pvclust166, which uses 
multiscale bootstrap resampling to approximate a probability value for each observed cluster 
(probability values quoted are the Approximately Unbiased values). Principal component 
analysis was performed using R’s prcomp function with centering and scaling167. At the 
differential gene expression level, the feature vector for each study was defined as its log-fold 
change values over the gene-set defined by the union of the 50 highest-ranking genes (the union 
of expression signatures; i.e. the 50 genes in each study at a significance of p<0.05 with the 
highest absolute log-fold change in every study in the set) – for the PD studies, this is 1,008 
genes.  For hierarchical clustering, where high dimensionality affects the stability of clusters, 
this was reduced to the union of the top 10 highest-ranking genes, which for the PD studies is 
258 genes.    
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3.2.8 Meta-analysis of Parkinson’s disease microarray studies 
A meta-analysis over the 33 PD studies was carried out using a ‘vote-counting’ approach in 
which a gene was deemed to be of importance in a study if it was in the top 50 genes by absolute 
log-fold change, at a significance of p<0.05.  A gene was deemed to be significant by the meta-
analysis if it was considered to be of importance by more than three studies.  This threshold 
was chosen due to the low agreement between studies (see Results).  The results of the meta-
analysis were compared against a list of 694 PD-associated genes downloaded from the Centre 
for Therapeutic Target Validation (CTTV)168 on 8th March 2016.  Note that this resource was 
an early version of the OpenTargets platform169 used in Chapter 4.  The list includes genes 
identified by genetic associations, by PD drugs, and by text-mining; targets identified through 
reprocessing of previous RNA expression studies were excluded, as the studies used in the 
CTTV analysis could potentially overlap with those used here.  Similar results (in terms of the 
proportions of genes identified by each subgroup) were obtained when the meta-analysis was 
carried out over the top 10 or top 100 genes instead of the top 50.  
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3.3 RESULTS 
3.3.1 Higher concordance within human studies and within tissue groups 
 





The mean average pairwise concordance of differential gene expression signatures (i.e. the 
Pearson correlation over the top 50 genes by absolute log fold change, see Methods) over all 
33 Parkinson’s disease studies was 0.05 (Fig 1), indicating little agreement between different 
studies.  To identify how much of the observed inconsistency is due to differences in species, 
tissue, or microarray platform, concordance was examined within subgroups of studies that 
shared these characteristics (Table 3.1, Figure 3.1). 
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Table 3.1 Average concordance of differential gene expression signatures in 
microarray studies.   
Asterisks	 indicate	 subgroups	 where	 concordance	 significant,	 i.e.	 is	 within	 the	 top	 5%	 of	
concordance	 values	 over	 randomly	 sampled	 subgroups	 of	 PD	 studies.	 	 The	 threshold	 for	
significance	varies	with	the	number	of	studies	in	the	subset	(see	Methods,	Appendix	E).		




Whole dataset   
PD studies plus Alzheimer’s disease and 
glioblastoma studies 
42 0.04 
All PD studies 33 0.05 
Species 
    Human (inc. human cell lines) 19 0.08 
        Human patients 15 0.15* 
    Mouse models 9 0.03 
    Rat models  4 -0.04 
Disease model 
    All neurotoxic models  12 0.03 
        MPTP 6 0.09 
            MPTP, mice only 5 0.10 
        6-OHDA 4 -0.03 
    Genetic models 3 0.12 
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Tissue 
    Basal ganglia (SN (excluding isolated 
dopaminergic neurons) and striatum) 
18 0.11* 
        SN: tissue 8 0.30* 
        SN: isolated dopaminergic neurons 4 0.03 
        Striatum  9 0.07 
Platform 
    Affymetrix 27 0.06 




The first factor to be examined was species.  The average concordance of differential gene 
expression signatures increased from 0.05 over all PD studies to 0.15 in human in vivo studies.  
In the subset of mouse studies, however, average concordance of differential gene expression 
decreased compared to the full dataset, at 0.03, and average concordance within the three rat 
studies was actually negative.  This could be explained by the use of different disease models 
with distinct effects on gene expression: concordance within the MPTP and genetic models of 
PD was 0.09 and 0.12 respectively; although there was negative concordance between studies 
in the 6-OHDA group (Table 3.1).  
The next factor considered (independently of species) was the tissue type sampled.  Limiting 
the studies under consideration to those of an area highly affected in PD, the basal ganglia (here 
including studies of the striatum and the substantia nigra, which is functionally part of the basal 
ganglia), increased average gene-level concordance from 0.05 to 0.11, while further limiting 
the studies to just those of the substantia nigra yielded a substantial increase to 0.30 (Figure 
3.1).  This result is in agreement with a previous meta-analysis140, which also reported an 
increase in concordance when the analysis was confined to studies of the substantia nigra.  
Concordance within striatal studies was lower than that over all tissues of the basal ganglia at 
0.07; however, tissue selection was strongly associated with species, with substantia nigra 
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studies tending to be from humans (6 of 8 studies) and striatal studies tending to be from animal 
models (8 of 9 studies), and so the lower concordance within the striatal group perhaps reflects 
the general lower concordance between animal models.  To deal with issues of species 
dependence in tissue choice and other experimental parameters, the following subgroup 
analyses focus on human studies.   
 
3.3.2 High concordance of biological pathway enrichment in human PD 
Given the low average concordance of differential gene expression, correlation was also 
calculated at the level of biological pathway enrichment (see Methods).  As pathways are a 
higher-level biological concept, capturing concerted changes in gene expression, pathway 
enrichment might be expected to reveal higher concordance between studies, as previously 
shown in Sutherland et al.140  Whilst the concordance values at the pathway level are not 
directly comparable to those at the gene expression level (due to the differing feature vectors 
used), biological pathway enrichment demonstrated relatively good agreement across human 
studies, from 0.22 over all human patient studies to 0.3 over studies of human brain tissue, 
indicating that measured differential expression reflects the activation of similar biological 
processes (Figure 3.2; see Appendix G for a list of significant pathways).  In animals, in 
contrast to human studies, concordance at the pathway level was in most cases actually lower 
than that at differential expression level (Table 3.2).  One reason for this may be incomplete 




Figure 3.2 Average concordance within subgroups of human studies of PD 
Gene-	and	pathway-level	concordance	 increases	 in	studies	of	human	patients	 (i.e.	excluding	
human	cell	line	studies)	and	within	tissue	subgroups.		The	trend	seen	at	the	level	of	differential	




Table 3.2 Concordance results for different subgroups using biological pathway 
enrichment analysis	
Pathway-level	 concordance	 in	 human	 studies	 reflects	 the	 patterns	 seen	 at	 the	 level	 of	
differential	gene	expression	concordance;	in	animals,	by	contrast,	pathway-level	concordance	
is	lower	and	does	not	increase	by	model	type.	





Whole dataset   
PD studies plus Alzheimer’s disease and 
glioblastoma studies  
42  0.05  
All PD studies  33 0.08 
Species  
    Human PD  19  0.15  
        Human PD, in vivo studies only  15  0.22  
    Mouse models  9  0.01  
    Rat models  4  -0.10  
Disease model  
    All neurotoxic models  12  0.02  
        MPTP   6   0.03  
            MPTP, mice only  5  -0.02  
        6-OHDA  4  -0.01  
    Genetic models  3   -0.02  
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Tissue  
    Basal ganglia (SN (excluding isolated 
dopaminergic neurons), striatum, globus 
pallidus)  
18  0.10  
        SN: tissue  8  0.24  
        SN: isolated dopaminergic neurons  4  0.01  
        Striatum  9  0.00  
Platform  
    Affymetrix  27  0.09  
        U133 and U133 Plus arrays (human 
studies only)  
12  0.21  
 
3.3.3 Microarray platform type has little effect on average concordance of 
human PD studies  
The next factor examined was the effect of microarray platforms, which are intended to be 
species-specific (one macaque study run on the U133A platform was excluded from this 
analysis).  There was a very slight concordance increase when selecting for platform types, 
from 0.08 over all 19 human studies to 0.09 over all Affymetrix platforms (15 studies) and 0.10 
for those studies run on the most common platform types in the dataset, the Affymetrix U133A 
and U133 Plus 2.0 series (12 studies).  It should be noted that although the U133 microarrays 
are distinct platforms, they are technically very similar, as the probe set of the U133A arrays 
represents a non-random subset of the U133 Plus 2.0 arrays151, and so are considered as a single 
platform type for the purpose of this analysis.  At the pathway level, the concordance increase 
within the U133 subgroup was much larger (Figure 3.2), and this may reflect the effect of a 
shared probeset in calculating pathway enrichment profiles, as the gene-set enrichment used 
here takes into account the expression of every measured gene.  
 59 
3.3.4 Smaller PD studies do not show lower concordance of differential 
gene expression  
The next factor examined was the study sample size.  When the smallest 25% of human studies 
(five studies with sample sizes of less than 10) were excluded, concordance within the 
remaining larger studies increased slightly from 0.08 to 0.11 at the differential gene expression 
level and from 0.15 to 0.17 at the pathway level.  Linear regression was then used to test 
whether there was an overall association between sample size and average concordance across 
all (human) datasets.  There was no significant relationship between sample size (case plus 
control) and average concordance of differential gene expression signatures or of biological 
pathway enrichment (Figure 3.3), suggesting that smaller studies are no more likely to be 




Figure 3.3 Average concordance against sample size for gene expression and 




3.3.5 Visualizing the gene expression landscape of PD studies reveals a distinct subset of human studies 
 
	






The relationships between studies in differential gene expression space (here defined as the 
1,008 genes in the union of expression signatures across all studies; see Section 3.2.7) were 
visualised using principal component analysis (PCA, Figure 3.4).  PCA enables representation 
of the 1,008-dimensional expression signature space in a lower-dimensional space which 
captures the greatest amount of variance amongst studies170.  The visualization of samples in 
this space shows an outlying group of human studies which appear distinct from other human 
and animal studies (Figure 3.4). This is most clearly seen in the second and third principal 











The principal component plots in Figure 3.4 show several studies which are outliers in principal 
component space, which may result from high average log-fold change magnitudes.  One way 
to address this is to perform PCA on the sign of the differential expression signatures, 
discarding the magnitude information.  These plots should be interpreted with caution, as they 
force the assignment of directionality to even very small gene expression changes, but the 
advantage is that the outlier effect is removed, allowing clearer visualisation of the separation 











To further examine the distinct group of human studies seen in Figure 3.4, hierarchical 
clustering was performed over the 258 genes in the union of the top 10 most differentially 
expressed genes over all 33 studies (Figure 3.6; see Appendix H for list of 258 genes). This 
shows a distinct cluster composed mainly of human studies of the substantia nigra (the most 
highly-affected tissue in PD) and studies of the cerebral cortex (SFG and PFC-Brodmann area 
9)171,172 (which are also affected in PD, although the cortex is affected at a later stage of 
disease173).  The bootstrap probability value of the highlighted cluster (see Section 3.2.7) is 
0.99, indicating that this cluster remains highly stable under resampling of the dataset.  A 
heatmap of the differential expression signatures (Figure 3.7) reveals that studies in this cluster 
share downregulation in a set of genes which are enriched for the Panther pathway ‘synaptic 
vesicle trafficking’ (the pathway enrichment method used here is described in Section 4.2.6).  
It should be noted that a sixth study of the substantia nigra, which was run on an Agilent 
platform (all other studies were run on Affymetrix platforms), does not cluster with the others, 
showing a distinct differential expression pattern in which the majority of genes are up-
regulated (Figure 3.7). 
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Figure 3.7 Heatmap of differential expression in Parkinson’s disease studies  
Green	 represents	 upregulated	 genes,	 red	 represents	 downregulated	 genes.	 	 The	 heatmap	




The clustering in Figure 3.6 uses average linkage; when complete linkage is used, the six SN 
studies form a cluster on their own (bootstrap probability value 0.96), indicating that there are 
also expression patterns which are specific to the SN and not shared by the frontal cortex or 
dopaminergic neuron samples.   
Other clusters that can be seen include 4 of the 6 MPTP models of PD, 3 of the 4 studies in 
blood, and clustering of iPSC studies with the appropriate tissue (dopaminergic neurons) or 
model (genetic animal models), although bootstrap probability values of these clusters are less 
than 95%, indicating a less stable clustering.  Otherwise, there is no clear effect of any factor 
(such as microarray platform or treatment with L-DOPA) on study distribution within the 
clustering, reflecting the low concordance seen in these groups.  Concordance in microarray 
studies of PD may therefore be partly explained by the different gene expression signals present 




3.3.6 Differential gene expression in human tissues highly-affected in PD 
is distinct from other brain diseases 
  
  
Figure 3.8 Principal component analysis of differential gene expression in Parkinson’s 
disease, Alzheimer’s disease and brain tumour studies 
Top	row:	PCA	based	on	differential	expression	over	the	1,152	genes	in	the	union	of	42	expression	
signatures	(including	AD	and	tumour	studies).		Bottom	row:	PCA	based	on	sign	of	differential	
expression	 (discarding	 the	magnitude)	 over	 these	1,152	genes.	 	 The	 tumour	 studies	appear	
highly	 distinct	 from	 AD	 and	 PD	 studies	 in	 the	 principal	 component	 representation	 of	 gene	
expression	space.		Even	if	only	the	sign	of	differential	expression	is	taken	into	account	(bottom	
row),	 the	 tumour	 studies	 appear	 at	 the	 outer	 edges	 of	 the	 second	 principal	 component,	
suggesting	highly	distinct	patterns	of	gene	expression	in	the	two	disease	groups.		By	contrast,	




In order to examine the disease specificity of gene expression in PD, PD studies were compared 
with studies of other diseases – namely Alzheimer’s disease (AD), a neurodegenerative 
disorder which can present similar pathology to PD172, and brain tumours (glioma), which are 
clinically unrelated to PD.  As before, PCA was used to provide a low-dimensional 
visualisation of the separation of samples in differential expression space (Figure 3.8); the first 
three principal components here represent 42% of the variance.  When magnitude of 
differential expression is taken into account, the cancer studies vary mostly across the first and 
third principal components, whilst the AD and PD studies vary across the second principal 
component, suggesting highly distinct patterns of gene expression in cancer compared to in the 
neurodegenerative diseases.   
When only the sign of differential expression is taken into account (removing variation due to 
different magnitudes of expression changes, in order to focus on the general patterns of 
regulation), the cancer studies still appear distinct from the AD and PD studies, here showing 
the greatest variance across the second principal component.  Interestingly, the cancer studies 
here split into two groups – one containing studies of human cerebellum, human whole brain, 
and mouse whole brain; the other containing studies of human blood and murine dorsal brain 
run on an Illumina platform – which appear at opposite edges of the second principal 
component.  This means that when the magnitude information is discarded, there is greater 
variation within the cancer studies than between the cancer studies and the neurodegenerative 
diseases.   
In all PCA plots, the AD studies appear less distinct from those of PD.  The separation between 
human and animal studies seen in PCA of the PD studies only (Figure 3.4, Figure 3.5) appears 
reduced in this plot, illustrating that the variation between tumours and neurodegenerative 
diseases is much greater than the variation between human and non-human neurodegenerative 
diseases. 
The relation between these studies can be further examined by clustering based on differential 
expression across the union of the top ten genes in all studies (as above).  Interestingly, this 
plot shows one of the groups of tumour studies clustering near to the group of human substantia 
nigra studies (Figure 3.9).  Examination of the heatmap reveals that their overall gene 
expression patterns are different, but that they share down-regulation in a cluster of genes at 
the bottom of the heatmap; pathway analysis reveals the Panther pathway ‘synaptic vesicle 
trafficking’ and GO biological process ‘dopamine metabolic process’ to be significantly 
enriched in these genes.  A fourth tumour study taken from a blood sample clusters together 
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with all but one of the other blood-based studies on the outer edge of the heatmap, suggesting 
that blood displays overall different gene expression patterns from brain tissue, although the 





Figure 3.9 Heatmap of differential gene expression in Parkinson’s disease, 
Alzheimer’s disease, and brain tumour studies   
The	heatmap	illustrates	differential	expression	across	the	315	genes	in	the	union	of	the	top	10	
most	 differentially	 expressed	 genes	 over	 all	 studies	 (see	 Appendix	 I	 for	 rownames).	 	 The	








3.3.7 Inclusion of non-human and non-nigral tissue studies reduces the 
percentage of Parkinson’s disease-associated genes identified in a 
meta-analysis  
A key aim of this study is to determine whether gene expression in surrogate tissue (i.e. non-
brain tissue) or in animal models of disease is reflective of gene expression in the brain of a 
human patient.  In order to establish this, a meta-analysis was carried out across different 
subgroups of studies, where a gene was deemed to be significant if it was included in the top 
fifty most highly differentially expressed genes in more than three studies (this vote-counting 
methodology was chosen due to the low agreement between studies).  The results of the meta-
analysis were compared with a list of 694 potential PD-associated genes downloaded from the 
Centre for Therapeutic Target Validation168.  These genes were selected on the basis of 
previous association with PD through genetic, drug target, or text-mining association (see 
Section 3.2.8) and represent numerous pathways including those involved in signal 
transduction (such as RAF/MAP kinase cascade and G alpha and AKT signalling events) and 
the immune system (such as interleukin-1 signalling and proteasome degradation).   
 
Table 3.3 Genes highly differentially expressed in multiple Parkinson’s disease studies 
Table	shows	the	number	of	times	a	gene	is	in	the	top	50	genes	by	absolute	log-fold	change	in	
each	study.	
Gene All studies Human studies Studies of the SN 
Up-regulated 
HSPA1A 4 3 3 
RELN 4 4 3 
PTPRC 3 2 0 
LCN2 3 0 0 
PLIN4 3 0 0 
MAFF 3 2 2 
SLCO4A1 3 3 2 
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HSPA1B 3 3 3 
IGF2BP2 3 0 0 
CDKN1A 3 0 0 
ENC1 3 2 1 
Down-regulated 
EGR2 6 0 0 
FOS 5 2 1 
RGS4 5 5 3 
TAC1 5 4 3 
SLC6A3 4 3 3 
AGTR1 4 4 3 
FGF13 4 3 4 
PCSK1 4 3 2 
NPTX2 4 1 1 
GABBR2 4 3 2 
NR4A2 4 3 4 
EIF1AY 3 2 2 
SATB2 3 0 0 
RET 3 1 2 
SNCA 3 3 0 
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TTR 3 0 0 
CCK 3 0 0 
DDC 3 3 3 
SLC18A2 3 3 3 
ALDH1A1 3 3 3 
KCNJ6 3 2 2 
TMEM255A 3 3 3 
SCG2 3 3 3 
GPR26 3 2 3 
DCLK1 3 2 0 
DUSP1 3 2 1 
HPCAL4 3 2 1 
SYNGR3 3 3 2 
PREPL 3 3 0 
STMN2 3 3 2 
VSNL1 3 3 2 
NTS 3 2 3 
 
The overall agreement in differentially expressed gene lists over all 33 studies was low, with 
no gene consistently differentially expressed in more than 6 studies (Table 3.3).  Even if larger 
expression signatures including the top 100, 250 or even 500 most highly dysregulated genes 
(of a total 2,372 shared genes) were used, the findings were not much different, with no gene 
consistently regulated in more than 6, 8, and 10 studies respectively.  The most common 
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findings shown in Table 3.3 include significant downregulations in genes including 
ALDH1A1, TTR, TAC1, and solute carrier genes SLC18A2 and SLC6A3, and upregulation 
of the heat shock protein genes HSPS1A and HSPS1B in multiple studies.  This is consistent 
with the findings of a previous meta-analysis140 of human datasets, who reported concordance 
as low as ‘20 genes… consistently differently regulated across 6 of 13 datasets’, whilst 
cautioning that the downregulation seen in DDC and other genes could be the result of ‘a 
disproportionate number of SN dopaminergic neurons between cases and controls’.  Other 
findings include downregulation of FOS, which is more commonly associated with 
overexpression following L-DOPA treatment, in two animal (non-L-DOPA treated) and one 
human experiments.  SNCA is also downregulated in multiple human studies, which previous 
studies have suggested may be related to long post-mortem intervals in PD cases174.  
Over all data sets, 26% of the 43 genes called significant by the meta-analysis (Table 3.3) were 
included in the list of previously PD-associated genes.  If the meta-analysis was limited to 
human studies, however, 36% of the 22 significant genes had previous evidence of association 
with PD (Figure 3.10).  The inclusion of non-human studies therefore reduced the enrichment 
of PD-associated genes in the list, i.e. the likelihood of each identified gene having a previously 
evidenced association with PD is lower.  If the meta-analysis is limited to just animal models 
of PD, this was reduced to 10% of the 10 significant genes.  There was a similarly noticeable 
difference between studies of different tissues.  32% of the 28 genes considered significant in 
a meta-analysis of the 18 basal ganglia studies (here including studies of the substantia nigra 
and striatum, excluding those which considered isolated dopaminergic neurons from the SN) 
had been previously associated with PD, and increasing to 40% when only substantia nigra 
studies were considered (Figure 3.10), suggesting that gene expression changes in these tissue 
types capture genes and gene products highly relevant to PD.  
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Figure 3.10 Percentage (bar) and number (number above bar) of potential PD targets 
amongst genes considered significant by a meta-analysis in each grouping 
Gene	lists	from	human	studies	and	studies	using	tissue	from	the	basal	ganglia	(here	including	
studies	of	the	striatum	and	substantia	nigra)	are	more	enriched	for	genes	and	proteins	that	






The low concordance between microarray studies of Parkinson’s disease echoes recent 
concerns about the reproducibility of microarray studies between different labs111,119,140,151 and 
between humans and animal models144,146–148,175.  This study aimed to determine the major 
factors of study design influencing the observed lack of concordance.   
The results presented here confirm that the differences between human studies and model 
systems, and between tissues, are larger than those caused by other experimental factors such 
as microarray platform or sample size (Figure 3.1, Figure 3.2, Figure 3.4). This analysis seems 
to indicate a split between human brain tissues and other study types (animal models and human 
studies of other tissues, including isolated dopaminergic neurons).  It is possible that these 
human brain studies, particularly studies of the human substantia nigra, reflect a distinct 
‘characteristic’ transcriptional signature specific to human PD; whereas the non-human studies 
and human studies of non-brain tissue reflect other, more general disease-associated molecular 
changes that take place in multiple tissues and systems (Figure 3.7).  The inclusion in the 
‘characteristic’ group of tissues affected later in the disease e.g. frontal cortex173 (Figure 3.6) 
is noteworthy – given the progressive nature of PD, the late-affected tissues may display a 
signal of the early stages of neurodegeneration, which may be masked in the substantia nigra 
by the extent of cell death in this region at the time of post-mortem, as suggested by Sutherland 
et al.140   
Although there are large differences between the results from animal models and human 
studies, it is encouraging to note that animal models (both genetic and neurotoxic) are not 
completely separated from human neurodegenerative disease in differential gene expression 
space (Figure 3.4, Figure 3.5).  In particular, one of the two animal models sampling tissue 
from the SN appears very similar to human studies in hierarchical clustering (Figure 3.6).  It is 
possible that these simply reflect the ‘terminal cytoarchitectural differences’140 related to 
neuronal loss in the SN.  However, the observed similarity of studies of the frontal cortex – 
which does not show such severe neuronal loss140 compared to the SN, where next to no 
dopaminergic neurons remain post-mortem172 – to studies of the SN (Figure 3.4, Figure 3.5, 
Figure 3.6) points towards at least partly shared gene expression patterns which are reflective 
of other biological processes.  
There is much interest in the use of non-brain tissues for gene expression studies, as these can 
be relatively easily obtained pre-mortem and could reflect processes associated with early-
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stage PD, as well as potentially offering direct patient benefit.  Studies which use human cell 
lines, such as iPSCs derived from PD patients, do not appear to replicate the differential 
expression patterns found in tissue samples from PD patients.  Using hierarchical clustering, 
however, iPSC-derived dopaminergic neurons appear similar to dopaminergic neurons isolated 
post-mortem, while iPSCs harbouring SNCA mutations cluster with Pink1- and SNCA-based 
genetic animal models of PD (Figure 3.6), suggesting the potential for these study types to 
replicate relevant gene expression patterns in PD.  Similarly, studies in blood samples cluster 
together, appearing distinct from gene expression in brain tissue (Figure 3.6) but also appearing 
distinct from gene expression in blood studies of brain tumours (Figure 3.9), suggesting a 
common transcriptional pattern that could function as a marker of neurodegenerative disease.  
These are encouraging results for the development of surrogate tissue approaches for studying 
gene expression in PD. 
In practice, the concordance between microarray studies from different experimental groups 
will never reach 100%.   Experimental factors including sample amplification, labelling, array 
scanning, wash protocols, etc.116,176,177 exert a significant effect on the results and 
reproducibility of studies; in the context of PD, there are a number of experimental factors 
which influence measured RNA expression in the brain including the impact of age, gender, 
and post-mortem interval120,154,178 and other confounding factors including long-term anti-
Parkinsonian drug treatment and the co-occurrence of other diseases such as Alzheimer’s 
disease141.  More detailed meta-data associated with studies uploaded to public repositories 
would be immensely helpful in aiding meta-analysis and identification of differences between 
studies.   This could be disease-specific, such as distinguishing between idiopathic and genetic 
PD cases; or more general, such as distinguishing between drug-treated and drug-naïve 
patients, or providing a measure of RNA integrity such as RIN179 (especially key in post-
mortem studies where RNA quality is affected by the agonal state180). 
Nevertheless, this study aims to illustrate the amount of agreement that can be expected 
between different microarray studies in the context of PD; further, its general conclusions may 
be equally applicable in studies of other conditions.  This study acts as a guide to the 
‘representativeness’ of different tissues and disease models to the human condition (which is 
of special significance in PD due to the inaccessibility of PD-affected tissues in living patients), 
and as a guide to the use of animal models, at a time of increasing importance of transcriptomics 
and other molecular-level analyses in drug discovery and development181.  The identification 
of a specific ‘characteristic’ signal of PD in human brain tissues could explain the apparent 
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discordance between microarray studies of PD, and is hence of more general interest for the 
study of PD at the transcriptomic level. 
  
 81 
4 USING DYSREGULATED SIGNALLING PATHS 
TO UNDERSTAND DISEASE 
	
SUMMARY  
Network-based methods of gene expression analysis have recently become popular, allowing 
gene expression changes to be interpreted by relating them on to each other on a known 
framework.  However, gene networks produced by these methods are often large and difficult 
to interpret.  In this chapter, a ‘bottom-up’ method of subnetwork identification based on 
weighted shortest-paths (termed ‘path-set analysis’) is described, which highlights smaller 
network regions which are dysregulated in disease.  This method, in contrast to similar 
approaches, is based solely on differentially expressed genes.  Each edge is therefore disease-
specific, rather than including ‘bystander’ nodes resulting purely from network topology.  This 
makes path-set analysis particularly suited to the comparison of expression changes in disease, 
allowing comparison at a granular (edge-wise) level instead of comparing large subnetworks.  
The ability of path-set analysis to identify relevant dysregulated processes in disease is 
confirmed by the enrichment of known disease-associated genes in the returned paths.  
Comparing path-sets across the 141 transcriptomic studies in the dataset reveals commonly 
dysregulated genes which are included in the path-sets of multiple disease studies.  There is a 
moderate relationship between the number of studies in which a gene is included and its 
network importance (quantified by degree), suggesting that path-set analysis identifies 
‘pressure points’ in the network which can influence the progression of diverse disease types.  
Disease studies that share dysregulated paths are 2.5 times more likely to be in the same Disease 
Ontology subcategory than those that don’t, and more than twice as likely to share drugs, 
confirming the relevance of path-sharing to known disease relationships.  Over half of shared 
paths between disease pairs contain a drug-interacting gene, suggesting the utility of this 
approach in forming early-stage drug repurposing hypotheses. 
This work represents the first application of path-based network analysis to the comparison of 
diseases, including understudied rare diseases.  This analysis reveals the underlying processes 
dysregulated in disease, helping to develop our understanding of disease and disease 
relationships, which could ultimately lead to novel treatments. 
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4.1 INTRODUCTION 
The analysis of gene expression data can give valuable insight into the underlying processes 
taking place in disease.  However, as illustrated in Chapter 3, transcriptomic data can be noisy, 
displaying high variation even between studies of the same condition.  Gene expression data is 
therefore often interpreted by translation to a higher biological level, such as biological 
pathways, under the assumption that different observed gene expression changes can reflect 
similar underlying processes.  A limitation of this gene set analysis, however, is that canonical 
biological pathways represent inflexible, high-level descriptions of a complicated process 
which obscure the individual gene expression changes.  
A middle ground between analysis of individual gene dysregulation and gene set analysis is 
network-based analysis, which relates genes on the interactome.  The interactome describes the 
interactions between gene products (chiefly proteins) without reference to known pathways or 
processes, thereby enabling the discovery of novel regions of interest182.  This type of analysis 
often involves the detection of dysregulated subnetworks of interacting genes and gene 
products that are active in disease.  Distinct from ‘functional module’ approaches which 
partition the interactome into clusters based on topology183,184, ‘active’ subnetwork approaches 
incorporate experimental information such as genomic or transcriptomic data (covered in a 
comprehensive review by Mitra et al.185).   
An alternative to ‘top-down’ subnetwork identification is the ‘bottom-up’ identification of 
individual dysregulated paths: subunits of networks which have defined start and end points.  
The advantage of using paths is that unlike subnetworks, paths can represent isolated patterns 
of dysregulation which may involve only two or three gene products.  This approach is 
commonly used to study drug response by identifying paths connecting drug targets to 
differentially expressed genes186 or toxicity-related proteins187; or to connect known genetic 
variations in disease with differentially expressed genes188.  However, it is not always possible 
(or desirable) to define these start and end points in advance, in which case a priori path 
identification approaches are required.   
Of most relevance is the method developed by Sambarey et al.121, who used a weighted 
shortest-paths approach to identify a common response network shared by multiple 
tuberculosis gene expression datasets.  Briefly, dysregulated paths are identified by computing 
weighted shortest-paths on the signalling network, where the weights are inversely proportional 
to the differential expression magnitude of each gene.  Those paths whose lengths are most 
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highly changed from the unweighted base network (representing signalling in a healthy person) 
therefore contain the most highly dysregulated genes.  Using this method, the authors could 
identify commonalities between the datasets that were not found by traditional differentially 
expressed gene list analysis.  They confirmed the specificity of the identified response network 
by comparing it to response networks in four other diseases (sarcoidosis, Still’s disease, 
pneumonia, and systemic lupus erythematosus).  
Whilst this approach looked for differences (specificity) between the tuberculosis response 
network and other diseases, such path-based approaches could also be valuable for the 
identification of commonalities between diseases.  Previous studies have integrated multiple 
datasets from a shared phenotype to discover common differential-expression based 
subnetworks across related diseases182,189,190.  For example, one study used topological network 
clustering of differentially expressed genes in oesophagitis and oesophageal cancer to discover 
functional modules common to both diseases190.  Alroobi et al.189 integrated datasets within 
phenotypic classes including ‘gastroenteritis’, ‘carcinoma’, ‘neoplastic process’ and ‘cell or 
molecular dysfunction’ to find subnetworks shared within these classes. However, few 
previous approaches have compared differential expression-based networks across different 
types of disease.  One exception is the 2009 study by Suthram et al.107 described in Section 
1.4.1.2, who compared 54 diseases by mapping their gene expression to precomputed 
functional modules, finding significant disease correlations between e.g. Crohn’s disease and 
malaria.  
Here, a method inspired by the weighted shortest-paths approach of Sambarey et al.121 (see 
Section 4.2.4 for discussion of the key differences) is applied to the comparison of 141 gene 
expression datasets representing 119 diseases, as well as 19 drug-induced gene expression 
profiles.  In this method, which is termed path-set analysis, the initial network for each disease 
(or drug) is constructed from all genes with non-zero differential expression.  The use of this 
non-conservative differential expression threshold enables path-set analysis to discover groups 
of genes which may not be highly differentially expressed individually, but which represent a 
flow of dysregulation along the network.  Unlike traditional analysis methods, where the 
importance of a gene in a particular disease is determined solely by its individual log-fold 
change or significance value, in path-set analysis the importance of a gene is determined in a 
more holistic manner by taking into account the activity of its interacting genes. 
An advantage of this approach (in contrast to the work of Sambarey et al., where paths combine 
differentially expressed genes with non-differentially expressed ‘bystander’ nodes) is that each 
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individual edge is disease-specific, i.e. each edge connects two genes which are differentially 
expressed in that disease, as opposed to connecting a differentially expressed gene with each 
of its neighbours. This property of edge specificity enables the comparison of diseases at a 
granular (edge-wise) level, rather than across whole (sub-) network modules as in the work of 
Suthram et al., allowing the identification of disease pairs which share dysregulated processes.  
In this chapter, I use path-set analysis to interpret gene expression data across diverse 
conditions, including 141 microarray studies of disease representing 119 different diseases, and 
19 drug response studies in human patients.  The relevance of the paths for each disease is 
evaluated using the presence of known disease-associated genes and drug-interacting genes in 
each path.  For the first time, I use path-based analysis to compare diseases, identifying paths 
which are shared between diseases and highlighting dysregulated processes common to diverse 
disease types.  Finally, I explore the relevance of these common processes to the identification 












4.2.1 Gene expression dataset construction 
Suitable gene expression datasets were identified by manually searching Gene Expression 
Omnibus44 for specific diseases and by searching for the keywords ‘disease’, ‘syndrome’ and 
‘cancer’ and selecting those for which high-quality patient transcriptomic data were available, 
according to the criteria described in Section 2.2.  This resulted in 141 datasets covering 119 
distinct diseases, including 35 rare genetic diseases (defined as inheritable diseases with a 
prevalence of less than 1 in 10,000 where known).  Due to limitations of the available data, 
some of the gene expression profiles are based on in vitro samples from cell lines, rather than 
in vivo samples directly from patient tissue (this is mostly for rare diseases where fewer studies 
are available).  Where technical replicates e.g. multiple repeats of the same cell line are used, 
only the first is taken in order to have a consistent ‘one-patient, one-sample’ structure 
throughout each dataset.  Datasets and sample selection are listed in Appendix B.  In order to 
classify diseases, disease names were manually mapped to Disease Ontology191 terms and their 
top- and second-level classes were recorded. 
All datasets were downloaded and processed as described in Section 2.3, resulting in 
differential expression profiles of diseased vs healthy patients.  A non-conservative threshold 
of p<0.05 was used to call significant differential expression; log-fold changes of non-
significant genes were set to 0.  This non-conservative threshold represents a departure from 
traditional gene expression analysis, which relies on the significance of individual gene 
expression changes to select a list of individually ‘important’ genes.  Instead, this method 
considers the dysregulation of a gene in combination with that of its neighbours, representing 
a network-based view of ‘importance’.  At this threshold, a median of 27% of the genes in a 
disease experiment have non-zero differential expression, although only 1.6% of genes on 
average have an absolute log-fold change value greater than 1.  
Drug gene expression datasets were identified by manually searching Gene Expression 
Omnibus using keywords including ‘drug’, ‘treatment’, ‘compound’, ‘placebo’.  This resulted 
in 19 datasets covering 16 different drugs.  These were downloaded and processed as described 
in Section 2.3, resulting in differential profiles from e.g. the patient after drug treatment vs after 
taking a placebo, or the patient after drug treatment vs before drug treatment.   
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4.2.2 Identifying disease-associated and drug-interacting genes 
Data on disease-associated genes was obtained from the OpenTargets platform in December 
2016 using the provided REST API169.  Diseases were mapped to their closest disease concepts 
in OpenTargets, although in some cases the match is to a less specific concept (e.g. ‘breast 
lobular carcinoma’ maps to ‘breast carcinoma’; ‘non-small cell lung carcinoma’ maps to ‘lung 
cancer’, ‘teratozoospermia’ maps to ‘male infertility’). Genes with an evidence score >0.2 in 
‘genetic association’ or ‘somatic mutation’ were defined as disease-associated genes.  For drug 
response datasets, disease genes corresponding to the disease in which the drug was tested were 
used. 
To identify drug-interacting genes related to diseases (for use with the disease datasets), drug 
indication data was obtained from ChEMBL version 22.1192 
(https://www.ebi.ac.uk/chembl/downloads, files chembl_drug_indication and 
chembl_mol_dict), and approved drugs or drugs in Phase III clinical trials were retained.  
Genes related to these drugs were downloaded from the Drug Gene Interaction Database 
(http://www.dgidb.org/) in November 2016.  Genes corresponding to primary targets of drugs 
(for use with the drug response datasets) were identified using the ‘Mechanisms of action’ 
information from the OpenTargets platform, which translates ChEMBL mechanism of action 
information into target space. 
 
4.2.3 Signalling pathway network construction 
OmniPath82 was used as the basis of the signalling network.  OmniPath is a recently published 
resource containing ‘literature-curated human signalling interactions’82 from 27 different 
resources including SignaLink, Reactome, IntAct, WikiPathways, Signor and others, resulting 
in coverage of ‘~39% of the human proteome’82.  Only those interactions of known direction 
(causal interactions, which are the basis of signalling pathways) are retained, resulting in a 
network of 6,942 nodes. 
In this work, as in common in canonical pathway analysis, changes in gene expression (i.e. 
mRNA abundance) are treated as a proxy measure of changes in pathway activity, recognising 
that gene expression is not directly correlated to the abundance of the corresponding 
proteins193, but that they may function as a broad indicator of dysregulation in a particular 
pathway.  The proteins in the network are therefore represented by their corresponding genes, 
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with the UniProt IDs used in OmniPath converted to gene symbols supplied by the Hugo Gene 
Nomenclature Committee (conversion tool downloaded from https://www.genenames.org/cgi-
bin/download).  Where a UniProt ID maps to more than one gene (or vice versa), both 
mappings were kept in order to retain the maximum number of interactions.  Duplicate entries 
and self-loops were removed.   
In order to test the dependence of the results on the underlying network, the analysis was 
repeated with an independent network resource, HIPPIE (Human Integrated Protein-Protein 
Interaction rEference)83.  Unlike OmniPath, HIPPIE is not based on signalling interactions, but 
on experimentally determined protein-protein interactions.  HIPPIE provides a confidence 
score based on the available evidence supporting each interaction, allowing the filtering of the 
network to retain only high-confidence interactions (score >=0.73).  Following this filtering, 
HIPPIE contains 62,615 interactions between 12,162 proteins compared to the 43,693 
interactions between 6,972 proteins in OmniPath.  Although the resulting path-sets contained 
different nodes (due to the small overlap between interactions in HIPPIE and OmniPath) and 
contained slightly fewer disease-associated genes, overall properties of HIPPIE path-set 
analysis in terms of shared edges and enrichment of disease-associated genes compared to other 
methods were not substantially different to those obtained with OmniPath (discussed in 
Appendix J), indicating that the results presented in this chapter are not dependent on the 
specific topology of the OmniPath network. 
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4.2.4 Identification of dysregulated signal paths in each disease 
 
Figure 4.1 Identification of dysregulated signal paths 
Path-set	analysis	uses	weighted	shortest-paths	on	a	directed	signalling	network	to	find	paths	










Path-set analysis calculates, for each disease, the paths which link the most highly differentially 
expressed nodes.  This process is summarised in Figure 4.1 and detailed in full below.  Steps 
1-3 describe the construction of the base signalling network, steps 4-6 describe the construction 
of the weighted signalling network, and steps 7-11 describe the selection of dysregulated paths. 
1. First, an initial base network is created from OmniPath by excluding nodes which are 
not differentially expressed in the disease (at a threshold of p<0.05).  This prevents 
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the algorithm from simply returning all possible paths between two non-neighbouring 
genes, ensuring that each edge is disease-specific rather than based on network 
topology.   
2. All nodes in the base network must have at least one outgoing edge, because it is the 
outgoing edge that is considered in the weighted shortest path calculation (step 6).  
Any ‘leaf’ nodes which do not have children in this network are therefore connected 
to a ‘dummy’ child node.   
3. The resulting interactions list is converted to a graph representation using the 
graph_from_edgelist function from the R package igraph194 (version 1.1.2).  
Unweighted shortest path distances are computed along this base network, using 
igraph’s distances function with mode=out, resulting in a distance matrix where first 
neighbours have a distance of 1, neighbours of first neighbours have a distance of 2, 
and so on, which is the base distance matrix, baseDist. 
4. An edge weight vector initialWeights is initialised where for each edge p->q, the 
weight is set to the absolute log-fold change value of the source node p.   
5. The weights are inverted: 
!"#$ℎ&' = max #,#&#-./"#$ℎ&' − #,#&#-./"#$ℎ&'	
so that the most highly differentially expressed gene has a weight of 0 (a small positive 
value d is added to this gene to avoid having a 0-length path) and therefore the smallest 
path cost, and the least highly differentially expressed gene has the highest weight 
(equal to the highest absolute log-fold change) and therefore the highest path cost.   
6. The distance computation via distances is repeated with the weights from the previous 
step, yielding the weighted shortest path distance matrix, weightedDist.  
7. In order to be comparable with the weighted distances, baseDist is multiplied by a 
constant equal to the maximum log-fold change observed in the disease.  This creates 
a new distance matrix, scaledBaseDist, which is equivalent to performing weighted 
shortest-paths on a network where all differential expression values are zero (and 
therefore has longer path lengths than any in weightedDist).  
8. Path dysregulation scores are calculated as the difference between the scaled base 
distance matrix and the weighted distance matrix, normalized by the length of the path: 
2#33"4",5" = ('5-."27-'"8#'& − !"#$ℎ&"28#'&)/;-'"8#'& 
Note that the normalization here could equally be division by scaledBaseDist. 
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9. A threshold is set which specifies the number of paths to consider for each disease, 
here set to the 100th or 500th highest value of the difference matrix depending on the 
application.  All differences less than this threshold are set to 0, so that in further 
analysis the (roughly) 100/500 most highly dysregulated paths are considered.   
10. For each node pair whose path dysregulation score is above this threshold, the vertices 
of the shortest path(s) between them are returned by igraph’s all_shortest_paths 
function, again with mode=out and weights as calculated in step 5.  
11. The returned paths are then pruned according to the following criteria: 
a. Paths must link at least two nodes after removal of the dummy node.   
b. Any paths which are shorter subsets of other paths are removed. 
Diseases are then represented by the set of edges resulting from the union of these paths, the 
path-set for each disease.   
A threshold of the 100th highest distance was used for the first part of the analysis, which 
focuses on paths in individual diseases.  A more relaxed threshold of the 500th highest distance 
was used for the second part of the analysis (Sections 4.3.5 and 4.3.6), in order to increase the 
possible number of paths shared between diseases.   
One potential limitation of the shortest-paths method is that by recording only the shortest path 
between two nodes, the algorithm may potentially miss other paths between the two nodes 
which may also meet the threshold.  An adjustment of the algorithm is possible which takes 
this into account by incorporating every path between two nodes which meets the threshold, 
but this increases the run-time of the algorithm exponentially without adding many new nodes 
to the path-set.  The shortest-path formulation was therefore retained for this version of the 
algorithm. 
In order to compare path-set analysis to traditional differential expression analysis, an LFC-set 
is also constructed for each disease.  The LFC-set is simply the top n most highly differentially 
expressed genes (where n is the number of nodes in the path-set of that disease) by absolute 
log-fold change at p<0.05, restricted to those genes which are contained in OmniPath.  Genes 
in OmniPath may have different properties than those genes which are not in OmniPath 
(possibly associated with being more well-studied), so this allows a fairer comparison between 
the two methods.  In order to examine the contribution of network information in the absence 
of log-fold change information, 100 random-path-sets are also constructed.  These are 
constructed as the real path-sets, but with permuted log-fold change values within each disease. 
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Path-set analysis is inspired by the method proposed by Sambarey et al.121 who used weighted 
shortest-paths to identify response networks in tuberculosis, but differs in several key details 
including the calculation of the node and edge weights and the use of directed interactions on 
a signalling network to represent signal flow; and further in the use of only differentially 
expressed genes to define the network, so that the resulting paths are composed solely of 
differentially expressed genes rather than including ‘bystander’ neighbour nodes.   
 
4.2.5 Identification of shared dysregulated signalling paths between 
diseases 
In order to compare dysregulated signalling paths across diseases, a common-path-set was 
additionally constructed for each disease.  The common-path-set is constructed as above, but 
takes into account the diversity of platform types (each measuring different sets of genes) in 
the dataset by restricting the analysis to the 3,724 genes measured on all platforms, 2,306 of 
which are in OmniPath.  The common-path-set was used for analyses involving comparison 
across disease datasets (Sections 4.3.5, 4.3.6). 
Using the common-path-sets, the number of edges shared between two diseases is calculated.  
An edge is shared between two diseases if: 
1. The edge is in the common-path-set of both diseases 
2. The direction of the log-fold change associated with the nodes linked by the edge is 
the same in both diseases.   
A random permutation test is used to calculate if the number of shared edges between two 
diseases is significant.  For each disease, a random edge-set is created which contains the same 
number of edges as in the original path-set by sampling edges from the shared base network 
according to the frequency of these edges over all common-path-sets.  The number of 
overlapping random edges between each disease pair is then calculated as above (randomly 
assigning a direction of log-fold change to each node).  This procedure is repeated 1000 times 
for each disease pair, and the highest random overlap is taken as the significance threshold for 
each disease pair.   
Finally, the disease similarity score is calculated as the number of shared edges divided by the 
total number of edges in the path-set of each disease.  Where the number of shared edges is 
less than the significance threshold, the similarity score is set to 0. 
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4.2.6 Pathway enrichment analysis 
Pathway enrichment analysis was carried out using the Panther Classification System62 version 
13.1 (http://www.pantherdb.org).  Gene lists were uploaded to Panther and an 
overrepresentation test was performed specifying an appropriate reference list as the 
background (i.e. all genes in the network).  Gene lists were analysed against the Panther GO-
Slim biological process termset.  The Fisher’s exact test was used to determine significance; 
pathways with a Benjamini-Hochberg FDR < 0.05 (the default reported by Panther) were 
reported as significant.   
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4.3 RESULTS 
4.3.1 Path-set analysis of gene expression changes in disease reveals 
shared dysregulation amongst interacting gene products 
To quantify the extent to which path-set analysis differs from traditional log-fold change 
analysis (which considers the most strongly differentially expressed genes in each disease), the 
n genes comprising a disease’s path-set were compared to the disease’s n most highly 
differentially expressed genes in OmniPath (the LFC-set, see Methods).  Across all diseases, a 
median average of 22% of genes are common to the path-set and the LFC-set of a disease, i.e. 
the path-sets capture 22% of the disease’s most highly differentially expressed genes.   
Simply mapping the highly differentially expressed genes in the LFC-sets to the OmniPath 
network results in very small network sizes: most of these genes do not interact with each other, 
meaning that the resulting networks cover a median of only 18% of the genes in the LFC-sets.  
On the other hand, trying to connect more of the LFC-set genes e.g. by including all first-
neighbour genes results in a very large network: whilst the median LFC-set size is 82 genes, 





Figure 4.2 Distribution of path-set size 
At	a	threshold	of	the	100	top	paths,	most	diseases	have	a	path-set	comprising	around	50-100	
dysregulated	 nodes,	 although	 a	 few	 path-sets	 (for	 hepatocellular	 carcinoma	 and	 Turner	
syndrome)	are	much	larger.	
 
Path-set analysis represents an alternative to network-based analysis of DEG lists, which rather 
than selecting the top most differentially expressed genes, highlights genes which interact in a 
dysregulated biological process (in this case, signalling).  The initial network for each disease 
is built from all genes with non-zero differential expression; across all diseases, there is a 
median of 4,714 genes with non-zero differential expression per disease, resulting in a median 
initial network size of 1,408 nodes.  The top most dysregulated paths are then selected from 
this network (see Section 4.2.4), resulting in a median path-set size of 82 nodes (Figure 4.2).   
This type of analysis can be particularly useful for experiments where few genes show high 
log-fold changes.  One example of this is the experiment for asthma (see Appendix B for 
details), where the highest absolute log-fold change (at p<0.05) is only 0.56.  By comparison, 
the median highest absolute log-fold change across all diseases in the dataset is 3.91.  
 95 
  
Figure 4.3 Dysregulated signalling paths in asthma  
The	path-set	of	asthma	(based	on	the	top	100	paths)	includes	two	connected	components,	one	
centred	 around	 the	 network	 ‘hub’	 gene	MAPK1	 and	 its	 downstream	 genes,	 and	 the	 other	
centred	around	the	inflammatory	chemokine	receptor	CCR5	and	its	ligands.		18	of	the	58	genes	
in	the	path-set	are	also	in	the	set	of	most	highly	differentially	expressed	genes	(the	LFC-set),	but	
the	LFC-set	does	not	 include	the	key	nodes	MAPK1	and	CCR5	which	 form	the	basis	of	 these	
components.	 	 The	 pale	 node	 colours	 indicate	 low	 magnitude	 of	 differential	 expression	 in	
comparison	to	later	figures,	which	are	plotted	on	the	same	colour	scale.	
	
Figure 4.3 shows the genes comprising the dysregulated paths (the path-set) for the asthma 
dataset; overlaying the individual paths onto the OmniPath network in this way shows how the 
expression changes are related to each other. 18 of the 58 genes in the asthma path-set are also 
captured by its LFC-set; however, the LFC-set does not capture the key network-specific ‘hub 
genes’ mitogen-activated protein kinase 1 (MAPK1) and C-C chemokine receptor type 5 
(CCR5).  MAPK1 in particular has a central position in the human signalling network (it has a 
degree of 476, one of the highest-degree nodes in OmniPath) and so it is unsurprising to see 
that this hub structure is retained in the asthma path-set.   
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As OmniPath is a signalling network, links between dysregulated genes are not a casual 
explanation (e.g. under-expression of gene A leads to under-expression of gene B).  Rather, 
path-set analysis highlights groups of interacting genes with shared dysregulation, suggesting 
broader underlying dysregulation e.g. of a particular signalling pathway.  It should also be 
noted that as mRNA expression levels are not necessarily correlated with protein abundance193, 
expression dysregulation provides at best a rough suggestion of what might be taking place at 
the protein level.  Bearing these points in mind, the observed expression changes can be 
interpreted as indicators of signalling events that may be dysregulated in asthma.  Throughout 
this chapter, protein symbols will be given in italics to distinguish them from gene symbols. 
For instance, the hub gene MAPK1 is shown to interact with PDE4D, a subtype of 
phosphodiesterase 4.  Its product, mitogen-activated protein kinase 1, phosphorylates the 
product of PDE4D, but whether this has an activating or inhibitory effect depends on the exact 
isoform of PDE4D that is translated (PDE4D has an intron variant in asthma which could 
potentially affect this)195.  The upregulation of PDE4D, if this translates to increased levels of 
its protein product, chimes with the fact that inhibitors of PDE4 are currently being developed 
for the treatment of asthma (although the PDE4D subtype specifically is associated with the 
side effect of nausea and vomiting)196.    
Another component of interest is formed by the inflammatory chemokines CCL2, CCL4, and 
CCL5, and the chemokine receptor CCR5.  Previous studies have found levels of their 
corresponding proteins to be increased in asthma197, however, here all four chemokines and 
their receptors are downregulated.  The fact that these chemokines interact with each other 
suggests that their downregulation is not just a chance observance but is part of a co-ordinated 
process, which is particularly important to establish as the observed magnitude of the fold 
changes is so low.  Interestingly, whilst the LFC-set captures the four ligands CCL2, CCL4, 
CCL5, and CCL8, indicating that they are some of the most highly dysregulated genes in 
asthma, the receptor CCR5 is not strongly differentially expressed enough to be included in 




4.3.2 Dysregulated paths are enriched for disease-associated genes and 
drug-interacting genes 












What proportion of sets 
contained at least one 
KDG? 
0.58 0.56 0.54 0.43 
How many KDGs were 
found per set on 
average? 
2.95 1.89 2.40 1.18 
What percentage of 
genes in the set were 
KDGs on average? 
3.2% 2.4% 2.5% 1.3% 
 
The presence of genes associated with a disease, and genes which interact with drugs for this 
disease (together ‘known disease-associated genes’; KDGs) in a path-set can indicate the 
interaction of the dysregulated paths with causative or therapeutic processes taking place in the 
disease. The presence of KDGs in each path-set was therefore used as a proxy measure to 
evaluate the biological relevance of the discovered paths (Table 4.1).  In this study, disease-
associated genes are defined as genes which have a variation or somatic mutation which has 
been previously associated with the disease.  Drug-interacting genes are defined as genes which 
interact in some way with drugs prescribed for the disease (e.g. a drug inhibits a product of this 
gene) (see Section 4.2.2).   
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Across all diseases with at least one KDG (130 diseases), 58% contained at least one KDG in 
their path-set, with a mean average of 2.95 KDGs per path-set.  If the less strict threshold of 
500 is used, these values increase to 72% of path-sets, containing a mean average of 7 KDGs.  
Path-sets capture more KDGs than LFC-sets, which find only 1.89 KDGs per disease on 
average.  Surprisingly, the random-path-sets (in which the log-fold change values for each 
gene are permuted, repeated 100 times) also capture many KDGs in disease.  Although the 
difference between the real and random path-sets is statistically significant (t-test p-value 
<2.2e-16 for percentage of datasets containing at least one KDG and for number of KDGs 
found), the magnitude of the difference is small.  This is not seen in the random-gene-sets 
(gene-sets of the same length as the path-sets randomly selected from the genes in OmniPath, 
repeated 1000 times), suggesting that the path-set method inherently selects for KDGs, 
regardless of gene expression information. 
The enrichment of KDGs in random path-sets can be explained by the tendency of path-sets to 
return genes of high network importance, quantified here by the degree of the node, i.e. the 
number of nodes with which it interacts (calculated using igraph’s degree function).  The 
median degree of genes in the real path-sets is 15.5, and 19 in the random-path-sets.  By 
comparison, this figure is only 5 for both the LFC-sets and the random-gene-sets.  This 
illustrates how the path-set analysis method selects for genes which have a greater number of 
interactions, which have greater chance to be included in a dysregulated path. 
KDGs also tend to have higher degree on average than non-KDGs (median degree of 7 for 
drug-interacting genes vs 4 for non-drug-interacting genes, Wilcox p-value <4.46e-12; median 
degree of 7 for disease-associated genes vs 4 for non-disease-associated genes, Wilcox p-value 
<2.20e-16).  The performance of the random-path-sets at identifying KDGs suggests that the 
ability of path-sets to identify KDGs may be partly based on the incorporation of the network 
structure information.  However, the LFC-sets do much better than the random-gene-sets at 
finding KDGs, suggesting that fold change information is also important for identifying paths 
which contain KDGs; it is therefore unsurprising that path-sets, which combine fold-change 




4.3.3 Dysregulated paths interact with known disease-associated genes 
and drug-interacting genes 
It should be noted that not all of a disease’s KDGs can be captured by path-set analysis.  Only 
KDGs which are: 
1. Measured by the gene expression platform used for that disease 
2. In OmniPath (median of 30% of measured genes in each experiment) 
3. Differentially expressed in the associated disease (median of 36% of KDGs, compared 
to the 27% of all measured genes with non-zero differential expression on average 
across diseases) 
can be returned by this method.  Whilst path-set analysis focuses only on differentially 
expressed genes (in order to improve understanding of differentially expressed gene lists in 
disease), there will also be many genes involved in disease which are not dysregulated, such as 
the 64% of KDGs which are not differentially expressed in their associated disease.  By relating 
genes in the path-sets to first-neighbour KDGs, other ‘key players’ can be captured which 
despite not showing changes in their expression levels may influence or be influenced by the 
dysregulated processes captured in the path-sets.  A median of 12.5 KDGs per path-set are 








Figure 4.4 Dysregulated paths in type 1 diabetes interact with non-dysregulated 






Figure 4.4 shows an example visualisation of a path-set and (non-differentially expressed) first-
neighbour KDGs in type 1 diabetes mellitus (T1D), an autoimmune condition in which insulin-
producing beta cells in the pancreas are destroyed by the body’s own immune system, resulting 
in an inability to control glucose levels in the bloodstream.  Again, the Figure reveals 
interactions between groups of dysregulated genes, such as the coordinate overexpression 
between the chemokine receptors CXCR1 and CXCR2 (referred to as ‘master regulators of 
diabetes pathogenesis’198 due to their role in the autoimmune destruction of insulin-secreting 
beta cells199) and their ligands, CXCL1, CXCL2, and CXCL8 (shown on the right-hand side 
of the Figure).   
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The Figure also illustrates how the nodes in the path-set interact with (non-differentially 
expressed) first-neighbour KDGs.  The path-set together with first-neighbours now captures 
23.6% of the 93 drug-interacting genes associated with T1D, and 9.8% of the 122 known 
disease-associated genes.  Again, examining the relations between genes in the path-set and 
their first-neighbours can reveal more about the patterns of dysregulation seen in disease.  One 
example is PIK3R1, which has only one neighbour in the path-set, but which takes on a more 
central ‘hub’ position when the first-neighbour KDGs are added, suggesting its potential 
importance in T1D.  PIK3R1 is the p85α regulatory subunit of PI3K, which mediates insulin 
signalling200,201; lowered PIK3R1 expression has been found to prevent insulin resistance in 
obese mice202, and so the under-expression seen in this dataset might be associated with lower 
blood insulin levels by increasing insulin sensitivity. 
	
4.3.4 Path-sets reveal genes frequently dysregulated in disease 
Comparing the path-sets across the 141 experiments in the dataset (here using the shared-genes 
path-sets, which are based on only the 3724 genes measured in all experiments) allows 
identification of genes which are frequently dysregulated in many different diseases.  These 
genes may represent a ‘stress response’ which is not specific to the disease, but which form a 
more general response to disease e.g. involvement of the immune system.  Note that 15 diseases 
are represented twice in the dataset, 2 diseases represented thrice, and one disease (multiple 
sclerosis) being represented four times, leaving a total of 119 unique diseases.  Given the 
difference that can exist between two measurements of the same disease (as has been shown in 
Chapter 3) these replicate experiments were retained for the following analysis, which 
therefore more properly refers to genes dysregulated in multiple experiments, rather than 
diseases. 
Ignoring those genes which do not appear in any path-sets, each gene appears in a median of 4 
path-sets; however, some genes are in many more path-sets, with 54 genes appearing in the 
path-sets of 25 or more experiments (Appendix K).  One gene, the epidermal growth factor 
receptor (EGFR), is in the path-sets of 66 experiments, which include cancers (EGFR is known 
to play a role in many cancers203) as well as other disease types including skin diseases and a 
number of rare syndromes.  
Gene Ontology biological process (GO BP) enrichment analysis of these 54 genes returned 14 
terms, mostly related to signalling, including biological regulation, signal transduction and 
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cell communication.  This is unsurprising given that the dysregulated paths are based on the 
OmniPath network, which is designed to reflect signalling interactions; although other 
significant terms were not directly related to signalling, including negative regulation of 
apoptotic process and metabolic process (see Appendix K).  These terms suggest mechanisms 
through which these commonly dysregulated genes may influence the general response to 
disease.  
This analysis was repeated for genes in multiple LFC-sets and random-path-sets.  There is less 
overlap between the LFC-sets than between the path-sets, with genes in LFC-sets being 
dysregulated in a mean of 5.5 LFC-sets each, compared to the mean of 6.1 path-sets (although 
the median value for both is 4), and no gene appearing in the LFC-sets of more than 34 
experiments (compared to 14 genes appearing in more than 34 path-sets).  One explanation for 
this is that whereas LFC-sets focus on the individual genes with the highest differential 
expression, which will vary between diseases and experiments, path-set analysis returns sets 
of interacting genes which show co-ordinated expression dysregulation, which may be more 
likely to be replicated in multiple experiments due to e.g. the involvement of these gene sets in 
particular biological processes.    
Interestingly, despite the selection of genes in random path-sets having a strong relationship to 
their degree (Figure 4.5), there is comparatively little overlap between the random path-sets: 
taking the total number of occurrences of a gene in the 100 random path sets and dividing by 
100, genes are included in a mean of 4.5 random-path-sets each.  This suggests that the overlap 
seen in the path-sets is not simply due to the repeated selection of high-degree nodes across 
multiple experiments.   
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Figure 4.5 Moderate relationship between the number of dysregulated path-sets in 
which a gene is included and the degree of the gene in OmniPath 











GO BP enrichment analysis of the 54 genes most frequently in LFC-sets did not return any 
significant terms.  Enrichment analysis of the 54 genes most frequently in random-path-sets 
returned 8 terms, all of which were signalling pathways also returned by the analysis for the 
real path-sets (e.g. biological regulation, signal transduction and cell communication).  This 
could be explained by the relatively strong relationship between the number of random-path-
sets containing a gene and the degree of that gene (R2 of 0.679; Figure 4.5): high-degree nodes 
in a signalling network will tend to be linked to signalling-related functions.  This relationship 
confirms that in the absence of coherent log-fold change information, path-set analysis tends 
to select genes of high degree. 
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By contrast, there is almost no relationship between the number of LFC-sets containing a gene 
and the degree of that gene (R2 of 0.003).  The line of best fit shown in Figure 4.5 even suggests 
a slight negative trend, i.e. genes with high log-fold change values in multiple experiments do 
not tend to be central in the network.  This in contrast to the genes frequently in path-sets, 
which show a moderate trend towards higher degree (R2 of 0.470) but not as strongly as the 
random-path-sets.  These genes may represent ‘pressure points’ in the network whose 
dysregulation is often associated with further dysregulation in their network neighbours.  These 
genes would be expected to have higher-than-average degree, as they must interact with many 
different genes in order to influence diverse biological processes in different diseases; at the 
same time, the most important (highest degree) nodes in the network are unlikely to be 
frequently dysregulated, as these will be the critical nodes, dysfunction in which could be lethal 
to the cell.   
 
4.3.5 Shared edges between diseases reveal unexpected disease 
relationships which are enriched for shared drugs and drug-
interacting genes 
Path-set analysis enables the comparison of diseases through shared dysregulated edges.  A 
shared edge is an interaction between two genes that is contained in the path-set of both 
diseases, where each gene is regulated in the same direction in both diseases.  Whilst shared 
dysregulated genes might represent isolated points on the biological network, shared edges are 
a stricter method of comparison which helps to make a stronger case for common mechanisms 
between two diseases.   
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Figure 4.6 Disease similarity based on number of shared dysregulated edges shows known and novel similarities between diseases 





Figure 4.6 shows a clustering of diseases according the size of their shared-edge-set, based on 
676 significant disease pairs of a possible 9,870 pairs (see Methods for details of the similarity 
score calculation, including the permutation test to discover if the number of edges shared 
between two diseases is greater than would be expected by random chance).  The shared-edge-
sets were based on path-sets calculated from the 3,724 genes measured in all diseases, and 
using a more lenient threshold of 500 in order to capture as many shared edges between 
diseases as possible.  If a threshold of 100 was used for this analysis, proportionately fewer 
shared edges were found (Appendix L).   
Many of the clusters in Figure 4.6 reflect known disease relationships: there are strong edge 
similarities between multiple experiments measuring the same or similar diseases (renal clear 
cell carcinoma; nasopharyngeal carcinoma; Sjogren’s syndrome; Parkinson’s disease; 
ulcerative colitis and Crohn’s disease; Duchenne muscular dystrophy) as well as between 
diseases which are symptomatically (polycystic ovary syndrome and acne) or pathologically 
(head and neck and esophageal squamous cell carcinomas) related.  Overall, 45% of significant 
pairs are in the same Disease Ontology (DO) top-level class (e.g. ‘disease of anatomical 
entity’); 18% in the same DO sub-class (e.g. ‘musculoskeletal system disease’), making them 
2.5 times more likely to be in the same sub-class than diseases that do not share edges (Table 
4.2).  Interestingly, 17 of the 27 same-disease pairs (two experiments measuring the same 
disease) do not share significant numbers of edges, again illustrating the discordance between 
different measurements of the same condition. 
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In the same Disease Ontology top-level 
class 
44.7% 26.3% <2.20e-16 
In the same Disease Ontology sub-class 18.1% 7.2% <2.20e-16 
Share drugs (in Phase III clinical trials 
or approved) 
17.2% 8.0% 1.33e-13 
Share disease-associated genes 19.2% 10.8% 5.27e-10 
 
 
However, many disease pairs which share edges are not obviously related, such as the 
connections between diseases in different DO classes shown in Table 4.3.  Some of these 
relationships are not entirely unexpected – for instance, acne is a symptom of polycystic ovary 
syndrome, so it is unsurprising to find that these two share some dysregulated processes.  Other 
relationships are less obvious, such as between cervical intraepithelial neoplasia (CIN) and 
Dengue fever.  Table 4.3 shows that their shared-edge-set contains five drug-interacting genes 
for CIN, suggesting that the shared edges are strongly linked to a known (druggable) biological 
process dysregulated in CIN, which may also be relevant in Dengue fever.   
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different	Disease	Ontology	 (DO)	 classes	or	 subclasses)	and	 links	between	common	and	 rare	
diseases	(italicized).		

















In the same DO subclass 






Atopic dermatitis, psoriasis 51 STAT3  CCND1 
STAT3 
Cervical squamous cell carcinoma.1, esophageal 
squamous cell carcinoma 
96 RB1 TOP2A 
ITGB3 
In different DO (sub)classes 
Hutchinson-gilford progeria.1, thrombocythemia 54 PTPN11 - 









Acne, polycystic ovary syndrome 48 IRF1 ITGB2 
Actinic keratosis, sepsis 33 - PRKCA 
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Overall, 42% of significant shared-edge-sets contain a disease gene for at least one of the 
diseases, and 52% of significant shared-edge-sets contain a drug-interacting gene for at least 
one of the diseases.  This figure increases the greater the number of edges that are shared above 
random, so for the top 100 most significant disease pairings (of the 676 significant pairs, the 
100 pairs with the greatest difference in the number of edges shared from the median number 
of shared edges observed in the random permutation test – this is actually 106 pairs here, due 
to ties), 62% of shared-edge-sets contain a disease-associated gene and 75% a drug-interacting 
gene.  Excluding same-disease pairs (e.g. Parkinson’s disease, Parkinson’s disease.1), 7.4% 
and 15.9% of these genes respectively are relevant to both diseases. 
	








	 All 676 
significant 
disease pairs 
Top 100 most 
significant 
disease pairs 
Percentage of significant disease pairs which 
include a disease-associated gene for either 
disease in their shared-edge-set 
41.7% 62.2% 
Percentage of these genes associated with both 
diseases (excluding same-disease pairs) 
6.4% 7.4% 
Percentage of significant disease pairs which 
include a drug-interacting gene for either disease 
in their shared-edge-set 
51.9% 74.5% 
Percentage of these genes associated with both 
diseases (excluding same-disease pairs) 
9.8% 15.9% 
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The percentage of drug-interacting genes in shared edges which are applicable to both 
diseases suggests that within the shared-edge-sets, there may be other drug-interacting genes 
currently associated with only one of the diseases which could be applicable in the other 
disease.  This could imply the possibility for drugs to be repurposed from one disease to the 
other.  In fact, diseases that share edges are 1.78x as likely to share drugs than diseases that 
don’t share edges (Table 4.4), rising to 3.38x as likely for the top 100 most significant disease 
pairings. 
 
4.3.6 Shared paths highlight shared mechanisms between rare and 
common diseases which may be used for drug repurposing 
The shared-edges approach is particularly useful for investigating connections between 
common and rare diseases, enabling the discovery of potential disease-associated genes 
through an association transfer approach: common diseases are usually better studied than rare 
diseases, so are more likely to have known disease-associated genes.  If these KDGs are 
associated with processes shared by the two diseases, then they could feasibly also be important 
in the rare disease. 
One example of a connection between a common and a rare disease is the link between 
polycystic ovary syndrome and Pompe disease.  Polycystic ovary syndrome (PCOS) is a 
common condition in which elevated levels of androgens are produced in the ovaries, resulting 
in anovulation, irregular periods, and difficulty conceiving.  The exact cause is not known, but 
it is thought to be associated with high blood insulin levels caused by insulin resistance.  Pompe 
disease (otherwise known as Type II glycogen storage disease) is an inherited metabolic 
disease caused by deficiency in the acid alpha-glucosidase enzyme, which results in the 
accumulation of glycogen inside cellular lysosomes, causing progressive muscle wasting, liver 
enlargement, and respiratory difficulties. Interestingly, polycystic ovaries are known to appear 
in females with glycogen storage disease at a much higher prevalence than in healthy 
females204, although without necessarily displaying related symptoms such as amenorrhea205; 
the link is thought to be due to impaired glucose tolerance in Pompe disease patients. 
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Figure 4.7 shows the shared edges dysregulated in Pompe disease and PCOS.  The shared 
dysregulated components are centred around two hub genes, LYN and SYK.   Activation of 
spleen tyrosine kinase (Syk)206, and possibly tyrosine-protein kinase Lyn (Lyn)207, together with 
insulin-mediated activation of PI3-kinases208 (in Figure 4.7, represented by PIK3R2, PIK3CG, 
PIK3CD), is involved in activation of Akt (protein kinase B).  Akt inactivates glycogen synthase 
kinase 3 (GSK-3)207, inducing glycogen synthesis.  The upregulation in the genes 
corresponding to these kinases might therefore be indicative of increased glycogen synthesis, 
which would seem counter-intuitive: in PCOS, decreased insulin-stimulated glycogen 
synthesis has previously been reported in granulosa cells209.  It should be noted, however, that 
3 of the 7 PCOS samples in the gene expression study used here were from non-insulin-resistant 
patients, which might be one explanation for the observed upregulation in this part of the 
glycogen synthesis pathway.  In Pompe disease, increased glycogen synthesis also seems 
counter-intuitive, but could be related to the inability to break down stored glycogen – glycogen 
storage has previously been found to correlate with an increase in glycogen synthesis-
promoting factors with in a murine model of Pompe disease210. 
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Also highlighted in Figure 4.7 is the upregulated integrin-beta 2 (ITGB2), a drug-interacting 
gene in PCOS which participates in a two-way interaction with SYK.  ITGB2 is the beta subunit 
of the integrin LFA-1, which is inhibited by simvastatin211.  Statins, such as simvastatin, act by 
inhibiting HMG-CoA reductase, which has two possible therapeutic mechanisms in PCOS.  
The first is the reduction of cholesterol synthesis, which may in turn result in decreased 
androgen production; the second is through the reduced production of another product of the 
same pathway, dolichol212.  Dolichol is required for maturation of insulin receptors, so 
decreasing its levels may therefore reduce the effects of excess insulin in PCOS212; in Pompe 
disease, this could potentially support the reduction of glycogen synthesis through reduced 
insulin receptor levels.  Unfortunately, a literature search reveals that this finding may not be 
particularly promising due to the potential of statins to cause myopathy in patients with Pompe 
disease213.  It is also worth noting that the activity of simvastatin on the shared target ITGB2 
specifically is thought to produce an anti-inflammatory effect214 rather than being involved in 
the HMG-CoA pathway, therefore the shared path-set shown in Figure 4.7 might not be directly 




Figure 4.8 Paths dysregulated in polycystic ovary syndrome and Pompe disease, 






As discussed in Section 4.3.3, KDGs that are not differentially expressed in disease can be 
associated with dysregulated paths by searching the first-neighbour genes.  Amongst the first-
neighbour KDGs of the shared-edge set of PCOS and Pompe disease (Figure 4.8) is MTOR.  
The mechanistic target of rapamycin complex 1 (mTORc1), of which mTOR is a core 
component, is inhibited by metformin, a drug commonly prescribed for type II diabetes due to 
its ability to decrease high blood glucose levels, but which may also be used in PCOS215.  
Chronic activation of mTORc1 is known to play a role in insulin resistance due to feedback 
inhibition of insulin signalling, and so its inhibition by metformin may improve the metabolic 
profile in insulin-resistant individuals216.   
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In Pompe disease the problem is not insulin resistance but glycogen accumulation.  Here, 
mTOR inhibition is also of therapeutic interest: inhibition of mTOR via rapamycin has been 
shown to block amino-acid induced inactivation of glycogen synthase kinase 3, decreasing 
glycogen synthesis217, making it a potential therapeutic avenue for glycogen storage diseases.  
Rapamycin therapy has demonstrated some benefit in a canine model of glycogen storage 
disease type III218 and may also be potentially useful in Pompe disease (glycogen storage 
disease type II)219, although this is not without controversy220.  Given the similarity between 
PCOS and Pompe disease discussed here, perhaps metformin could also be considered as a 
useful mTOR inhibitor in Pompe disease. 
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4.3.7 Path-set analysis captures the mechanism of action of cediranib 
 
Table 4.5 Known disease-associated genes and drug targets (KDGs) in path-sets 
compared to in the same number of OmniPath genes by absolute log-fold change or 
random selection. 
Path-sets	 capture	more	KDGs	compared	 to	 selecting	 the	 same	number	of	genes	by	 log-fold	
change	(LFC-set)	or	random	selection.		






sets contained at 








0.47 0.32 0.34 0.23 
How many 
KDGs were 









1.05 0.74 0.60 0.31 
	
Path-set analysis was also applied to human drug response datasets, to investigate whether a 
drug’s path-set may be able to reveal details of its mechanism of action.  The analysis in Section 
4.3.2 was repeated for the drug response datasets, although here, the definition of a relevant 
gene is slightly different.  For drug response, a relevant gene is defined as a the gene 
corresponding to a target related to the drug’s primary mechanism of action (as defined in 
Section 4.2.2). Given that most drugs in this dataset have only one primary target, and that only 
33% of target genes show non-zero differential expression in the corresponding dataset, it is 
not surprising to find that the primary target could only be discovered in three of the 17 drug 
path-sets for which a primary target was available – cediranib, sunitinib, and tamoxifen. 
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However, the definition of a relevant target can also be extended to include disease-associated 
genes for the indication in which the drug experiment took place, under the assumption that an 
effective drug might target proteins located near to disease genes in the interactome (a 
loosening of the disease modules concept described in the work of Guney et al.221).  This could 
provide a way to evaluate whether the drug path-set contains genes related to its mode of action 
in cases where the target itself is not differentially expressed.  Under this definition, drug-
relevant targets are discovered in 9 of the 19 datasets, finding a mean of 1.05 targets per path-










The path-set of cediranib, a vascular endothelial growth factor receptor (VEGFR) inhibitor for 
the treatment of various cancers, was examined as a case study.  No known disease-associated 
genes of alveolar soft part sarcoma (the rare cancer in which cediranib response was studied) 
are seen in the cediranib path-set, but genes corresponding to its target VEGFRs (FLT1, FLT4, 
and KDR) are shown to be down-regulated (Figure 4.9).  The kinase Fyn, whose corresponding 
gene forms a hub in this path-set, is activated by VEGFR1 (FLT1) signalling222; FYN 
expression is decreased in this study, suggesting possible transcriptomic disturbance following 
VEGFR1 inhibition.  By contrast, the LFC-set of cediranib does not include its target FLT4, 
and does not capture the hub gene FYN, thereby missing a possible network structure through 
which transcriptomic signals of VEGFR inhibition may be transmitted in the cell.  Another 
cediranib target whose corresponding gene is shown in Figure 4.9 is platelet-derived growth 
factor receptor alpha (PDGFRA), which is also inhibited by cediranib due to its structural 
similarity to VEGFR223.  In contrast to the VEGFR genes, however, PDGFRA is upregulated 
following cediranib administration, suggesting a role for different transcriptomic feedback 





Given the noise inherent to gene expression data, new methods of analysis are needed which 
bridge the gap between individual fold change analysis and high-level biological pathway 
methods.  This chapter describes the use of path-set analysis to relate gene expression changes 
on the human signalling network, enabling the discovery of dysregulated signalling paths in 
disease and drug response.  The adaptation of the original framework proposed by Sambarey 
et al.121 constrains the paths to differentially expressed genes, forming disease-specific 
subpaths which can be used to compare dysregulated paths across diseases. 
The dysregulated paths are enriched for known disease-associated genes and drug-interacting 
genes (KDGs) compared to a gene-set of the same size based on magnitude of differential 
expression (Table 4.1).  Whilst the aim of path-set analysis is not to find putative disease-
associated genes (in which case limiting the path-sets to differentially expressed genes would 
be counter-productive), their presence confirms the relevance of the returned paths, and aids 
the interpretation of the observed gene expression by showing how dysregulated genes are 
interacting with genes known to influence the pathogenesis or treatment of disease.  In drug 
response datasets, while only a few path-sets captured the primary targets of the drug (possibly 
due to the low likelihood of the drug’s target to be differentially expressed in response to drug 
administration224,225), path-set analysis captured known disease variant genes for the disease in 
which the drug was given for 9 of the 19 drug path-sets.  This could be used as a measure of 
efficacy of a drug in a given disease, i.e., an ‘effective’ drug (one that treats the underlying 
cause of a disease rather than just the symptoms) is one that affects the expression of disease-
associated proteins.  This concept was introduced by Guney et al.221, who used the proximity 
of a drug’s targets to disease-associated proteins as a measure of efficacy, successfully applying 
this measure to make suggestions for drug repurposing.   
Applying path-set analysis over multiple diseases allows the identification of genes which are 
frequently dysregulated in disease. These genes may be acting as points of influence in the 
network whose modulation is associated with the development of a disease, either causal 
(resulting from a disruption in function through a variant or mutation) or opposing (alleviating 
symptoms of the disease through pharmacological interference).  The frequency with which 
these genes are involved in dysregulated paths shows a moderate correlation with their degree 
(one measure of network importance), which is not evident for genes which show high log-
fold changes in many diseases (Figure 4.5).  Previous research on the network topology of 
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disease-associated processes has been focused on genetic variants, and this has produced 
somewhat differing results226.  One key study found that ‘essential’ genes required for survival 
tended to be network hubs, whereas disease-associated genes tended to be non-essential, non-
hubs15.  However, genes which show somatic mutations in disease (i.e., cancer-associated 
genes) tend to have a more central network position15,226; and research looking specifically at 
rare diseases has found that genes associated with rare diseases do tend to be hubs227.  Similarly, 
drug targets should be ‘highly influential in, but not toxic to, the functioning of the entire 
network’228; drugs targeting hub genes tend to have more side effects229.  The moderate 
correlation between a gene’s frequency in path-sets and its degree may be explained by the 
same principle: genes that are moderately important in signalling are frequently in path-sets, 
but the most important (highest-degree) genes which are essential to the functioning of the cell 
tend not to show expression dysregulation, and are therefore not so likely to be included in 
path-sets.   
As every gene in a disease’s path-set is differentially expressed in the disease, path-set analysis 
can also be used to identify dysregulated paths which are shared between diseases.  Disease 
pairs that share edges are 2.5 times more likely to be in the same Disease Ontology subcategory 
than those that don’t (Table 4.2), confirming that shared edges reflect known disease 
relationships.  Potentially more interesting are the cases where dysregulated paths are shared 
between two diseases which are not known to be related.  The case study of PCOS and Pompe 
disease illustrated how path-set analysis can highlight dysregulated processes shared between 
phenotypically distinct diseases, and how drug-interacting genes in shared paths might be used 
to suggest potential drug-sharing options between the two diseases.  With 52% of disease pairs 
containing a drug-interacting gene for at least one of the diseases, this analysis could be 
extended to many other disease pairs.  This analysis can also be applied to non-differentially 
expressed first-neighbour genes, as shown with the example of metformin in PCOS and Pompe 
disease.  Targeting first-neighbours of differentially expressed genes has been proposed as a 
drug repurposing strategy in cancer230, and network proximity to differentially expressed genes 
has been shown to be a good predictor of potential drug targets for repurposing231, suggesting 
that this could be a viable repurposing strategy where diseases share dysregulated edges.  
A potential limitation of path-set analysis is the applicability of the general human signalling 
network on which this method is based.  The interactome is known to vary across different 
tissues and may be altered in disease232; future developments of path-set analysis could 
incorporate tissue- or disease-specific interactomes which would provide a more accurate 
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picture of interactions taking place in individual diseases.  Unfortunately, our knowledge of 
the general human interactome (much less condition-specific alterations) is highly 
incomplete84, and although this work is based on the most comprehensive signalling network 
published to date82, it will necessarily contain inaccuracies and omissions.  Related to this, 
genes with no known interactions are necessarily excluded from the analysis, meaning that 
important genes may potentially be omitted.  This situation should improve in future, as our 
knowledge of the interactome develops further.  Despite its current limitations, network data 
represents a valuable ‘extra dimension’ whose integration with gene expression data can result 
in improved interpretability and ease of analysis. 
Path-set analysis represents a valuable addition to the transcriptomic analysis toolkit, which 
can be used to identify interactions between dysregulated genes, genetic variants, and drug-
interacting genes in disease.  Here, path-set analysis was used to discover dysregulated 
processes shared between diseases, highlighting common molecular mechanisms underlying 
disease and revealing new connections between conditions.  As the vast amount of 
transcriptomic data continues to grow, this type of analysis will be key to improving our 
understanding of gene expression in disease. 
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5 UNDERSTANDING AND PREDICTING 
DISEASE RELATIONSHIPS THROUGH 
SIMILARITY FUSION 
 
This work was previously published as Erin Oerton, Ian Roberts*, Patrick S. H. Lewis*, Tim Guilliams*, Andreas 
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SUMMARY 
Relationships between diseases can be defined on multiple levels, from the observable 
phenotype down to molecular-level events.  Combining information across these levels could 
yield a systems-level view of disease relationships, aiding our understanding of common 
biological processes taking place in disease.  However, each of these levels differs in features 
and information content, and it is unclear how they could be most effectively combined.  In 
this chapter, a similarity fusion approach is proposed which enables comparison of diverse data 
types.  This method is applied to 6 different data types (ontological, phenotypic, literature co-
occurrence, genetic association, gene expression, and drug indication data) for 84 diseases to 
create a ‘disease map’: a network of diseases connected at one or more biological levels.  
The fused similarities are used to classify diseases into known categories from the Disease 
Ontology.  With a mean Random Forest AUROC of 0.95 for these two tasks, the disease map 
scores over 10% higher than the mean of its component spaces, confirming that the fused values 
are good predictors of known disease relationships.  As well as known relationships, 15% of 
links in the disease map are novel links that span traditional ontological classes, such as 
between psoriasis and inflammatory bowel disease.  62% of diseases linked in the disease map 
share drugs (approved or in Phase III clinical trials), illustrating the relevance of the disease 
map to the identification of potential therapeutic relationships.  The analysis presented here 
illustrates how similarity fusion can give greater insight into shared disease biology than 
individual data types alone. 
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5.1 INTRODUCTION 
Establishing relationships between diseases increases our understanding of disease biology, 
aiding the identification of shared mechanisms or development of new treatments, for 
example through drug repurposing. As discussed in Chapter 1, existing disease classification 
systems such as the International Classification of Diseases8 and Medical Subject Headings11 
are based on established clinical relationships between diseases.  There is therefore great 
biological and pharmacological interest in the identification of novel disease relationships 
using new types of evidence arising from the development of bioinformatics technologies.   
As well as the gene-expression based approaches to relating diseases covered in Section 
1.4.1.240,107, other -omics data types that have been used to explore disease relationships 
include disease-associated genes15,233,234, protein interaction networks84, pathways235 and 
biological processes236.  Rather than examining each of these different data types in isolation, 
however, recent studies have related diseases by considering multiple data types 
simultaneously.  These data integration approaches can provide a more comprehensive 
understanding of disease, potentially reflecting interactions between the different layers of 
the biological system237 where links at one layer (e.g. genetic variance) are associated with 
changes at another layer (e.g. gene expression or phenotype). Recent examples have 
demonstrated how this can be achieved through the use of heterogeneous networks, such as 
the DiseaseConnect web server developed by Liu et al.238, or through matrix factorization 
approaches, such as that presented by Zitnik et al.239. 
However, these approaches do not quantify the overall strength of the relationship across 
multiple levels.  Defining a measure of disease similarity that takes into account multiple data 
types is not straightforward, as such a measure must consider differences between properties 
such as information content122.  Sun et al.240 evaluated disease similarity by defining a feature 
vector for each disease in which every element (genes, chemicals, pathways, and GO terms) 
was weighted according to its information content.  The downside of this approach is that it 
requires an entry for each entity in the feature universe, needing a feature vector of tens of 
thousands of dimensions to represent just four spaces.  Computing similarity across multiple 
spaces by this approach therefore does not scale readily to large numbers of feature spaces.  
In this work, this issue is addressed by translating the feature vectors in each space into 
pairwise disease similarities, thus capturing disease relationships in a lower-dimensional 
space before performing the integration step to define an overall measure of similarity.  This 
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‘similarity fusion’ approach has been successfully applied to integrate data in drug 
repurposing241,242, gene prioritization243 and patient subtyping and survival analysis244,245.  
Yet there have been few applications of this approach to quantify disease similarity.  In one 
study, disease similarities were computed by integrating literature-based similarity of 
diseases with protein interaction network topology-based similarity of their associated 
genes246; more recent work related diseases through ‘meta-correlation’, combining similarity 
amongst gene expression and electronic health record profiles of diseases247.  Another study 
integrated similarity in nine different spaces according to a pre-defined ‘importance’, with the 
resulting relationships weighted towards genetic similarities248.  Although the relative 
‘importance’ of each relationship type naturally depends on the context in which the map is 
used, no study has yet defined a general method for the combination of multiple disease 
similarities in an unbiased manner.  In particular, unbiased combination of spaces requires 
consideration of the underlying distributions of similarity in each space.  Here, quantile 
normalization (usually associated with microarray statistics) is used to adjust the distributions 
of similarity in each space, enabling balanced comparison and combination of disease 
similarities across multiple spaces.   
In summary, in this chapter the proposed similarity fusion approach is applied to six different 
data types – ontological, phenotypic, literature co-occurrence, genetic association, gene 
expression, and drug data – to create a disease map: a network of diseases connected at one 
or more biological levels.  The disease links revealed by the map are explored, with a focus 
on disease pairs not previously known to be related, and evaluated against their relation to 






Figure 5.1 Disease similarity fusion workflow 








5.2.1 Disease dataset construction 
The disease dataset which formed the basis of this work was compiled based on available 
transcriptomic experiments as described in Section 2.2.  In order to ensure data coverage 
across all six spaces, this was limited to common diseases.  Where multiple transcriptomic 
experiments were present for a disease, one experiment was randomly selected to represent 
the disease.  This resulted in a dataset of 84 diseases, some of which were closely related (e.g. 
asthma and allergic asthma; see Appendix C).  39 of these diseases are in the Disease 
Ontology (DO) class disease of anatomical entity, 25 are in the DO class disease of cellular 
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proliferation, and the remainder are distributed across the other top level DO classes, with the 
exception of class physical disorder (no diseases in the dataset belong to this class).  These 
diseases were mapped to the most closely matching disease terms in each space (e.g. 
‘teratozoospermia’ may map to ‘azoospermia’ or simply ‘male infertility’, depending on what 
representation is available in each space; see Appendix D for details).   
Feature sets for each disease were then constructed as detailed below in each of ontological, 
phenotypic, literature co-occurrence, genetic, transcriptomic, and drug spaces (Figure 5.1) 
using R version 3.3.2133.  The feature set size of phenotypic space was restricted by the 
dataset used; the feature set size of drug space was restricted by the limited number of drugs 
prescribed for each disease.  For the remaining spaces, different feature set sizes of 20, 50, 
100, and 200 were tested.  A feature set size of 100 was chosen, as this captured sufficient 
information in each space whilst not being overly large compared to the fixed-size feature 
spaces (see Appendix M for exploration of different feature set sizes).  The exact number 
may be slightly more or less than 100 for some diseases due to e.g. ties in the data, this is 
detailed for each feature space below. 
Ontological feature space: The Disease Ontology191 was downloaded from 
http://ontologies.berkeleybop.org/doid.obo in December 2016 and used to match disease 
names to their Disease Ontology ID.  The DOSE package249 was used to measure semantic 
similarity between Disease Ontology IDs using Lin’s measure250, which minimizes the number 
of ties between terms.  The feature set for each disease was then calculated as the top 100 most 
similar diseases according to this metric, excluding self-similarity.  When there are ties for the 
top 100th similarity value, all tied diseases are retained, so some diseases have more than 100 
features (up to a maximum of 135).  Two diseases (irritable bowel syndrome and polycystic 
ovary syndrome) have no similar diseases according to DOSE, so these are assigned a feature 
vector of size zero in this space.   
Phenotypic feature space: Disease-phenotype associations were taken from the work of 
Hoehndorf et al.251 who matched diseases with terms from the Human and Mammalian 
Phenotype Ontologies based on literature co-occurrence.  This dataset, which comprises the 21 
most highly-associated Human/Mammalian Phenotype Ontology terms for each disease, was 
obtained from http://aber-owl.net/aber-owl/diseasephenotypes/data/ in November 2016, and 
this formed the feature set for the phenotypic feature space.  Duplicated phenotypes in the 
supplied data (e.g. the term ‘myocarditis’ is found in both the Human and Mammalian 
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Phenotype ontologies) were removed, resulting in 16 of the 84 diseases having only 19 or 20 
features in this space. 
Literature co-occurrence feature space: 13 million Medline abstracts (dating between 2000 
and 2016) were annotated with MeSH term identifiers using a recently published named entity 
recognition system, TaggerOne252.  The normalized pointwise mutual information (NPMI) 
score between MeSH terms in these abstracts was calculated as a measure of co-occurrence.  
This work was carried out by Patrick Lewis, as named in the author list at the beginning of the 
chapter.  These terms mostly represent MeSH disease concepts, although they also include a 
few more general concepts such as ‘body weight’ or ‘infection’, or higher level disease terms 
such as ‘nervous system diseases’ or ‘musculoskeletal abnormalities’.  The feature set for this 
space was the top 100 most highly co-occurring MeSH terms by NPMI score, excluding self-
similarity.  Three diseases had less than 100 co-occurring terms (allergic contact dermatitis 
with 23, male infertility with 55, and juvenile rheumatoid arthritis with 80).  Certain MeSH 
terms overlap with the Human/Mammalian Phenotype Ontology terms used for the phenotypic 
space (e.g. ‘diabetes mellitus’, ‘neoplasms’ and ‘carcinoma’ are examples of terms that are 
included in both sets), so there is a degree of overlap between these two spaces.   
Genetic feature space: Disease-gene associations were downloaded from DisGeNET253 
(http://www.disgenet.org/web/DisGeNET/menu/downloads) in November 2015.  These 
mostly represent associations of type ‘genetic variation’, which includes susceptibility 
mutations, causal mutations, and modifying mutations; there are also a small number of 
associations of type ‘post-translational modification’ and ‘therapeutic’.  Associations of type 
‘AlteredExpression’ were removed to avoid overlap with the transcriptomic feature space, and 
entries for the non-gene ‘NEWENTRY’ were removed.  The feature set was composed of the 
top 100 associated genes by evidence score.  There was high variation in the number of genes 
associated to each disease: 19 diseases have less than 100 associated genes (10 diseases have 
less than 20), but there were also a large number of ties in the data due to the calculation of the 
evidence score for each gene, leading some diseases to have more than 100 associated genes.  
10 diseases had more than 100 genes, up to a maximum of 207 genes for malignant pleural 
mesothelioma. 
Transcriptomic feature space:  Gene expression microarray experiments were selected as 
described in Section 2.2, and differential expression profiles for each probe were generated as 
described in Section 2.3.  The feature ‘universe’ was defined as the set of 4,482 genes measured 
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in all experiments; the feature set for each disease was then calculated as the top 100 of these 
genes by absolute log-fold change at a p-value threshold of <0.05.  
Drug feature space: Drug indication data was downloaded from ChEMBL version 22.1192 
(https://www.ebi.ac.uk/chembl/downloads), as in Section 4.2.2.  The feature set comprised 
approved drugs for each condition.  The number of approved drugs listed for each disease in 
ChEMBL ranges from 0 (for 11 conditions, including four diseases – dengue fever, leukopenia, 
limb-girdle muscular dystrophy, and measles – which could not be mapped to EFO or MeSH 
terms used by ChEMBL) to 72 (for type II diabetes). 
The spaces have different sparsities: phenotype is the most sparse space, with only 7.5% of 
disease pairs having any overlap in their phenotypes; followed by ontological at 12.9%, drug 
at 13.6%, co-occurrence at 58.5%, genetic at 83.3%, and finally transcriptomic space, with 
84.4% of disease pairs having some overlap.  This is related to the size of the feature set in 
each space relative to the size of the feature universe. 
 
5.2.2 Independent comorbidity dataset 
Comorbidity associations based on Medicare records of 13 million patients254 were 
downloaded from sbi.imim.es/data/hudine in July 2018.  Diseases are recorded in this data as 
ICD9 3-digit codes; mapping the set of 84 diseases to these codes resulted in duplicated codes 
for 14 diseases (e.g. type 1 and type 2 diabetes mellitus both map to 250 diabetes mellitus; 
bipolar disorder and major depressive disorder both map to 296 episodic mood disorders; see 
Appendix D for mappings).   
Disease pairs with less than 100 co-occurrences were filtered out (as the relative risk (RR) 
comorbidity measure tends to overestimate for pairs with small numbers of observed 
associations255), leaving 88,347 disease pairs for which comorbidity data was recorded.  800 
of these observations related to disease pairs in the dataset of 84 diseases, which when the 14 
duplicate mappings are included covers 938 (27%) of the 3,486 disease pairs in the dataset.  
Relative risk (RR) was used to quantify comorbidity, where a RR of 1 indicates that diseases 
occur together as often as expected by chance.  The lower quantile, median, and upper quantile 
values of RR in the 800 recorded pairs were 0.76, 1.07, and 1.62.   
RR thresholds of 1.5, 2, and 5 were used to define comorbid disease pairs, with 239, 125 and 
32 of the 800 observed disease pairs respectively meeting these thresholds.  Of the 938 disease 
pairs in the dataset for which comorbidity data exists, the percentage of the 63 disease pairs 
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linked in the map which were comorbid at these thresholds were compared to the percentage 
of the 875 disease pairs not linked in the map which were comorbid at these thresholds.  In 
both cases, duplicate pairs were counted twice (e.g. “type 1 diabetes-obesity” and “type 2 
diabetes-obesity” were counted as two separate pairs although they both map to “250-278” at 
the ICD code level). 
 
5.2.3 Similarity fusion 
Pairwise similarity scores between each of the 84 diseases were calculated based on the 
Jaccard index256 of their feature sets.  In the case of transcriptomic data, the up- and down-
regulated genes are considered separately, and so the Jaccard score was calculated as a 
weighted average of Jaccard scores for the two sets.   
As the distributions of similarity scores within each space are uneven, fusion of the raw 
similarity scores would cause those spaces with higher average scores to dominate the fused 
similarity.  Even if the scores are normalized to the same sum, the fused similarities would 
still be affected by the differences in distribution of similarity values in each space (e.g. 
causing sparse spaces to dominate the fused scores at high similarities).  Quantile 
normalization257 was therefore applied to adjust the distributions of similarity scores towards 
each other, enabling comparison and combination of each space independently of their 
distributions.  
Quantile normalization, which has been previously mentioned in the context of microarray 
normalization (Section 2.1.2), involves replacing each value with the mean value of the same 
rank across each space.  In the example shown in Table 5.1, the maximum similarity scores 
are 0.556 in phenotypic space and 1 in drug space, and so the maximum similarity score in 
both spaces is replaced with the mean of these two values: 0.778.  The second highest values 
are 0.481 in phenotypic space and 0.500 in drug space, so these scores are replaced in each 
space with the mean of 0.4905, and so on.  Adjustment for ties is used, so that tied ranks are 
















New value in 
drug space after 
quantile 
normalization 





Highest value 1 0.556 0.778 0.778 
2nd highest 
value 
0.500 0.481 0.491 0.491 
3rd highest 
value 
0.490 0.460 0.475 0.470 
… 0.480 0.460 0.470 0.470 
… 0.470 0.460 0.465 0.470 
 
Following quantile normalization of the similarity values using limma’s normalizeQuantiles 
function, a single ‘fused’ similarity score was computed by taking the mean of the quantile-
normalized similarity values for each disease across each space, resulting in a 3,486-
dimensional similarity vector (or an 84*84 symmetric similarity matrix) forming the basis of 
the disease map. Figure 5.1 shows an overview of this process.  The majority of the analysis 
presented here is based on an unweighted mean of spaces, although the method allows the 
specification of weights in order to adjust the influence of each space on the fused 
similarities, in which case a weighted mean of spaces is calculated.  
 
5.2.4 Defining a significance threshold for disease similarity 
To construct the disease map, a threshold of significant similarity t was defined above which 
diseases are linked, based on 1000 random similarity matrices.  Randomized feature vectors 
were constructed for each disease by sampling from the feature universe, defined as the union 
of all features in that space across all diseases in the dataset, according to their distribution 
(frequency) in the dataset.  Using these random feature vectors, 1000 random fused similarity 
matrices were created.  The 99.99th percentile of the random similarity scores (equivalently, 
the maximum similarity observed in 83% of the random matrices) was taken as the threshold 
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of similarity above which diseases were considered to be linked.  6.9% of similarity values in 
the network were above this threshold.  Cytoscape258 was used for network visualisation. 
  
5.2.5 Evaluating the fused similarity scores 
An initial evaluation of the fused similarity scores was carried out against the independent 
disease comorbidity dataset254 described in Section 5.2.2, which covers 938 of the 3,486 
disease pairs in the dataset.  Any disease-related evaluation data covering all diseases could 
also be used as a feature space, and so for more detailed evaluation a ‘hold-out’ style of 
evaluation was used measuring how well one feature space is represented in the remaining 
five.  Two feature spaces were chosen to capture different aspects of disease-relatedness.   
Firstly, drug approval information (obtained from ChEMBL as described in Section 5.2.2, 
although here drugs in Phase III clinical trials were also included) measures whether 
similarity between two diseases might indicate drug-sharing potential.  Secondly, 
membership of Disease Ontology top-level classes (e.g. disease of anatomical entity, disease 
of cellular proliferation) measures how closely disease associations match established 
notions of clinical similarity.   This was evaluated by training a random forest classifier on 
the pairwise similarity values, using the R package randomForest259 with default parameters.  
To ensure availability of sufficient training data, DO class prediction was split into two 
binary tasks – membership of disease of anatomical entity, and membership of disease of 
cellular proliferation (as these are the two largest classes within the dataset).  Model 
performance was evaluated using stratified Monte Carlo cross-validation, with an 80-20 split 
into training and test sets.  The true positive rate (TPR), false positive rate (FPR), and area 
under the ROC curve (AUROC) were calculated using the function performance from the 
package ROCR260 averaged over 1,000 runs.  In order to display ROC curves, TPR and FPR 
were averaged only over those runs where the mode average number of data points were 




5.3.1 Exploratory disease map analysis identifies existing and novel 
disease relationships  
Similarity fusion (Figure 5.1), which enables comparison and combination of heterogeneous 
data types, was used to create a ‘disease map’: a network of diseases that are linked at multiple 
biological levels.  Links in the disease map represent similarities above a threshold of 
significance (calculated as described in Methods) between the 84 diseases analysed here, as 
shown in Figure 5.2.  81 of the 84 diseases are included in the map, with cystic fibrosis, 
teratozoospermia, and placental malaria not showing any significant links to other diseases.  
Many links in the map correspond to the traditional ontological classes represented by the 
Disease Ontology (DO) – particularly within the DO classes disease of cellular proliferation, 
disease by infectious agent and respiratory system disease – but many novel links were 
additionally observed that span traditional disease categories, here defined as disease pairs 
which are not in the same top-level DO class.  These novel links, which are listed in Table 5.2, 
make up 15% of the links in the disease map. 
The network consists of two densely connected areas, the first containing cancers (yellow 
nodes) and the second composed of inflammatory bowel diseases, skin diseases, and immune 
system diseases (blue and purple nodes).  The strong interconnection between cancers has been 
noted in other disease similarity studies such as the Human Disease Network of Goh et al.261, 
which found that cancers were highly interconnected due to common involvement of tumour 
repressor genes; the disease map confirms that this commonality is replicated across different 
spaces, with different cancers presenting e.g. similar phenotypes, similar gene expression 
responses, and potential to be treated with similar drugs.  The second densely connected area 
links diseases which are less obviously related, which will be explored in Section 5.3.2.  
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Many of the novel links in the network represent diseases of distinct aetiology which share 
similar clinical presentations, such as actinic keratosis and psoriasis, or chronic obstructive 
pulmonary disease and malignant pleural mesothelioma.  The shared features between each of 
these links can help to understand how these similarities arise: given any linked disease pair, 
the shared features which contribute to their similarity can be identified by simply taking the 
intersection of their feature vectors in each individual space, as demonstrated in Table 5.2.  
 
Table 5.2 Novel links between diseases in different Disease Ontology classes 
Novel	links	are	disease	pairs	which	have	similarity	higher	than	the	significance	threshold,	but	
which	are	not	related	by	the	Disease	Ontology	top-level	classes.		Many	novel	links	are	related	
in	 multiple	 feature	 spaces,	 indicating	 similarities	 on	 different	 biological	 levels.	 	 Some	
relationships	which	 fall	 under	 this	 definition	 are	 expected,	 such	 as	 the	 connection	 between	
inflammatory	bowel	disease	(DO	class	‘disease	of	anatomical	entity’)	and	colorectal	cancer	(DO	
class	 ‘disease	 of	 cellular	 proliferation’),	 as	 they	 affect	 the	 same	 organ	 system.	 	 Other	
connections,	such	as	between	hepatitis	B	and	cervical	cancer,	seem	surprising,	and	in	such	cases	
it	is	helpful	to	interpret	the	features	shared	between	the	two	diseases.	
Novel link Number of shared: 








Acne Actinic keratosis 1 15 1 18 0 
Acne Polycystic ovary 
syndrome 
1 16 0 15 0 
Actinic keratosis Atopic dermatitis 0 10 0 23 0 
Actinic keratosis Psoriasis 0 15 6 25 0 
Actinic keratosis Rosacea 3 15 4 13 0 
Alcoholism Head and neck squamous 
cell carcinoma 
0 33 2 2 0 
Alzheimer's 
disease 
Down syndrome 0 4 17 3 2 
Bacterial 
meningitis 




Chronic hepatitis b 
(carrier) 















Non-small cell lung 
carcinoma 






2 2 2 19 0 
Colorectal 
adenocarcinoma 
Crohn's disease 3 34 12 21 0 
Colorectal 
adenocarcinoma 
Irritable bowel syndrome 0 29 9 7 0 
Colorectal 
adenocarcinoma 
Ulcerative colitis 3 35 16 26 0 
Crohn's disease Dengue fever 5 1 17 4 0 
Crohn's disease Irritable bowel syndrome 0 22 27 6 4 
Dengue fever Systemic lupus 
erythematosus 
0 10 15 22 0 
Dengue fever Ulcerative colitis 5 2 15 3 0 
Dengue fever Vulvar intraepithelial 
neoplasia 
0 0 0 24 0 
Down syndrome Huntington's disease 0 4 12 0 1 
Endometrial 
carcinoma 
Endometriosis 7 21 8 1 0 
Endometriosis Polycystic ovary 
syndrome 
3 12 7 1 0 
Endometriosis Prostate cancer 3 3 6 1 1 
Chronic hepatitis b 
(carrier) 
Hepatocellular carcinoma 3 29 0 2 2 
Chronic hepatitis b 
(carrier) 
Sarcoidosis 0 2 35 9 1 
Chronic hepatitis c Hepatocellular carcinoma 3 28 0 0 0 
Chronic hepatitis c Sarcoidosis 0 2 31 15 0 
Idiopathic 
pulmonary fibrosis 
Non-small cell lung 
carcinoma 
2 6 7 19 0 
Influenza Leukopenia 2 5 9 21 0 






Ulcerative colitis 0 24 27 8 1 
Myocardial 
infarction 
Type 1 diabetes mellitus 0 0 17 26 2 
Obesity Polycystic ovary 
syndrome 
0 27 4 1 3 
Sarcoidosis Type 1 diabetes mellitus 0 2 26 15 0 
Sickle cell disease Essential 
thrombocythemia 
0 10 14 5 1 
	
As an example of this analysis, the unexpected connection between cervical squamous cell 
carcinoma and hepatitis B can be examined.  Table 5.2 shows that they share 42 genetic 
associations, including genes in the human leukocyte antigen system involved in antigen 
presentation (HLA-A, HLA-B, HLA-C, HLA-DPB1, HLA-DQA1, HLA-DQB1, and HLA-
DRB1); this suggests that the link between the two diseases is driven by shared aspects of 
immunological response.  This may reflect the involvement of the human papillomavirus 
(HPV) in the majority of cervical cancer cases, with the immune response playing a key role 
in the development of cervical cancer from an initial HPV infection262.  Likewise, the hepatitis 
B virus is a causal risk factor in the development of hepatocellular cancer263, so shared 
processes between the two diseases could also reflect the interface between infection and 
carcinogenesis of these two DNA viruses. 
If diseases linked in the map are pathologically related, they may be more likely to co-occur in 
the same patient.  Links in the disease map were therefore compared to disease comorbidities 
based on the medical records of 13 million patients254.  The 63 links for which comorbidity 
scores are available had a median relative risk (RR) of 2.35 (i.e. diseases are 2.35 times more 
likely to co-occur than expected by chance), compared to a median of 1.06 for the 875 disease 
pairs (for which comorbidity scores are available) that are not linked in the disease map.  71% 
of these links co-occur in patients at a RR threshold above 1.5, compared to 27% of the non-
linked pairs, or 2.6 times more often.  At higher RR thresholds of 2 and 5, this ratio increases 
to 4.6 and 10.6 respectively.  This relationship suggests that links in the disease map represent 


















Figure 5.3 Diseases related to psoriasis 
As	well	as	known	links	to	other	skin	diseases	(light	blue	nodes),	psoriasis	has	links	to	a	number	
of	phenotypically	distinct	diseases	with	an	autoimmune	component,	such	as	alopecia,	arthritis,	





The disease map also allows us to focus on connections of a disease of interest.  As a case 
study, I examine psoriasis and its related diseases, which form a densely-connected region of 
the map (Figure 5.2).  Psoriasis is classified as a skin condition in Disease Ontology, but is 
known to have immune and hereditary components264.   This is reflected in the disease map, 
which links psoriasis to a number of autoimmune diseases as well as to other skin diseases 
(Figure 5.3).  One example is the relationship between psoriasis and the inflammatory bowel 
diseases Crohn’s disease (CD) and ulcerative colitis (UC).  The inflammatory bowel diseases 
are phenotypically distinct from psoriasis, but both diseases involve an autoimmune 




Examining the feature sets of psoriasis, CD, and UC shows that they share a number of 
associations in genetic space, including Interleukin family genes IL12B and IL23R, involved 
in cytokine-mediated immune response; STAT3, which is activated by the interleukin IL6 (also 
shared) to produce inflammatory T-cells266; and (in psoriasis and UC) human leukocyte antigen 
HLA-B, which also plays an important role in the immune system.  Psoriasis, CD, and UC also 
show shared dysregulation in the expression of several genes including upregulation in the pro-
inflammatory S100 family (S100A8, S100A9) and CXC chemokines CXCL8, CXCL9, and 
CXCL10 (associated with immune system activation).  Importantly, some of their shared 
features are relevant to the drugs prescribed for these diseases: the monoclonal antibodies 
adalimumab and infliximab are antagonists of tumor necrosis factor267, a pro-inflammatory 
cytokine whose corresponding gene, TNF, shows genetic variation in a number of diseases 
including CD, UC, and psoriasis.  
 
5.3.3 Similarity conversion allows comparison of information content 
between feature spaces 
The use of quantile normalization allows the direct comparison of disease relationships present 
in the individual and fused feature spaces.  This can be quantified by the Pearson correlation 
between the pairwise disease similarities in each space (Figure 5.4).  The most similar spaces 
are phenotype and literature co-occurrence, with a Pearson correlation of 0.56.  Both spaces 
are based on literature-mining, and there is also a degree of overlap between MeSH disease 
terms and phenotypes (e.g. ‘diabetes mellitus’ is both a MeSH disease term and a phenotype 
in the Human Phenotype Ontology) so the two spaces are not completely orthogonal.  The 
ontological space also has high correlation with these two spaces, suggesting that these spaces 
capture ‘traditional’ knowledge of disease relationships.  By contrast, the low correlation (<0.2) 
across the three ‘non-traditional’ representations (genetic association, gene expression, and 






Figure 5.4 Correlation of pairwise similarity scores between feature spaces 
The	 high	 correlation	 between	 phenotypic-,	 ontological-,	 and	 literature-based	 similarity	
indicates	 that	 relationships	 in	 these	 ‘traditional’	 spaces	 are	 relatively	 similar	 to	 each	other,	
whereas	 there	 is	 little	 resemblance	 between	 relationships	 in	 genetic	 association,	 gene	
expression,	and	drug	spaces.		The	fused	space	resembles	relationships	in	all	spaces,	but	appears	





Whilst the fused similarities have high correlation with each of the individual spaces, the fused 
space seems to resemble the three ‘traditional’ spaces more than the others, despite each space 
contributing equally to the fused similarities.  As may be anticipated, shared similarities in the 
‘traditional’ spaces cause the averaged similarities in the fused space to reflect these shared 
similarities more highly.  This can be adjusted by down-weighting these spaces so that they 
have less influence on the fused similarities.  Weighting the ‘traditional’ spaces so that they 
together make up one-third of the total similarity (instead of half), the similarity of the 
‘traditional’ spaces to the fused becomes 0.56, 0.65, and 0.68 for ontological, phenotypic, and 
literature-based spaces respectively; and 0.58, 0.63, and 0.61 for genetic, expression, and drug 




map does not appear substantially different (see Appendix N), suggesting that the disease map 
is not overly affected by the similarity of the ‘traditional’ spaces.  The disease map therefore 
fundamentally resembles these traditional spaces, whilst inclusion of the diverse relationships 
from the genetic association, gene expression, and drug spaces adds novel similarities which 
distinguish the disease map from traditional classification systems.  
 
5.3.4 Top disease links in the fused space show high overlap in shared 
drugs relative to the individual spaces 
 
Figure 5.5 Mean Jaccard overlap of drugs (approved or in Phase III clinical trials) 







One aim of the disease map is the identification of similarities between diseases that could 
indicate where two diseases might be treated with the same drug.  The extent to which links in 
the disease map correspond to drug-sharing relationships was therefore evaluated, including 
drugs that are in phase 3 clinical trials (as opposed to approved drugs only, which were used to 




44.2% of links sharing approved drugs only).  Even if the information from drug space is 
excluded, still 50.8% of links in the top 6.9% of the non-drug fused values (the significance 
cut-off used to construct the full disease map) share drugs. 
Rather than simply looking at the percentage of links which share at least one drug, the mean 
Jaccard drug overlap of diseases linked by the map can be evaluated.  This accounts for 
differences in the number of drugs prescribed for each disease, as well as the number of drugs 
shared.  However, this score is less intuitive and is best understood in comparison with the 
individual disease maps.  Excluding any information from drug space, the remaining individual 
spaces were therefore compared to a disease map constructed from the fusion of these five 
spaces.  At the cut-off of the top 6.9% of similarity values, links in the non-drug fused space 
have a higher Jaccard overlap of drugs approved and in Phase III trials (0.050) than any of the 
individual spaces (mean of 0.040). 
This analysis was repeated across multiple similarity thresholds, from all values to the top 1% 
highest similarity scores (Figure 5.5).  As expected, the higher the similarity threshold used, 
the greater the mean Jaccard drug score of diseases linked in the resulting map.  Indeed, at the 
top thresholds of similarity (the top 5% or above), links in the fused map show greater mean 
drug overlap than links in any of the maps constructed from individual spaces, although the 
difference is relatively small.  Importantly, drug overlap at the top thresholds is higher for the 
fused similarities than the mean over the five spaces (grey line on Figure 5.5), despite the fact 
that the fused map is constructed from the mean of similarities in each space.  A similar result 
was also seen when considering only approved drugs (Figure 5.6) and for the weighted disease 
map (Appendix N), although for these cases ontological and/or literature spaces slightly 







Figure 5.6 Mean drug overlap (by Jaccard score) of diseases linked at different 
thresholds of similarity, approved drugs only 
The	fused	space	has	a	high	proportion	of	 links	which	share	approved	drugs	relative	to	other	
spaces.		At	the	threshold	of	the	top	6.9%	most	similar	values	(the	threshold	used	for	the	disease	
map),	 the	 fused	matrix	 (mean	 Jaccard	 score	0.038)	 is	outperformed	only	by	 the	ontological	
space	(mean	Jaccard	score	0.040). 
	
If only novel links (those that are in different top-level Disease Ontology classes) are 
considered, the ontological and literature co-occurrence spaces outperform the fused space. 
Ontological space does contain some disease pairs which are given high similarity (according 
to Lin’s similarity measure) despite being in different top-level classes, but as expected this 
number is very small compared to the other spaces, with e.g. 24 novel links at a similarity 
threshold of 0.9 compared to 92 for the non-drug matrix and 117 for the literature co-
occurrence matrix. Examination of the novel links at a threshold of 0.9 suggests that the 
reduced performance of the (non-drug) fused space is due to the failure to identify links 
between neurodegenerative and mental disorders which share drugs, such as major depressive 
disorder/bipolar and Parkinson’s disease (identified in literature co-occurrence space) or 
Alzheimer’s/Parkinson’s/Huntington’s diseases and Down syndrome (identified in ontological 
space).  Literature co-occurrence space identifies a number of additional novel drug-sharing 
pairs not in the fused space, such as polycystic ovary syndrome and type II diabetes, or cystic 





5.3.5 Fused similarities outperform individual similarities in the prediction 
of Disease Ontology classes 
	
	
Figure 5.7  Ability of similarity scores from fused and individual spaces to predict 
Disease Ontology classes  
 Individual	 spaces	differ	widely	 in	 their	predictive	ability,	with	 literature-based	similarity	and	
phenotypic	similarity	performing	particularly	well.	 	The	fused	similarity	scores	outperform	all	
individual	spaces	for	the	prediction	of	 ‘disease	of	cellular	proliferation’	(AUROC	0.986,	right-
hand	plot).	 	 The	 fused	 similarity	 scores	also	outperform	 the	 individual	 spaces	 for	predicting	




A Random Forest classifier was used to examine how well the similarities in fused and 
individual spaces (excluding the ontological space) correspond to known disease categories 
(see Methods), reasoning that the ability of the fused similarities to reconstruct known 
categories would grant greater confidence that any novel relationships are likely to be 
biologically relevant.  To ensure the existence of sufficient training data to build a robust 
classifier, the two largest Disease Ontology classes disease of anatomical entity and disease of 
cellular proliferation were predicted.  Receiver Operating Characteristic curves for each space 
show that there is high variation between each space, although all spaces did better than random 
(Figure 5.7).  Of the individual spaces, literature-based similarities were best able to classify 
diseases into known categories, with an AUROC of 0.905 for disease of anatomical entity and 
0.968 for disease of cellular proliferation. Phenotypic similarities were also good predictors of 
disease classes, with an AUROC of 0.901 and 0.927 for disease of anatomical entity and 
disease of cellular proliferation respectively.  Genetic and transcriptomic spaces do not closely 
correlate with the known categorizations (Figure 5.7), which is expected as traditional disease 




The fused kernel outperformed any of the individual kernels, with AUROC scores of 0.920 for 
disease of anatomical entity and 0.986 for disease of cellular proliferation, despite the 
integration of spaces which are not such good predictors of disease classes. The mean 
performance over the five individual spaces was 0.795 for the prediction of disease of 
anatomical entity and 0.910 for the prediction of disease of cellular proliferation, meaning that 
the fused similarities in the disease map outperformed the individual similarities by 10% on 
average (mean AUROC over both tasks of 0.953 for the fused kernel vs 0.852 for the individual 
kernels).  Largely similar classification results were seen for different feature vector sizes 
(Appendix M), although phenotypic and/or literature spaces slightly outperformed the fused 
space at some feature set sizes.  Weighting the fused similarities so that the overlapping 
phenotype and literature co-occurrence spaces accounted for only 25% of the fused similarities 
(instead of 40%, as ontological space is excluded) did not significantly affect classification of 
disease of cellular entity, but slightly reduced the AUROC score to 0.891 for disease of 









This chapter introduced a method, similarity fusion, to integrate biological data across multiple 
domains through conversion of features into normalized similarity scores, such that each space 
contributes evenly to the fused similarity.  For the first time, the similarity fusion approach was 
applied across six feature spaces (ontological, phenotypic, literature co-occurrence, genetic 
association, gene expression, and drug indication data) in an unbiased manner.  Following the 
normalization step, spaces may be weighted according to the desired application of the map (in 
terms of the importance placed on finding novel links vs reflecting known links, for instance).  
Here, a balanced fusion of disease relationships was used to create a ‘disease map’: a network 
linking diseases with significant similarities across multiple spaces.   
The disease map reveals novel connections between diseases in different ontological categories 
(Figure 5.2), and highlights shared features between diseases – for example, shared gene 
expression patterns which may underlie an observed common phenotype.  The case study of 
psoriasis illustrated how genetic variants shared with inflammatory bowel diseases were also 
targeted by drugs used for both conditions, illustrating how the identification of similarities 
between diseases at a ‘molecular’ level can indicate potential opportunities for sharing drugs, 
and to generate potential drug repurposing hypotheses in a ‘guilt-by-association’ approach268.  
Similar links have been identified in previous studies of -omics data integration, such as the 
DiseaseConnect web server238 (association between psoriasis and inflammatory bowel 
disease); the interactome-based approach of Menche et al.84 (association between psoriasis and 
other autoimmune diseases, their Supplementary Material); and the Integrated Disease 
Network240 (connections between Crohn’s and autoimmune conditions including parapsoriasis 
and psoriatic arthritis).  This example illustrates how ‘molecular’ (e.g. genetic- and gene- 
expression based) approaches to disease similarity can identify disease relationships which are 
not captured by traditional disease classifications: the link between psoriasis and autoimmune 
disease, for example, is present in SNOMED but absent from other major classifications 
including MeSH, DO, and ICD.   
Through the fusion of multiple data types, the disease map gives a new perspective on disease 
relationships, where aspects of disease (such as genetics and gene expression) not ordinarily 
considered by established classification systems reveal novel similarities between diseases.  
These spaces contain similarities not captured in our ‘traditional’ understanding of disease 
relationships (Figure 5.4), and therefore contribute greater depth of interest to the disease map.   




the description of the biological system becomes.  Using a ‘hold-out’ evaluation style, all six 
data types included in this study could be incorporated into the map, without designating any 
data types as reserved for evaluation purposes.   
In agreement with previous studies showing how inclusion of more data types leads to greater 
accuracy in the prediction of disease relationships239,240, the first evaluation task showed that 
the integrated disease map outperformed any individual space in predicting disease class 
membership, despite the inclusion of spaces that individually had little relation to known 
disease classes (Figure 5.7).  In fact, the disease map, which is based on averaging similarity 
values, outperformed the average of individual similarity values by a mean of 10% across the 
two classes.  One explanation for this is that the two spaces that are most similar to the 
ontological space (phenotypic and literature co-occurrence spaces) are also the most similar to 
each other (Figure 5.4), as they are based on literature mining of phenotype terms and MeSH 
terms respectively, and there is some overlap between these term sets.  The similar disease 
relationships contained in these spaces therefore reinforce each other in the fused similarities.  
However, even if these two spaces are down-weighted (with a corresponding increase in 
influence of the ‘non-traditional’ spaces), the fused similarities still markedly outperform the 
average of other spaces in the prediction of disease classes (Appendix N).  This suggests that 
the classification performance is not driven purely by these spaces; rather, the benefit in 
similarity fusion lies in the prioritization of disease relationships common to multiple spaces. 
The second evaluation measure was the sharing of drugs (either approved or in Phase 3 clinical 
trials) between diseases linked by the disease map.  Although the drug sharing space is highly 
distinct from any of the other spaces (Figure 5.4), drug sharing relationships were captured 
well by the fused space, which had a high mean Jaccard overlap of drugs shared amongst its 
most similar disease pairs relative to the individual spaces (Figure 5.5).  This not only increases 
confidence in the biological relevance of the linked diseases, it further illustrates the value of 
incorporating multiple data types into the disease map.  This pattern fits what has generally 
been seen in computational drug repurposing approaches: while approaches based on 
individual data types such as genome-wide association studies269 or transcriptomics270–272 are 
possible, successful drug repurposing methods often incorporate multiple data types241,273; data 
fusion may therefore become an increasingly important approach in drug discovery. 
In summary, this chapter has demonstrated the utility of similarity fusion for integrating 




data is not only able to reconstruct known disease and drug-sharing associations, but also offers 
the possibility of highlighting new relationships between diseases.  The similarity-based 
approach proposed here will be particularly suited for the integration of high-throughput data 
sets where dimensionality would otherwise pose a problem, such as proteomics and 
metabolomics data, as the technology matures and the data becomes available for a large 
enough number of diseases.  This approach could be extended to any number of spaces, leading 
to the possibility of a fully comprehensive disease map.   Such a map could transform our 
current understanding of disease and disease relationships, revealing shared mechanisms 
behind diverse diseases which could eventually help to drive novel drug repurposing and 







6.1 SUMMARY OF FINDINGS 
The aim of this thesis was to explore the comparative analysis of gene expression data to 
understand disease and disease relationships, including the comparability of the transcriptomic 
disease signal across different study types; the analysis and comparison of gene expression 
changes through translation to the level of signaling interactions; and finally, the integration of 
gene expression data with other data types to explore how disease relationships extend across 
different biological levels.   
This work began with the research described in Chapter 3, Concordance of Microarray Studies 
of Parkinson’s Disease, which showed that gene expression studies of the substantia nigra in 
Parkinson’s disease patients shared expression patterns which were distinct from those in 
studies of other tissues and disease models.  Previous research has studied the effects of 
individual factors such as microarray platform type on the resulting gene expression 
profile117,149–151, and examined the concordance between disease models and human 
patients144,146–148.  However, in a comparative analysis setting, multiple factors come into play 
when selecting experiments that will be representative of the condition under study.  The work 
described in this chapter therefore considered the effects of four key factors – tissue, platform, 
sample size, and disease model – using the agreement between studies of the same disease to 
understand how these affect the gene expression representation of disease.  The improved 
concordance within the most highly-affected tissue in human patients suggested that these 
studies formed a characteristic representation of gene expression in PD; also notable was a lack 
of effect of factors such as the platform type (at least within Affymetrix-type microarrays) on 
concordance.  The general study selection guidelines set out in this research were employed in 
selecting studies to be included in the larger disease dataset used for the next chapters. 
The relatively low concordance observed between even the two most closely related PD studies 
illustrates the noisiness inherent to gene expression data.  In the next chapter, Using 
Dysregulated Signalling Paths to Understand Disease, the weighted shortest-paths method of 
Sambarey et al.121 was adapted in order to make more informative comparisons between 
diseases.  Each disease was represented by a set of dysregulated paths on the human signaling 




biological pathways.  The work described in this chapter is the first to use a path-based 
approach to compare multiple diseases, and reveals the existence of shared signaling processes 
between common and rare diseases.  52% of the paths shared between disease pairs contained 
a drug-interacting gene for at least one of the diseases, suggesting that this approach could be 
used to identify drug repurposing hypotheses, as detailed in a case study of the link between 
polycystic ovary syndrome and the rare condition Pompe disease.  As well as comparing 
diseases, this chapter also examined more general properties of gene expression, finding that 
genes in dysregulated networks of multiple diseases have a moderate tendency to have higher 
degree, suggesting an influential (but not central) role in dysregulated signaling networks 
across diverse disease types.   
In the final chapter, Understanding and Predicting Disease Relationships Through Similarity 
Fusion, the comparison of diseases was extended to multiple bioinformatics spaces.  Following 
the direct network integration approach used in the previous chapter, a more generalized 
integration method was introduced to link diseases across different biological levels, from the 
molecular (genetic variation, gene expression, and drug indication) to the clinical (phenotype, 
literature co-occurrence, and ontological relationships).  When quantifying the strength of 
relationships across such different data types, it is imperative to take into account the differing 
properties of each space122, such as sparsity and the size of the feature universe.  However, 
current methods to address this (such as the work of Sun et al.240) are limited in terms of the 
number of feature spaces that can be included.  The similarity fusion method introduced in this 
chapter uses quantile normalization to adjust the distributions of pairwise similarity vectors 
towards each other, making them comparable and combinable.  While the disease map 
contained mostly known relationships, 15% of links were novel links between diseases not 
related by traditional classification systems, such as between psoriasis and inflammatory bowel 
disease, or cervical cancer and hepatitis B.  Importantly, links in the disease map were 
indicative of drug-sharing, with 62% of the links in the full disease map sharing drugs; this 
provides further indication of the potential of disease similarity approaches for drug 
repurposing. 
Although the focus of this thesis has been comparative analysis of gene expression across 
diseases, the findings will be of interest in broader settings.  The conclusions of this work 
translate most clearly to meta-analysis design, as many of the same considerations (such as the 
effect of tissue, platform, and disease model) apply to determining study selection criteria.  By 




different diseases, this work also contributes to wider questions around the strength and 
specificity of gene expression representations of disease.  Following on from this, the method 
developed in Chapter 4 is not only applicable to comparing disease, but is of broader interest 
for the interpretation of individual gene expression datasets (including drug response data, as 
shown here) in the context of signaling pathways.  Finally, the data integration method 
developed in Chapter 5 can be applied to diverse data types as a general data integration 
method, particularly for the analysis of high-dimensional data.   
 
6.2 LIMITATIONS  
The research in this thesis confirms what countless previous studies have demonstrated: gene 
expression is noisy, representing a snapshot of the disease state under highly specific 
conditions.  This is most clearly illustrated by the study of gene expression datasets in 
Parkinson’s disease, where the low agreement between studies of the same condition may 
reflect the effect of multiple factors.  These range from deliberate factors such as the choice of 
tissue to sample (as different tissues will show a different transcriptomic response to disease), 
to inherent factors such as biological and technical variation.  Further complicating the 
interpretation of gene expression data is the well-established lack of predictivity of gene 
expression to the abundance of its corresponding protein product193.  Gene expression data is 
therefore at best a partial representation of cellular state, which gives limited information 
compared to other measurements such as the proteome. The second and third chapters of this 
work therefore incorporate other data types in order to provide additional evidence for disease 
relationships.   
Even assuming that a ‘representative’ gene expression profile is available, a further issue in 
gene expression data analysis (one that is common to other dynamic -omics measurements 
including the proteome and metabolome) is that measured gene expression may reflect not only 
disease pathogenesis, but also the body’s compensatory responses (e.g. immune system 
activation).  This further complicates the comparison of diseases: shared gene expression 
profiles may not necessarily represent shared mechanisms of disease, but may simply represent 
a shared response to different pathological processes, as shown with the case study of 
polycystic ovary syndrome and Pompe disease in Chapter 4.  This can be useful – for example, 
the inflammatory response underlying the symptoms of many diseases can be treated with non-




establish a causal relationship between gene expression and disease, as is (sometimes) possible 
with e.g. genetic data.   
In addition to the general limitations of comparative analysis of microarray data discussed here 
and in the Introduction, a broader limitation of this work stems from its reliance on public data.  
Despite the rapidly increasing number of gene expression profiles of disease, research 
questions are inevitably constrained by the availability of suitable studies: in Chapter 3, for 
instance, the scarcity of non-Affymetrix microarray studies of Parkinson’s disease prevented 
drawing a stronger conclusion on the effect of microarray platform type on study concordance.  
As the popularity of transcriptomic analysis continues to grow in line with its decreasing cost, 
the amount of public transcriptomic data should further increase, providing greater statistical 
power and enabling a wider range of questions to be answered from the re-analysis of existing 
data.   
 
6.3 FUTURE DIRECTIONS 
Given the limitations of gene expression data, an obvious extension of this research would be 
to employ multi-omics data to study disease relationships in more detail.  A basic version of 
this idea is already implemented in Chapter 4, with the inclusion of genetic variant data in 
dysregulated signaling pathways helping to give context to the observed gene expression 
changes; this could easily be extended to other -omic data types and/or incorporated into the 
path-finding algorithm directly.  This would help to determine whether shared gene 
expression patterns between two diseases are associated with shared genetic, epigenetic, 
and/or proteomic features, leading to a greater understanding of shared disease biology.  
Multi-omics approaches are already being applied in disease subtyping244,274 and precision 
medicine275,276, although available multi-omics profiles are so far largely confined to cancer 
datasets such as The Cancer Genome Atlas91.  It would be an interesting next step to apply 
this type of analysis to identify similarities between different cancers or, when the data 
becomes available, more diverse disease types.   
Whilst it may be several years until this type of analysis is feasible on a large scale, one topic 
that would be of more immediate benefit is the identification of patterns of drug-induced 
gene expression in transcriptomic studies of disease.  As mentioned previously, gene 
expression in disease may be affected by the drug treatment history of the patient; one way to 




differential expression profiles from large-scale resources such as CMAP49 and LINCS50, 
which contain in vitro drug response data from thousands of drugs tested in multiple cancer 
cell lines.  The methods used here to study disease gene expression can equally be applied to 
understand gene expression in response to drugs, as shown by the drug-response case studies 
in Chapter 4; the next step would then be to directly compare these patterns between diseases 
and the drugs that are prescribed for them.  Preliminary studies of the path-set analysis from 
Chapter 4 on CMAP data did not show substantial overlap between drug-induced differential 
expression profiles and those of their corresponding diseases; possible explanations for this 
include differences between drug response in vivo and in vitro, or the variable ‘transcriptional 
activity’30,277 of drugs.  Given the prevalence of drug response as a confounding factor in 
transcriptomic studies of disease, a more detailed investigation would be of great benefit for 
this field. 
The ultimate goal in studying disease is to find treatment to overcome it, and so a key 
consideration in this work is how the comparative analysis of gene expression data can be 
applied to discovering drug treatments for disease, specifically through drug repurposing.  
Examples in the preceding chapters have demonstrated how the methods introduced here can 
be used to suggest potential drug repurposing hypotheses, both gene-expression based 
(Chapter 4) and data integration-based (Chapter 5).  The next step would be to ascertain 
which of the potential drug-sharing links identified here might be a promising candidate for 
experimental validation.  This could be done at the small-scale, which would require disease 
experts to closely examine the feasibility of the proposed mechanism in the new indication.  
However, given the number of potential hypotheses, this could be a laborious task.  Most 
successful bioinformatics drug repurposing approaches also use drug-side (cheminformatics) 
evidence such as structure and bioactivity data17, giving a more comprehensive 
characterization of the potential match between a drug and a disease.  The methods proposed 
in this thesis could easily be extended to incorporate drug-side information: for instance, the 
data integration method in Chapter 5 could be applied to combine different types of drug 
data, in an approach similar to the PREDICT method241, which combined disease similarity 
with drug similarity in order to predict drug indications.   
The comparison of gene expression across diseases not only enables the identification of 
shared disease biology, in turn revealing more about processes taking place in the individual 
diseases, but also helps to develop a greater understanding of the properties of gene 




expression studies, the power of comparative analysis (including other approaches which re-
use public data, such as meta-analysis) is steadily increasing, both in terms of statistical 
power and in terms of the breadth and depth of questions that can be answered.  The findings 
in this thesis therefore aim to serve as a timely investigation into some of the issues 
surrounding this new approach to understanding disease.  Whilst the work presented here 
represents only a small subset of the vast field of gene expression data analysis, I hope that 
the framework set out here for comparative analysis of diseases could eventually aid our 
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APPENDIX A: DATASET USED FOR CHAPTER 3  
Note: in order to minimize the impact of laboratory effects on the concordance analysis, where multiple datasets were contributed by the same 
investigator and less than a year apart, only one of the two was retained.  However, the two studies GSE20141 and GSE20153 contributed by 
Middleton were first reported in the associated meta-analysis; it is not stated whether they originate from the same group so both have been 
retained.  
 








Platform Tissue  # case # control Species Model Sample selection 
GSE6613 Scherzer CR 
17215369 
Dec 2006 U133A Whole blood 50 22 Human - Parkinson's disease v 
healthy control; 
GSM153411 and 
GSM153454 removed as 
did not pass quality checks 
GSE7621 Mullen JF 
Lesnick TG 
17571925 
Apr 2007 U133 Plus 
2.0 
Substantia nigra 16 9 Human - - 
GSE20141 Middleton FA 
Zheng B 
20926834 






10 8 Human - - 
GSE20153 Middleton FA 
Zheng B 
20926834 





8 8 Human  - - 
GSE20163 Miller RM 
Zheng B 
20926834 




GSE20164 Hauser MA 
Zheng B 
20926834 
Feb 2010 U133A Substantia nigra 6 5 Human - GSM506020 removed as 
did not pass quality checks 

















Feb 2010 U133A Cerebellum 4 4 Human - GSM509109 removed as 
did not pass quality checks 
GSE20333 Edna G Feb 2010 HGFocus Substantia nigra 6 6 Human - GSM509556 and 
GSM509557 removed as 









8 9 Human - - 
GSE43490 Corradini BR 
25525598 
Jan 2013 AgilentPN Substantia nigra 8 5 Human - SN parkinson's disease v 
SN control 
GSE4788 Miller RM 
15329391 
May 2006 MurU74 Substantia nigra 4 4 Mouse MPTP MPTP MML v saline 
GSE24233 Cadet JL Sep 2010 IlluminaRa
t 
Striatum 6 4 Rat 6-
OHDA 
Saline lesioned v saline 
control; GSM596030 
removed as did not pass 
quality checks 
GSE4550 Nahon J 
Storvik M 
20206263 
Mar 2006 U133A Putamen 4 4 Macaque MPTP Putamen MPTP day 25 v 
putamen saline 
GSE58710 Lipton JW 
Kanaan NM 
25992874 
Jun 2014 Rat1.0ST Substantia nigra 3 3 Rat 6-
OHDA 
Wk4 6-OHDA v Wk4 
vehicle; GSM1417209 
removed as did not pass 
quality checks 
GSE8030 Chin MH 
18173235 
Jun 2007 430A Striatum 3 3 Mouse MPTP MPTP v control 




GSE17542 Phani S 
20462502 




3 3 Mouse MPTP 10 day MPTP SN v control 
SN; GSM437382 removed 





Feb 2012 U133A Neuroblastoma 
cell line 
3 3 Human rotenone 50nm rotenone 4 week v 
0nm rotenone 4 week 
GSE8397 Moran LB 
16344956 
Jul 2007 U133A Frontal cerebral 
cortex - superior 
frontal gyrus 
5 3 Human - - 
GSE31458 Soreq L 
22198569 
Aug 2011 430A2 Striatal caudate-
putamen 
2 2 Mouse MPTP CPU MPTP FVB/N v CPU 
naive FVB/N 
Note: pooled design, each 
‘sample’ contains RNA 
from 3-4 of 6 mice per 
condition. 
GSE52584 Dorval V 
24427314 
Nov 2013 MG1.0ST Striatum 4 4 Mouse LRRK2 LRRK2 KO vs WT 
GSE60413 Kurz A 
Gispert S 
25296918 
Aug 2014 4302 Striatum 3 3 Mouse Pink1 KO 6 week v WT 6 week 





3 3 Human AD Alzheimer's disease v 
normal 











21 22 Human AD Superior frontal gyrus, age 
>= 70; GSM300250 
removed as did not pass 
quality checks 
GSE36980 Nakabeppu Y 
Hokama M 
23595620 









Whole cortex 5 5 Mouse AD PS2APP 3 month vs WT 3 
month 
GSE15824 Morin PJ 
Grzmil M 
21406405 
Apr 2009 U133 Plus 
2.0 
Whole brain 12 2 Human Tumour Glioblastoma v normal 
brain 
GSE44971 Lambert SR 
23660940 
Mar 2013 U133 Plus 
2.0 
Cerebellum 49 9 Human Tumour - 
GSE31095 Nilsson RJ 
21832279 
Aug 2011 AgilentFN Blood platelets 8 12 Human Tumour - 
GSE64230 Giachino C 
26669487 
Dec 2014 MG1.0ST Whole brain 4 4 Mouse Tumour PDGF+p53-/- tumour v 
control 
GSE57036 Sheila AL Apr 2014 IlluminaM
ouse 
Dorsal brain 5 5 Mouse Tumour Tumour v dorsal control 
GSE74382 Loiodice S Oct 2015 Rat2302 Dorsal striatum 7 7 Rat SNCA Lesion L-dopa saline vs 
sham saline saline 
GSE55096 Heiman M 
24599591 
Feb 2014 4302 Striatal neurons 20 20 Mouse 6-
OHDA 
low L-dopa 6-OHDA v 
saline ascorbate, Drd1a 
and Drd2 neurons 
GSE72267 Roncaglia P 
Calligaris R 
26510930 
Aug 2015 U133A 2.0 Blood 40 19 Human - - 
GSE54536 Alieva AK 
24804238 
Jan 2014 Illumina 
HT12v4 
Blood 4 4 Human - Exclude pooled RNA 
GSE93695 Chen G Jan 2017 Rat 2.0 Striatum 3 3 Rat 6-
OHDA 
PD v normal 








WT-MP v WT 
GSE57475 Scherzer CR 
Locascio JJ 
26220939 
May 2014 Illumina 
HT12v3 
Blood 93 49 Human - - 
GSE49036 Dijkstra AA 
26087293 
Jul 2013 U133 Plus 
2.0 






removed as did not pass 
quality checks 




Oct 2013 HG1.0ST iPSC-derived 
DA neurons 
9 4 Human - GSM1255326_SP02 
removed as did not pass 
quality checks 
GSE89883 Haenseler W Nov 2016 Illumina 
HT12v4 





U133A:   Affymetrix Human Genome U133A Array 
U133A 2.0:  Affymetrix Human Genome U133A 2.0 Array 
U133 Plus 2.0:  Affymetrix Human Genome U133 Plus 2.0 Array 
Illumina HT12v3:  Illumina HumanHT-12 V3.0 expression beadchip 
Illumina HT12v4: Illumina HumanHT-12 V4.0 expression beadchip 
HGFocus:   Affymetrix Human HG-Focus Target Array 
X3P:    Affymetrix Human X3P Array 
AgilentPN:   Agilent Whole Human Genome Microarray 4x44K (Probe name version) 
AgilentFN:   Agilent Whole Human Genome Microarray 4x44K (Feature number version) 
MurU74:   Affymetrix Murine Genome U74A Array 
IlluminaRat:   Illumina ratRef-12 v1.0 expression beadchip 
Rat1.0ST:   Affymetrix Rat Gene 1.0 ST Array 
430A:    Affymetrix Mouse Expression 430A Array 
4302:    Affymetrix Mouse Genome 430 2.0 Array 
430A2:   Affymetrix Mouse Genome 430A 2.0 Array 
MG1.0ST:   Affymetrix Mouse Gene 1.0 ST Array 
HG1.0ST:   Affymetrix Human Gene 1.0 ST Array 
AgilentMouse (v2):  Agilent Whole Mouse Genome Microarray 4x44K (v2) 
IlluminaMouse:  Illumina MouseWG-6 v2.0 expression beadchip 




APPENDIX B DATASET USED FOR CHAPTER 4 
– in sample selection indicates that all provided samples were used.  Platform identifiers are GEO identifiers for individual microarray types, e.g. 
GPL96 is the Affymetrix Human Genome U133A Array.   
 
Disease dataset 
GSE Accession     Condition Platform Tissue Sample selection 
GSE6475 acne GPL571 skin Lesion v non-acne-patient normal skin (6 case, 6 control) 
GSE63107 actinic keratosis GPL570 skin AK pre-treatment v uninvolved skin pre-treatment (6 case, 6 control) 
GSE9476 acute myeloid leukemia GPL96 peripheral blood Peripheral blood only (19 case, 10 control) 
GSE8514 adrenal adenoma GPL570 adrenal gland - 
GSE44456 alcoholism GPL6244 hippocampus - 
GSE6281 allergic contact dermatitis GPL570 skin 96 hour timepoint only (6 case, 4 control) 
GSE45512 alopecia areata GPL570 skin - 
GSE36980 alzheimer's disease GPL6244 hippocampus Hippocampus only (7 case, 10 control) 
GSE28146 alzheimer's disease GPL570 hippocampus Severe v control (7 case, 8 control) 
GSE26969 aortic aneurysm GPL570 cranial artery - 
GSE70683 arterial tortuosity syndrome GPL6244 dermal fibroblasts - 
GSE35571 asthma GPL570 peripheral blood Exclude NA (60 case, 64 control) 
GSE44971 astrocytoma GPL570 cerebellum - 
GSE5667 atopic dermatitis GPL96 skin Lesional atopic dermatitis v normal healthy (6 case, 5 control) 




GSE40586 bacterial meningitis GPL6244 peripheral blood - 
GSE12654 bipolar disorder GPL8300 prefrontal cortex Bipolar disorder v control (11 case, 15 control) 
GSE3167 bladder cancer GPL96 bladder Exclude cystectomy samples (9 case, 41 control) 
GSE19205 bloom syndrome GPL571 fibroblasts Bloom and control only (3 case, 3 control) 
GSE54502 bloom syndrome GPL5175 fibroblasts Exclude BLM fibroblasts (14 case, 12 control) 
GSE5764 breast lobular carcinoma GPL570 lobular cells Tumour lobular v ductal carcinoma normal lobular (5 case, 5 control) 
GSE31243 cerebral palsy GPL571 skeletal muscle Gracilis only (10 case, 10 control) 
GSE7803 cervical squamous cell carcinoma GPL96 cervix Squamous cell carcinoma v normal cervix (21 case, 10 control) 
GSE9750 cervical squamous cell carcinoma GPL96 cervix Cervical cancer v normal cervix (33 case, 12 control) 
GSE63514 cervical intraepithelial neoplasia GPL570 cervix CIN 3 v control (40 case, 24 control) 
GSE26725 chronic lymphocytic leukemia GPL570 peripheral blood - 
GSE42057 chronic obstructive pulmonary disease GPL570 
peripheral blood 
mononuclear cells - 
GSE8581 chronic obstructive pulmonary disease GPL570 lung tissue Exclude unclassified samples (16 case, 19 control) 
GSE8671 colorectal adenocarcinoma GPL570 colonic mucosa - 
GSE4107 colorectal cancer GPL570 colon mucosa - 
GSE8440 congenital disorders of glycosylation type I GPL96 dermal fibroblasts Rep 1 only (9 case, 3 control) 
GSE64034 cornelia de lange syndrome GPL17889 dermal fibroblasts First replicate only; exclude CHOPS syndrome (2 case, 4 control) 
GSE6731 crohn's disease GPL8300 colon Crohn's affected v normal (7 case, 4 control) 
GSE59071 crohn's disease GPL6244 colon CD v control (8 case, 11 control) 




GSE51808 dengue fever GPL13158 whole blood Dengue fever v control (18 case, 9 control) 
GSE14335 diamond-blackfan anaemia GPL571 fibroblasts - 
GSE3585 dilated cardiomyopathy GPL96 left ventricular tissue - 
GSE52471 discoid lupus erythematosus GPL571 skin Discoid lupus v Normal Affy (7 case, 10 control) 
GSE5390 down syndrome GPL96 dorsolateral prefrontal cortex - 
GSE6011 duchenne muscular dystrophy GPL96 skeletal muscle Exclude technical rep (22 case, 14 control) 
GSE38417 duchenne muscular dystrophy GPL570 skeletal muscle - 
GSE1004 duchenne muscular dystrophy GPL8300 skeletal muscle Samples run on GPL8300 only (12 case, 11 control) 
GSE1122 emphysema GPL80 lung Exclude AAD-related emphysema (5 case, 5 control) 
GSE63678 endometrial carcinoma GPL571 endometrium Endometrial cancer v normal endometrium (7 case, 5 control) 
GSE6364 endometriosis GPL570 endometrium Mid-secretory phase only (9 case, 8 control) 
GSE28315 epidermolysis bullosa simplex GPL6244 epidermis - 
GSE26050 familial hemophagocytic lymphohistiocytosis GPL570 
peripheral blood 
mononuclear cells - 
GSE16334 fanconi anemia GPL96 bone marrow - 
GSE62721 fragile x syndrome GPL6244 fibroblasts Exclude iPSCs and neurons (3 case, 2 control) 
GSE79973 gastric adenocarcinoma GPL570 gastric mucosa - 
GSE79704 generalized pustular psoriasis GPL19983 skin Exclude plaque psoriasis (32 case, 20 control) 
GSE31014 guillain-barre syndrome GPL96 peripheral blood leukocytes - 
GSE6631 head and neck squamous cell carcinoma GPL8300 
head & neck 
mucosa - 




GSE62232 hepatocellular carcinoma GPL570 liver - 
GSE2171 hiv GPL201 peripheral blood mononuclear cells - 
GSE47044 hodgkin's lymphoma GPL6244 b cells NLPHL v control (10 case, 5 control) 
GSE8762 huntington's disease GPL570 blood lymphocyte - 
GSE3860 hutchinson-gilford progeria GPL96 fibroblasts Sample 1 only (3 case, 3 control) 
GSE69391 hutchinson-gilford progeria GPL570 dermal fibroblasts Exclude old healthy (6 case, 3 control) 
GSE9499 icf syndrome GPL96 lymphoblastoid cell line Biological rep 1 only (3 case, 5 control) 
GSE24206 idiopathic pulmonary fibrosis GPL570 lung Advanced IPF, upper lobe v control (5 case, 6 control) 
GSE40568 IgG4-related disease GPL570 labial salivary glands Exclude Sjogren's (5 case, 3 control) 
GSE27131 influenza GPL6244 peripheral blood Day 0 v control (7 case, 7 control 
GSE36701 irritable bowel syndrome GPL570 rectal colon Part 1 only: IBS-C and IBS-D v healthy volunteers (87 case, 40 control) 
GSE42955 ischemic cardiomyopathy GPL6244 left ventricular tissue Ischemic cardiomyopathy v normal (12 case, 5 control) 
GSE22255 ischemic stroke GPL570 peripheral blood mononuclear cells - 
GSE48574 ISCU myopathy GPL570 muscle - 
GSE80060 juvenile idiopathic arthritis GPL570 whole blood Day 1 placebo v control (22 case, 22 control) 
GSE71935 juvenile myelomonocytic leukemia GPL570 bone marrow Exclude peripheral blood (33 case, 9 control) 
GSE47642 kindler syndrome Illumina skin - 
GSE42331 klinefelter syndrome GPL6244 whole blood Exclude female controls (35 case, 15 control) 




GSE16020 leukopenia GPL570 blood leukocytes - 
GSE11681 limb-girdle muscular dystrophy GPL96 muscle - 
GSE38961 loeys-dietz syndrome GPL570 blood endothelial cells - 
GSE19804 non-small cell lung carcinoma GPL570 lung - 
GSE44593 major depressive disorder GPL570 amygdala - 
GSE6872 teratozoospermia GPL570 semen - 
GSE51024 malignant pleural mesothelioma GPL570 lung - 
GSE5808 measles GPL96 peripheral blood Entry v control (5 case, 3 control) 
GSE14882 melas syndrome GPL96 peripheral blood Note: pooled controls 
GSE23832 multiple sclerosis GPL6244 peripheral blood mononuclear cells - 
GSE21942 multiple sclerosis GPL570 peripheral blood mononuclear cells Exclude technical rep (12 case, 15 control) 
GSE16461 multiple sclerosis GPL570 blood CD8+ t cells - 
GSE43591 multiple sclerosis GPL570 blood t-cells - 
GSE58831 myelodysplastic syndrome GPL570 bone marrow CD34+ cells - 
GSE48060 myocardial infarction GPL570 peripheral blood - 
GSE13597 nasopharyngeal carcinoma GPL96 nasopharynx - 
GSE12452 nasopharyngeal carcinoma GPL570 nasopharynx - 
GSE65170 nestor-guillermo progeria GPL5175 iPSCs Exclude fibroblasts (4 case, 2 control) 
GSE9624 obesity GPL570 adipose tissue - 




GSE22855 ollier disease Illumina cartilage - 
GSE55235 osteoarthritis GPL96 synovium 
Exclude rheumatoid arthritis samples (10 case, 10 
control). Note same publication as GSE55457 but 
different submitter and institution. 
GSE7429 osteoporosis GPL96 blood lymphocytes - 
GSE56815 osteoporosis GPL96 blood monocytes - 
GSE14245 pancreatic cancer GPL570 saliva - 
GSE7621 parkinson's disease GPL570 substantia nigra - 
GSE8397 parkinson's disease GPL96 substantia nigra Medial substantia nigra (15 case, 8 control) 
GSE20291 parkinson's disease GPL96 striatum - 
GSE7586 placental malaria GPL570 placenta Exclude past malaria (10 case, 5 control) 
GSE34526 polycystic ovary syndrome GPL570 ovarian follicle (granulosa cells) - 
GSE38680 pompe disease GPL570 biceps Exclude quadriceps and control 10 (later diagnosed with MELAS) (9 control, 9 disease) 
GSE12767 preeclampsia GPL570 placenta - 
GSE36314 prolactinoma GPL8300 pituitary gland - 
GSE55945 prostate cancer GPL570 prostate Exclude corrupted files GSM1348937 and GSM1348948 (12 case, 7 control) 
GSE14905 psoriasis GPL570 skin Exclude 'Uninvolved skin' (33 case, 21 control) 
GSE53408 pulmonary arterial hypertension GPL6244 lung - 
GSE36895 clear-cell renal cell carcinoma GPL570 kidney Exclude mouse tumourgraft (29 case, 23 control) 
GSE6344 clear-cell renal cell carcinoma GPL96 kidney - 
GSE75303 rett syndrome Illumina frontal cortex Exclude temporal cortex (3 case, 3 control) 




GSE55457 rheumatoid arthritis GPL96 synovium 
Exclude osteoarthritis samples (13 case, 10 control). 
Note same publication as GSE55235 but different 
submitter and institution. 
GSE65914 rosacea GPL570 skin - 
GSE19314 sarcoidosis GPL570 whole blood Sarcoidosis v control (38 case, 20 control) 
GSE70019 schnitzler’s syndrome Illumina peripheral blood mononuclear cells Exclude drug-treated (3 case, 3 control) 
GSE13205 sepsis GPL570 skeletal muscle - 
GSE16524 setleis syndrome GPL570 dermal fibroblasts - 
GSE32057 shwachman-diamond syndrome GPL570 bone marrow mononuclear cells - 
GSE11524 sickle cell disease GPL570 blood platelets - 
GSE61120 silver-russell syndrome GPL13667 dermal fibroblasts Exclude hypomethylated clones (4 case, 4 control) 
GSE66795 sjogren's syndrome Illumina whole blood Mid fatigue level only (74 case, 29 control) 
GSE48378 sjogren's syndrome GPL5175 Peripheral blood mononuclear cells - 
GSE61203 smith-lemli-opitz syndrome GPL5175 iPSCs Cholesterol-deficient 7d only (4 case, 4 control) 
GSE27200 sotos syndrome GPL570 dermal fibroblasts Exclude retinoic acid (9 case, 9 control) 
GSE10325 systemic lupus erythematosus GPL96 perhipheral blood - 
GSE30153 systemic lupus erythematosus (quiescent) GPL570 
blood 
lymphocytes - 
GSE26049 essential thrombocythemia GPL570 whole blood Essential thrombocythemia v control, RMA only (19 case, 21 control) 
GSE3678 thyroid carcinoma GPL570 thyroid - 




GSE55098 type 1 diabetes mellitus GPL570 peripheral blood mononuclear cells - 
GSE9006 type 1 diabetes mellitus GPL96 peripheral blood mononuclear cells Newly diagnosed T1D only (43 case, 20 control) 
GSE38642 type 2 diabetes mellitus GPL6244 pancreatic islets - 
GSE25724 type 2 diabetes mellitus GPL96 pancreatic islets - 
GSE38713 ulcerative colitis GPL570 colon Active UC, involved mucosa v control (15 case, 13 control) 
GSE5563 vulvar intraepithelial neoplasia GPL570 vulva - 
GSE48761 werner syndrome GPL6244 dermal fibroblasts Exclude iPSC/ESC; rep1 only (5 case, 5 control) 
GSE16715 williams syndrome GPL570 skin fibroblasts - 






Drug response dataset 
 
GSE Accession Drug Condition Platform Tissue Sample selection Dose and time 
GSE32569 cediranib alveolar soft 
part sarcoma  
GPL570 tumor - Baseline vs 3-5 
days after 
treatment 





- Baseline vs 24 
hours after 
treatment 
GSE10433 isotretinoin acne GPL571 skin -  Baseline vs 1 
week after 
treatment 
GSE5462 letrozole breast 
carcinoma 
GPL96 breast - NA 
GSE45867 methotrexate rheumatoid 
arthritis 
GPL570 synovium Exclude methotrexate NA 
GSE19136 paclitaxel - GPL570 artery Exclude control (non-stented) Paclitaxel stent 
vs bare metal 
stent after 48h 
GSE32357 resveratrol obesity GPL11532 vastus 
lateralis 
muscle 
- 30 days 
placebo vs 30 
days 
reseveratrol 
GSE68421 resveratrol non-alcoholic 
fatty liver 
disease 
GPL16686 liver Exclude placebo Baseline vs 6 
months 
treatment 
GSE38663 ribavirin hepatitis c GPL570 liver Exclude IFN, IFN+RBV NA 
GSE58837 sunitinib breast 
carcinoma 
GPL6244 breast Exclude T3 NA 
GSE12665 tamoxifen breast 
carcinoma 
Agilent  arm Exclude ER-negative Baseline vs 
treatment 














Week 24 vs baseline Week 24 vs 
baseline 
GSE58558 cyclosporine atopic 
dermatitis 









Week 12 vs baseline Week 12 vs 
baseline 
GSE24742 rituximab rheumatoid 
arthritis 
GPL570 synovium Week 12 vs baseline Week 12 vs 
baseline 




Week 5 vs baseline; exclude CD Week 5 vs 
baseline 
GSE45867 tocilizumab rheumatoid 
arthritis 
GPL570 synovium Week 12 vs baseline Week 12 vs 
baseline 











APPENDIX C: DATASET USED FOR CHAPTER 5 
– in sample selection indicates that all provided samples were used.  Platform identifiers are GEO identifiers for individual microarray types, e.g. 
GPL96 is the Affymetrix Human Genome U133A Array. 
 
Accession Condition Platform Tissue Sample selection 
GSE6475 acne GPL571 skin Lesion v non-acne-patient normal skin (6 case, 6 
control) 
GSE63107 actinic keratosis GPL570 skin AK pre-treatment v uninvolved skin pre-treatment 
(6 case, 6 control) 
GSE9476 acute myeloid leukemia GPL96 peripheral blood Peripheral blood only (19 case, 10 control) 
GSE8514 adrenal adenoma GPL570 adrenal gland - 
GSE44456 alcoholism GPL6244 hippocampus - 
GSE41649 allergic asthma GPL96 bronchus - 
GSE6281 allergic contact dermatitis GPL570 skin 96 hour timepoint only (6 case, 4 control) 
GSE45512 alopecia areata GPL570 skin - 
GSE28146 alzheimer's disease GPL570 hippocampus Severe v control (7 case, 8 control) 
GSE26969 aortic aneurysm GPL570 cranial artery - 
GSE35571 asthma GPL570 peripheral blood Exclude NA (60 case, 64 control) 




GSE5667 atopic dermatitis GPL96 skin Lesional atopic dermatitis v normal healthy (6 case, 
5 control) 
GSE18123 autism GPL570 peripheral blood Autism v control (31 case, 33 control) 
GSE40586 bacterial meningitis GPL6244 peripheral blood - 
GSE12654 bipolar disorder GPL8300 prefrontal cortex Bipolar disorder v control (11 case, 15 control) 
GSE3167 bladder cancer GPL96 bladder Exclude cystectomy samples (9 case, 41 control) 
GSE5764 breast lobular carcinoma GPL570 lobular cells Tumour lobular v ductal carcinoma normal lobular 
(5 case, 5 control) 
GSE31243 cerebral palsy GPL571 skeletal muscle Gracilis only (10 case, 10 control) 
GSE9750 cervical squamous cell carcinoma GPL96 cervix Cervical cancer v normal cervix (33 case, 12 
control) 
GSE63514 cervical intraepithelial neoplasia GPL570 cervix CIN 3 v control (40 case, 24 control) 
GSE26725 chronic lymphocytic leukemia GPL570 peripheral blood - 
GSE8581 chronic obstructive pulmonary disease GPL570 lung tissue Exclude unclassified samples (16 case, 19 control) 
GSE8671 colorectal adenocarcinoma GPL570 colonic mucosa - 
GSE59071 crohn's disease GPL6244 colon CD v control (8 case, 11 control) 
GSE15568 cystic fibrosis GPL96 rectum - 
GSE51808 dengue fever GPL13158 whole blood Dengue fever v control (18 case, 9 control) 




GSE52471 discoid lupus erythematosus GPL571 skin Discoid lupus v Normal Affy (7 case, 10 control) 
GSE5390 down syndrome GPL96 dorsolateral prefrontal cortex - 
GSE38417 duchenne muscular dystrophy GPL570 skeletal muscle - 
GSE1122 emphysema GPL80 lung Exclude AAD-related emphysema (5 case, 5 
control) 
GSE63678 endometrial carcinoma GPL571 endometrium Endometrial cancer v normal endometrium (7 case, 
5 control) 
GSE6364 endometriosis GPL570 endometrium Mid-secretory phase only (9 case, 8 control) 
GSE79973 gastric adenocarcinoma GPL570 gastric mucosa - 
GSE6631 head and neck squamous cell carcinoma GPL8300 head & neck mucosa - 
GSE58208 chronic hepatitis b (carrier) GPL570 peripheral blood mononuclear cells Exclude hepatocellular carcinoma (12 case, 5 
control) 
GSE49954 chronic hepatitis c GPL570 t lymphocytes High viral load, CD4+ cells v control (5 case, 5 
control) 
GSE62232 hepatocellular carcinoma GPL570 liver - 
GSE2171 hiv GPL201 peripheral blood mononuclear cells - 
GSE47044 hodgkin's lymphoma GPL6244 b cells NLPHL v control (10 case, 5 control) 
GSE8762 huntington's disease GPL570 blood lymphocyte - 





GSE27131 influenza GPL6244 peripheral blood Day 0 v control (7 case, 7 control 
GSE36701 irritable bowel syndrome GPL570 rectal colon Part 1 only: IBS-C and IBS-D v healthy volunteers 
(87 case, 40 control) 
GSE42955 ischemic cardiomyopathy GPL6244 left ventricular tissue Ischemic cardiomyopathy v normal (12 case, 5 
control) 
GSE22255 ischemic stroke GPL570 peripheral blood mononuclear cells - 
GSE80060 juvenile idiopathic arthritis GPL570 whole blood Day 1 placebo v control (22 case, 22 control) 
GSE16020 leukopenia GPL570 blood leukocytes - 
GSE11681 limb-girdle muscular dystrophy GPL96 muscle - 
GSE19804 non-small cell lung carcinoma GPL570 lung - 
GSE44593 major depressive disorder GPL570 amygdala - 
GSE6872 teratozoospermia GPL570 semen - 
GSE51024 malignant pleural mesothelioma GPL570 lung - 
GSE5808 measles GPL96 peripheral blood Entry v control (5 case, 3 control) 
GSE21942 multiple sclerosis GPL570 peripheral blood mononuclear cells Exclude technical rep (12 case, 15 control) 
GSE48060 myocardial infarction GPL570 peripheral blood - 
GSE12452 nasopharyngeal carcinoma GPL570 nasopharynx - 
GSE9624 obesity GPL570 adipose tissue - 




GSE55235 osteoarthritis GPL96 synovium Exclude rheumatoid arthritis samples (10 case, 10 
control).  
GSE56815 osteoporosis GPL96 blood monocytes - 
GSE14245 pancreatic cancer GPL570 saliva - 
GSE7621 parkinson's disease GPL570 substantia nigra - 
GSE7586 placental malaria GPL570 placenta Exclude past malaria (10 case, 5 control) 
GSE34526 polycystic ovary syndrome GPL570 ovarian follicle - 
GSE12767 preeclampsia GPL570 placenta - 
GSE36314 prolactinoma GPL8300 pituitary gland - 
GSE55945 prostate cancer GPL570 prostate Exclude corrupted files GSM1348937 and 
GSM1348948 (12 case, 7 control) 
GSE14905 psoriasis GPL570 skin Exclude 'Uninvolved skin' (33 case, 21 control) 
GSE53408 pulmonary arterial hypertension GPL6244 lung - 
GSE36895 clear-cell renal cell carcinoma GPL570 kidney Exclude mouse tumourgraft (29 case, 23 control) 
GSE77298 rheumatoid arthritis GPL570 synovium - 
GSE65914 rosacea GPL570 skin - 
GSE19314 sarcoidosis GPL570 whole blood Sarcoidosis v control (38 case, 20 control) 
GSE13205 sepsis GPL570 skeletal muscle - 




GSE10325 systemic lupus erythematosus GPL96 perhipheral blood - 
GSE26049 essential thrombocythemia GPL570 whole blood Essential thrombocythemia v control, RMA only 
(19 case, 21 control) 
GSE3678 thyroid carcinoma GPL570 thyroid - 
GSE55098 type 1 diabetes mellitus GPL570 peripheral blood mononuclear cells - 
GSE25724 type 2 diabetes mellitus GPL96 pancreatic islets - 
GSE38713 ulcerative colitis GPL570 colon Active UC, involved mucosa v control (15 case, 13 
control) 




APPENDIX D: DISEASE NAME MAPPING USED FOR CHAPTER 5 
 








acne acne acne vulgaris acne acne 706 diseases of 
sebaceous glands 
actinic keratosis actinic keratosis actinic keratosis keratosis, actinic actinic keratosis 702 other dermatoses 




205 myeloid leukemia 




227 benign neoplasm of 
other endocrine 
glands and related 
structures 
alcoholism alcohol dependence alcohol dependence alcohol abuse or 
dependence 
alcohol dependence 303 alcohol dependence 
syndrome 









contact dermatitis 692 contact dermatitis 
and other eczema 
alopecia areata alopecia areata alopecia areata alopecia areata alopecia areata 704 diseases of hair and 
hair follicles 





aortic aneurysm aortic aneurysm aortic aneurysm aortic aneurysm aortic aneurysm 441 aortic aneurysm and 
dissection 
asthma asthma asthma asthma asthma 493 asthma 
astrocytoma astrocytoma astrocytoma astrocytoma astrocytoma 191 malignant neoplasm 
of brain 
atopic dermatitis atopic dermatitis atopic dermatitis adult atopic 
dermatitis 
atopic eczema 691 atopic dermatitis and 
related conditions 
autism autistic disorder autistic disorder autistic disorder autism 299 pervasive 
developmental 
disorders 
bacterial meningitis bacterial meningitis bacterial meningitis meningitis, bacterial bacterial meningitis 320 bacterial meningitis 
bipolar disorder bipolar disorder bipolar disorder bipolar disorder bipolar disorder 296 episodic mood 
disorders 
bladder cancer urinary bladder cancer urinary bladder cancer carcinoma of bladder bladder carcinoma 188 malignant neoplasm 
of bladder 
breast lobular carcinoma invasive lobular 
carcinoma 
breast cancer breast cancer, lobular breast carcinoma 174 malignant neoplasm 
of female breast 
cerebral palsy cerebral palsy spastic diplegia cerebral palsy cerebral palsy 343 infantile cerebral 
palsy 
cervical squamous cell 
carcinoma 
cervical squamous cell 
carcinoma 
cervical cancer cervix carcinoma cervical carcinoma 180 malignant neoplasm 
of cervix uteri 
cervical intraepithelial 
neoplasia 
cervix uteri carcinoma 
in situ 
cervix uteri carcinoma in 
situ 
high grade cervical 
intraepithelial 
neoplasia 


































colorectal cancer colon cancer colorectal cancer colorectal 
adenocarcinoma 
153 malignant neoplasm 
of colon 
crohn's disease crohn's disease crohn's colitis crohn disease crohn's disease 555 regional enteritis 




dengue fever dengue disease dengue disease dengue not found 61 dengue 















373 inflammation of 
eyelids 















emphysema pulmonary emphysema emphysema pulmonary 
emphysema 








182 malignant neoplasm 
of body of uterus 
endometriosis endometriosis endometriosis of uterus endometriosis endometriosis 617 endometriosis 
gastric adenocarcinoma gastric adenocarcinoma stomach cancer stomach carcinoma gastric 
adenocarcinoma 
151 malignant neoplasm 
of stomach 
head and neck squamous 
cell carcinoma 




cell of head and neck 
carcinoma, squamous 
cell of head and neck 
head and neck 
squamous cell 
carcinoma 
195 malignant neoplasm 
of other and ill-
defined sites 
chronic hepatitis b 
(carrier) 
hepatitis b hepatitis b hepatitis b, chronic chronic hepatitis b 
infection 
70 viral hepatitis 
chronic hepatitis c hepatitis c hepatitis c hepatitis c, chronic chronic hepatitis c 
infection 
70 viral hepatitis 









155 malignant neoplasm 









hiv infections hiv infection 42 human 
immunodeficiency 
virus [hiv] disease 





hodgkins lymphoma 201 hodgkin's disease 

















516 other alveolar and 
parietoalveolar 
pneumonopathy 
influenza influenza influenza influenza, human influenza infection 487 influenza 
irritable bowel syndrome irritable bowel 
syndrome 









cardiomyopathy cardiomyopathy ischemic 
cardiomyopathy 
cardiomyopathy 414 other forms of 
chronic ischemic 
heart disease 


























not found 359 muscular 
dystrophies and 
other myopathies 
non-small cell lung 
carcinoma 
non-small cell lung 
carcinoma 




non-small cell lung 
carcinoma 
162 malignant neoplasm 















teratozoospermia azoospermia male infertility teratospermia azoospermia 792 nonspecific 







mesothelioma, malignant pleural malignant 
mesothelioma 
mesothelioma 163 malignant neoplasm 
of pleura 
measles measles measles measles not found 55 measles 
multiple sclerosis multiple sclerosis multiple sclerosis multiple sclerosis multiple sclerosis 340 multiple sclerosis 










147 malignant neoplasm 
of nasopharynx 













150 malignant neoplasm 
of esophagus 
osteoarthritis osteoarthritis osteoarthritis osteoarthritis osteoarthritis 715 osteoarthrosis and 
allied disorders 
osteoporosis osteoporosis osteoporosis osteoporosis osteoporosis 733 other disorders of 
bone and cartilage 
pancreatic cancer pancreatic cancer pancreatic cancer pancreatic carcinoma pancreatic carcinoma 157 malignant neoplasm 
of pancreas 















256 ovarian dysfunction 
preeclampsia pre-eclampsia pre-eclampsia pre-eclampsia preeclampsia 642 hypertension 
complicating 
pregnancy, 
childbirth, and the 
puerperium 
prolactinoma prolactinoma prolactinoma prolactinoma hyperprolactinemia 253 disorders of the 
pituitary gland and 
its hypothalamic 
control 
prostate cancer prostate cancer prostate cancer prostate carcinoma prostate carcinoma 185 malignant neoplasm 
of prostate 










416 chronic pulmonary 
heart disease 
clear-cell renal cell 
carcinoma 
renal clear cell 
carcinoma 
clear-cell metastatic 
renal cell carcinoma 
non-hereditary clear 
cell renal cell 
carcinoma 
clear cell renal 
carcinoma 
189 malignant neoplasm 
of kidney and other 
and unspecified 
urinary organs 







rosacea rosacea rosacea rosacea rosacea 695 erythematous 
conditions 
sarcoidosis sarcoidosis sarcoidosis sarcoidosis sarcoidosis 135 sarcoidosis 
sepsis disease by infectious 
agent 
sepsis sepsis sepsis 995 certain adverse 
effects not elsewhere 
classified 
























238 neoplasm of 
uncertain behavior 
of other and 
unspecified sites and 
tissues 
thyroid carcinoma thyroid carcinoma thyroid cancer thyroid carcinoma thyroid carcinoma 193 malignant neoplasm 
of thyroid gland 
type 1 diabetes mellitus type 1 diabetes mellitus type 1 diabetes mellitus diabetes mellitus, 
type 1 
type i diabetes 
mellitus 
250 diabetes mellitus 
type 2 diabetes mellitus type 2 diabetes mellitus type 2 diabetes mellitus diabetes mellitus, 
type 2 
type ii diabetes 
mellitus 
250 diabetes mellitus 
ulcerative colitis ulcerative colitis ulcerative colitis colitis, ulcerative ulcerative colitis 556 ulcerative colitis 
vulvar intraepithelial 
neoplasia 
vulva cancer vulva cancer vulvar intraepithelial 
neoplasia, usual type 
vulvar intraepithelial 
neoplasia 






APPENDIX E: SIGNIFICANCE THRESHOLDS OF CONCORDANCE FOR 
DIFFERENT SUBGROUP SIZES 
95th percentile values of the distribution of average correlation over randomly selected 
subgroups of PD studies.  For a correlation in any (real) subgroup to be considered significant, 
it must be greater than or equal to the 95th percentile value of random subgroup correlation for 
its size.   Smaller subgroups are more likely to show higher correlation through chance alone, 
and therefore smaller subgroups need higher average concordance to be considered significant. 
 
Subgroup size 95th percentile 
 
Subgroup size 95th percentile 
 3  0.26 17 0.09 
4  0.20 18  0.09 
5  0.18 19  0.09 
6 0.16 20   0.08 
7  0.15 21    0.08 
8  0.13 22  0.08 
9  0.13 23  0.08 
10   0.12 26  0.08 
11  0.11 27  0.07 
12  0.11 28    0.07 
13 0.11 29   0.07 
14  0.10 30  0.07 
15  0.10 31  0.06 






APPENDIX F: CONCORDANCE OVER BASE VS SUBSET SHARED 
GENES 
Concordance calculated over the base set of genes, consisting of the 2,513 genes shared 
between all studies, vs concordance calculated over the larger sets of genes shared between 
subsets of studies.  In most cases the result is not substantially different; concordance over the 
base set was reported in the main text in order not to bias the results due to changing geneset 
sizes. 
  
Subset Subset size  Score over 
2,372 genes  
Score over 
shared genes  
Number of 
shared genes  
All PD studies 33  0.05 -   2,513  
SN  8  0.30 0.30  2,976 
Striatum  9  0.07 0.06  6,153  
Human  19 0.08  0.09  4,776  
Human, in vivo  15  0.15 0.15   5,082  




APPENDIX G: PATHWAY ENRICHMENT RESULTS FOR PARKINSON’S 
DISEASE STUDIES 
 
Reactome pathways identified by gene set enrichment analysis of 
differential gene expression in human Parkinson's disease studies 
 
Upregulated pathways (NES>0, FDR<0.25) Number of human 
studies in which 
pathway is in top 
50 pathways by 
abs(NES): 
Attenuation phase 4 
Interferon alpha/beta signaling 4 
Diseases associated with the TLR signaling cascade 3 
Diseases of Immune System 3 
Cellular response to heat stress 3 
HSF1-dependent transactivation 3 
Initial triggering of complement 3 
Eukaryotic Translation Elongation 3 
Viral mRNA Translation 3 
Peptide chain elongation 3 
Eukaryotic Translation Termination 3 
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex 
(EJC) 
3 
Formation of a pool of free 40S subunits 3 
Influenza Viral RNA Transcription and Replication 3 
SRP-dependent cotranslational protein targeting to membrane 3 
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex 
(EJC) 
3 
Nonsense-Mediated Decay (NMD) 3 
Influenza Life Cycle 3 
3' -UTR-mediated translational regulation 3 
L13a-mediated translational silencing of Ceruloplasmin expression 3 
Interferon gamma signaling 3 
GTP hydrolysis and joining of the 60S ribosomal subunit 3 
Influenza Infection 3 
Cap-dependent Translation Initiation 3 
Eukaryotic Translation Initiation 3 
Translation 3 
Regulation of Complement cascade 3 
 
Downregulated pathways (NES <0, FDR<0.25) 
The citric acid (TCA) cycle and respiratory electron transport 10 
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and 





Respiratory electron transport 9 
Vpu mediated degradation of CD4 8 
Vif-mediated degradation of APOBEC3G 7 
Antigen processing: Ubiquitination & Proteasome degradation 7 
Ubiquitin-dependent degradation of Cyclin D 7 
Ubiquitin-dependent degradation of Cyclin D1 7 
GLI3 is processed to GLI3R by the proteasome 7 
Degradation of GLI2 by the proteasome 7 
SCF-beta-TrCP mediated degradation of Emi1 7 
Dectin-1 mediated noncanonical NF-kB signaling 6 
Cross-presentation of soluble exogenous antigens (endosomes) 6 
Autodegradation of the E3 ubiquitin ligase COP1 6 
Regulation of activated PAK-2p34 by proteasome mediated degradation 6 
Regulation of Apoptosis 6 
degradation of AXIN 6 
SCF(Skp2)-mediated degradation of p27/p21 6 
CDK-mediated phosphorylation and removal of Cdc6 6 
Stabilization of p53 6 
Autodegradation of Cdh1 by Cdh1:APC/C 6 
Degradation of GLI1 by the proteasome 6 
CDT1 association with the CDC6:ORC:origin complex 6 
AUF1 (hnRNP D0) destabilizes mRNA 5 
p53-Independent DNA Damage Response 5 
p53-Independent G1/S DNA damage checkpoint 5 
Transmission across Chemical Synapses 5 
APC/C:Cdc20 mediated degradation of Securin 5 
Hedgehog ligand biogenesis 5 
Cdc20:Phospho-APC/C mediated degradation of Cyclin A 5 
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of 
the cell cycle checkpoint 
5 
Hh mutants abrogate ligand secretion 5 
Hh mutants that don't undergo autocatalytic processing are degraded by 
ERAD 
5 
Assembly of the pre-replicative complex 5 
Degradation of beta-catenin by the destruction complex 5 
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A 4 
Regulation of ornithine decarboxylase (ODC) 4 
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 
targeted proteins in late mitosis/early G1 
4 
Cyclin A:Cdk2-associated events at S phase entry 4 
Cyclin E associated events during G1/S transition  4 
Hedgehog 'off' state 4 




Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic 
proteins 
4 
Orc1 removal from chromatin 4 
degradation of DVL 4 
Asymmetric localization of PCP proteins 4 
Host Interactions of HIV factors 3 
Neuronal System 3 
Dopamine Neurotransmitter Release Cycle 3 
Serotonin Neurotransmitter Release Cycle 3 
Na+/Cl- dependent neurotransmitter transporters 3 
Norepinephrine Neurotransmitter Release Cycle 3 
HS-GAG degradation 3 
Protein folding 3 
Chaperonin-mediated protein folding 3 
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding 3 
Regulation of APC/C activators between G1/S and early anaphase 3 
APC/C-mediated degradation of cell cycle proteins 3 
Regulation of mitotic cell cycle 3 
Mitochondrial translation initiation 3 








Reactome pathways identified by gene set enrichment analysis of 
differential gene expression in Parkinson's disease studies: humans and 
animal models    
	 	 	 	
 Number of times pathway is in top 10 pathways 
by abs(NES) in: 





Upregulated pathways (NES > 0, FDR<0.25) 
Eukaryotic Translation Elongation 6 3 3 
Viral mRNA Translation 6 3 3 
Eukaryotic Translation Termination 6 2 2 
Peptide chain elongation 6 3 3 
Formation of a pool of free 40S subunits 4 1 1 
3' -UTR-mediated translational regulation 4 2 3 
GTP hydrolysis and joining of the 60S 
ribosomal subunit 
3 1 2 
L13a-mediated translational silencing of 
Ceruloplasmin expression 
3 1 2 
Nonsense Mediated Decay (NMD) independent 
of the Exon Junction Complex (EJC) 
3 2 1 
 
Downregulated pathways (NES <0, FDR<0.25) 
The citric acid (TCA) cycle and respiratory 
electron transport 
7 6 3 
Respiratory electron transport 6 5 3 
Respiratory electron transport, ATP synthesis 
by chemiosmotic coupling, and heat production 
by uncoupling proteins 
6 5 3 
Antigen processing: Ubiquitination & 
Proteasome degradation 
3 2 0 
Phosphorylation of CD3 and TCR zeta chains 3 2 1 
Vif-mediated degradation of APOBEC3G 3 3 1 
Degradation of GLI2 by the proteasome 3 3 2 
Hh mutants abrogate ligand secretion 3 3 2 
Amyloids 3 1 0 





APPENDIX H: UNION OF TOP 10 GENES ACROSS ALL 33 
PARKINSON’S DISEASE STUDIES 
Reading across each successive row of the table, this list corresponds to the rows of the heatmap 
in Figure 3.7. 
 
AMH MAP3K6 SH2D2A SLC7A8 WNK1 SLC6A3 CFLAR FLNB 
GLI2 ZFP36 CRK CXCL2 CYP1B1 CH25H ADM NFKBIA 
SGK1 ST3GAL6 ALB CDKN1A NFE2L2 TFCP2 MAFF TTR 
TYMS CD74 OXT CAPN3 FOXO3 SPP1 CX3CR1 HLA-DRB1 
UGT8 AZGP1 CXCR4 ANGPT2 RCN1 AQP4 RAB3IL1 EEF1D 
ITGAM SERPINB1 MTF2 TIA1 PIM1 TINF2 GADD45B IER3 
ATF3 TULP4 SAT1 ANXA3 PRSS23 INHBA SSTR2 FOS 
EGR1 TH NR4A2 TBL1X UIMC1 RND2 SLC6A8 BOK 
CD22 ABCA1 MAP4K4 MLLT10 VIM LPL CD14 C1QB 
PTPRC SPARC RPS11 COTL1 BAG3 HSPB1 AXL CASP4 
CD4 VCAN FMOD PCBD1 SLC6A13 SMAD5 NFIX SLC9A3R2 
COPE CRLF1 IGFBP2 JUP DUSP1 JUNB IDH1 GPX2 
AGT MID1 CLTA GFAP CD44 CHI3L1 CASP1 VAMP8 
CEBPG ANXA4 LGALS1 CAV1 CSRP1 KLKB1 RAB31 CP 
CTSC UBL5 GPX3 PFKFB2 PPARGC1A NOS1 VEGFC GRIK1 
ADCYAP1 DDX6 XIAP ZFX TSPAN12 ARHGAP5 MAN2A1 CDH1 
MAP7 SLC4A7 SDC1 SMARCA4 ACOT7 ACTN1 DPYSL4 PTK2B 
MMP9 LAMB3 BCL2L1 ATP1B2 HTR4 SEC14L1 ITM2C EPHX1 
PLEC TMEM176A PHGDH GUSB SLC4A1 GABBR1 ACTC1 FAM65B 
LPP BAX CYTH3 DRD2 SEPT9 SMPD1 HS3ST1 CA4 
DUSP6 MARK2 GFRA2 KIF5C GNAS ZNF148 TCF4 SPOCK1 
ZFPM2 AP1S2 ENC1 YWHAZ LAPTM4B MAPK10 GABRG2 YWHAH 
SNCB VAMP2 CIRBP TPBG DDC DLK1 PAX6 FABP7 
PPAT RIOK3 GOSR1 CDKN1B RAD23B TPD52 EIF1AX TFPI 
HSD17B11 SLC16A1 NAMPT ME1 CFH OLR1 PDK4 DNAJB6 
RAD21 SDHD PKIA SMAD1 NAP1L4 RGS2 PDPK1 RAB1A 
RC3H2 SLC6A1 KCNB1 PSMB4 EIF2AK1 HAGH FECH BPGM 
RPL15 PDE1A MAP1B TTC3 FUT9 INPP4A NOV ITGB1BP1 
FEZ2 FGF9 CADPS AIF1 GMFB PIP4K2A ST13 SLC11A2 
TRIP12 RABEP1 RGS4 STMN2 GAP43 SNAP25 SYT1 PRKACB 
RCN2 PRKCB YWHAB SNX10 NSF CHGB TPPP3 MAP2 
SCG5 TAGLN3 NEFL THY1 CCK SNCA SERPINI1 CMAS 






APPENDIX I: UNION OF TOP 10 GENES ACROSS ALL 33 STUDIES 
PLUS ALZHEIMER'S DISEASE AND TUMOUR STUDIES 
Reading across each successive row of the table, this list corresponds to the rows of the heatmap 
in Figure 3.9. 
	
VIM TGFBI IGFBP3 ABCA1 ANGPT2 CTSC CD74 GPX3 
CCL4 CASP1 VAMP8 LGALS1 CAV1 C1QB CD14 CP 
NNMT ANXA1 CD44 CTSS OLR1 AZGP1 PTPRC CFH 
AQP4 SERPINB1 PRSS23 TMEM176A VCAN CASP4 AXL RAB31 
SPP1 PDGFRA CCND1 IL1RAP ME1 DUSP6 EGR1 FOS 
HCLS1 AIF1 CX3CR1 HLA-DRB1 ITGAM EEF1D CXCR4 INHBA 
ANXA4 BAG3 GEM CYR61 DUSP1 JUNB ZFP36 SGK1 
NFKBIA RC3H2 ST3GAL6 SMAD1 FHL2 ADM MMP9 HSPB1 
TBL1X SEC14L1 RND2 SPARC COTL1 ACTN1 HS3ST1 FMOD 
GFAP AGT ATF3 PIM1 TINF2 IER3 GADD45B TFPI 
CEBPG BCAT1 IL13RA2 SLC16A1 HSD17B11 PDK3 RABEP1 NAMPT 
CRK GOSR1 SLC4A7 CFLAR FLNB GLI2 UBL5 ARNTL 
TFRC ALB GPX2 RPS16 LTB GLTSCR2 KLF2 LCK 
CXCL2 DPYSL4 LAMB3 BCL2L1 CLTA KLKB1 AQP1 TYMS 
LPP IDH1 ITGB4 SMAD5 NFIX MYLK GUSB GRIK1 
ACTC1 COPE CYTH3 FOXO3 MLLT10 VEGFC RAB3IL1 CA2 
SLC9A3R2 PHGDH SLC4A1 JUP SLC6A13 FEZ2 TRIP12 LAPTM4B 
MAP2 MAP1B CADPS ZNF148 TCF4 ZFPM2 JAK1 AP1S2 
ENC1 YWHAH TTC3 RCN2 YWHAB YWHAZ SMARCA4 SDC1 
Sep-09 CIRBP DDX6 RPL18 RPS11 UIMC1 PTEN RAD21 
PKIA PDPK1 RAB1A PPAT RIOK3 EIF2AK1 BPGM FECH 
RAD23B COPS8 PITPNA PSMB4 PSMB7 PFKFB2 CDH1 NOS1 
BCAN PCBD1 BAX RXRA CD4 EPHX1 ATP1B2 IKZF2 
SERPINB9 RARA SLC6A8 MARK2 HTR4 GFRA2 CSRP1 CRLF1 
PLEC SMPD1 PDK4 DNAJB6 ACSL1 SPOCK1 NOV GJA1 
RGS2 GAD1 SNX10 THY1 PPP1R2 TPBG DLK1 DDC 
COL1A2 CA12 LPL RCN1 MMP15 PRC1 IGFBP2 ELAVL1 
MID1 FABP7 MTF2 GAP43 CYP1B1 CH25H CDKN1A FKBP5 
IL1R2 NFE2L2 TFCP2 MAFF CHI3L1 MAP3K6 AMH WNK1 
SH2D2A SLC7A8 SLC6A3 TTR STMN2 NEFL SYT1 KIF5C 
PVALB SNAP25 PRKCB CHGB FGF9 GABRA1 SLC12A5 TIA1 
PAX6 GNAS HIVEP3 NNAT SSTR2 TULP4 ANXA3 MAP4K4 
SH3GL3 OXT CAPN3 UGT8 GMFB CTTN MAN2A1 SLC11A2 
PRKACB TPD52 BOK CD22 MAP7 CDKN1B ARHGAP5 PIP4K2A 
TSPAN12 ZFX IVNS1ABP NAP1L4 SDHD XIAP ST13 KCNB1 
SLC6A1 FUT9 ITGB1BP1 PRNP EIF1AX SUMO1 EPS15 MAPK10 
GHITM CMAS TH NR4A2 CCK RGS4 PDE1A SNCA 
GABRG2 SERPINI1 TPPP3 SCG5 TAGLN3 PTK2B SYT5 DRD2 
FAM65B PPARGC1A HAGH GABBR1 INPP4A CA4 ADCYAP1 ACOT7 






APPENDIX J COMPARISON OF RESULTS USING HIPPIE AND 
OMNIPATH  
 
HIPPIE, which is based on protein-protein interactions rather than the signalling interactions 
contained in OmniPath, is a slightly larger network, recording interactions for a median of 51% 
of measured genes compared to OmniPath’s 30%.  This means that the available network size 
(the size of the ‘base’ network) is also larger, at a median of 2,413 nodes compared to 1,408 
nodes for OmniPath.  Surprisingly, this does not result in much larger path-sets: HIPPIE path-
sets contain a median of 90 nodes, compared to 82 for OmniPath.  
This may be linked to the degree of nodes in path-sets: the degree distribution of the two graphs 
is similar overall, but interestingly, nodes in OmniPath path-sets have a higher average degree, 
at a median of 15.5 compared to the median degree of 10 for nodes in HIPPIE path-sets.  
Overall, the distribution of path-set network component size is similar in both networks: the 
median of both is 3 (path-sets contain many small components and only a few larger ones), 
with a maximum component size of 306 for OmniPath and 355 for HIPPIE path-sets. However, 
the mean component size is 11.6 for OmniPath and 7.0 for HIPPIE, suggesting that the major 
connected components in HIPPIE paths tend to be slightly smaller.  These results are 
summarised in Table J.1.  
 
Table J.1 Comparison of network and path-set topology in OmniPath and HIPPIE  
 OmniPath HIPPIE 
Number of unique proteins 6,972 12,162 
Number of usable interactions  43,963 62,615 
Percentage of measured genes included in the 
network 
30% 51% 
Median available network size 1,408 2,413 
Median path-set size 82 90 
Median degree of nodes in path-sets 15.5 10 
Mean network component size of path-sets 11.6 7.0 
R2 of relationship between number of path-sets and 
degree of a gene 
0.47 0.45 
R2 of relationship between number of random-sets 






In general, the genes included in the path-sets are quite different between the two base 
networks.  Figure J.1 shows an example of this, comparing the dysregulated path-set for asthma 
in OmniPath (as shown in Figure 4.3 of the main text) to that in HIPPIE.  The difference 
between the two seems to be due to the low overlap between the signalling interactions included 
in OmniPath and the protein-protein interactions included in HIPPIE – of the 43,963 
interactions in OmniPath and the 62,615 interactions in HIPPIE, only 8,966 are common to 
both (a Jaccard overlap of 0.09).  The median Jaccard overlap of edges in both networks is 
correspondingly low at 0.05.  Nevertheless, the overall properties (in terms of ability to capture 
KDGs and shared edges between diseases) are similar, as shown in Tables J.2, J.3, and J.4. 
	
Table J.2 Known disease-associated genes and drug-interacting genes (KDGs) in 
path-sets in OmniPath and HIPPIE 
Results	in	HIPPIE	are	overall	similar	to	those	in	OmniPath,	albeit	slightly	lower.		One	notable	
difference	is	that	the	random-path-sets	perform	comparably	worse	in	HIPPIE.		The	relatively	
good	 performance	 of	 the	 random-path-sets	 in	 OmniPath	 was	 explored	 in	 Section	 4.3.2	 in	
relation	 to	 the	 tendency	 of	 path-set	 analysis	 to	 select	 genes	 of	 higher	 degree.	 	 Like	 in	
OmniPath,	 nodes	 in	 the	HIPPIE	 random	path-sets	 tend	 to	 have	 slightly	 higher	 degree	 than	
nodes	in	the	real	path-sets	(median	degree	of	11.75	in	the	random	path-sets	compared	to	10	
in	 the	 real	path-sets).	 	However,	unlike	OmniPath,	drug	 targets	 in	HIPPIE	do	not	have	very	
significantly	 higher	 median	 degree	 than	 non-drug-targets	 (median	 degree	 of	 4	 for	 both,	
Wilcoxon	 p-value	 0.012).	 	 This	 could	 explain	 the	 comparatively	 worse	 performance	 of	 the	
random-path-sets	in	HIPPIE.	




What proportion of 
sets contained at 
least one KDG? 
OmniPath: 0.58 0.56 0.54 0.43 
HIPPIE: 0.55 0.52 0.46 0.38 
How many KDGs 
were found per set 
on average? 
OmniPath: 2.95 1.89 2.40 1.18 
HIPPIE: 2.06 1.70 1.50 0.85 
What percentage of 
genes in the set 
were KDGs? 
OmniPath: 3.2% 2.4% 2.5% 1.3% 





















HIPPIE path-sets also yield similar numbers of disease pairs which share a significant number 
of edges, with 647 significant disease pairs of a median shared-edge-set size of 20 nodes, 
compared to 676 disease pairs in OmniPath which have a median shared-edge-set size of 21 
nodes.  Of these, 261 pairs are common to both.  The pairs are overall similar in terms of their 
biological relevance (Table J.3) and the disease-associated genes and drug-targets contained in 
their shared edges (Table J.4). 
	
	
Table J.3 Biological relevance of shared edges 
Significant	disease	pairs	in	OmniPath	and	HIPPIE	are	similar	in	terms	of	their	likelihood	to	be	in	
the	 same	 Disease	 Ontology	 category	 or	 to	 share	 drugs,	 but	 disease	 pairs	 in	 HIPPIE	 are	
comparatively	less	likely	to	share	disease-associated	genes.	








In the same Disease 
Ontology top-level class 
OmniPath: 44.7% 26.3% <2.20e-16 
HIPPIE: 45.0% 26.3% <2.20e-16 
In the same Disease 
Ontology sub-class 
OmniPath: 18.1% 7.2% <2.20e-16 
HIPPIE: 17.8% 7.3% <2.20e-16 
Share drugs (in Phase III 
clinical trials or 
approved) 
OmniPath: 17.2% 8.0% 1.33e-13 
HIPPIE: 14.5% 8.2% 2.03e-7 
Share disease-associated 
genes 
OmniPath: 19.2% 10.8% 5.27e-10 







Table J.4 Disease-associated and drug-interacting genes in shared edges 
A	slightly	smaller	percentage	of	disease	pairs	significant	in	HIPPIE	include	a	disease-associated	
or	 drug-interacting	 gene	 than	 pairs	 significant	 in	 OmniPath;	 however,	 the	 drug-interacting	
genes	tend	to	be	slightly	more	likely	to	be	relevant	to	both	diseases.	
	
	  All significant 
disease pairs 
Top 100 most 
significant 
disease pairs 
Percentage of significant disease pairs 
which include a disease-associated 
gene for either disease in their shared-
edge-set 
OmniPath: 41.7% 62.2% 
HIPPIE: 35.2% 45% 
Percentage of these genes associated 
with both diseases (excluding same-
disease pairs) 
OmniPath: 6.4% 7.4% 
HIPPIE: 6.5% 6.4% 
Percentage of significant disease pairs 
which include a drug-interacting gene 
for either disease in their shared-edge-
set 
OmniPath: 51.9% 74.5% 
HIPPIE: 47.8% 60% 
Percentage of these genes associated 
with both diseases (excluding same-
disease pairs) 
OmniPath: 9.8% 15.9% 






APPENDIX K: PATHWAY ENRICHMENT RESULTS FOR GENES IN 
MULTIPLE PATH-SETS 
 
List of 54 genes in the dysregulated path-sets of 25 or more diseases 
 
Gene # Path-sets Gene # Path-sets Gene # Path-sets 
EGFR 66 AKT1 30 EGR1	 27	
MAPK1 56 EP300 30 ITGB4	 27	
STAT1 55 JUN 30 LYN	 27	
STAT3 49 PIK3R2 30 MYC	 27	
SRC 48 PXN 30 PLAUR	 27	
CD44 46 RAC1 30 SYK	 27	
CTNNB1 37 RELA 30 CDKN1A	 26	
PRKCA 37 CCND1 29 CRK	 26	
AR 36 CREBBP 29 FAS	 26	
ESR1 36 FOS 29 IGF1R	 26	
MAPK14 36 PRKCD 29 SMAD4	 26	
PTPN11 36 BCL2 28 CALM1	 25	
SMAD3 36 CASP8 28 CBL	 25	
FYN 35 FGFR1 28 CTNND1	 25	
TP53 33 IRS1 28 JUP	 25	
RAF1 32 PLCG1 28 MDM2	 25	
MAPK8 31 SMAD2 28 PAK1	 25	










(all genes in 
network) 
Genes in multiple path-sets 
GO-Slim Biological Process # # Expected Fold 
Enrichment 
FDR 
negative regulation of apoptotic process 55 6 1.34 4.49 4.44E-02 
regulation of biological process 458 29 11.12 2.61 2.25E-05 
biological regulation 556 31 13.5 2.3 7.83E-05 
regulation of transcription from RNA 
polymerase II promoter 
123 11 2.99 3.68 4.94E-03 
metabolic process 964 37 23.41 1.58 1.22E-02 
transcription from RNA polymerase II 
promoter 
151 11 3.67 3 1.97E-02 
transcription, DNA-dependent 171 11 4.15 2.65 4.42E-02 
intracellular signal transduction 317 21 7.7 2.73 5.56E-04 
signal transduction 535 32 12.99 2.46 2.22E-05 
cell communication 590 32 14.33 2.23 9.43E-05 
cellular process 1348 48 32.74 1.47 1.48E-03 
cell surface receptor signaling pathway 242 16 5.88 2.72 4.93E-03 
phosphate-containing compound metabolic 
process 
336 18 8.16 2.21 1.84E-02 
response to stimulus 539 27 13.09 2.06 3.08E-03 






APPENDIX L SHARED EDGES RESULTS AT A THRESHOLD OF TOP 100 
PATHS 
 
Using path-sets based on the stricter threshold of the 100 top paths (median path-set size of 72) 
to identify shared edges between disease pairs, instead of the more lenient 500 top paths 
threshold (median path-set size of 195), results in fewer significant disease pairs (287 vs 676) 
and a smaller median shared-edge-set size (9 as opposed to 21 nodes), as may be anticipated.  
This makes little difference to the percentage of disease pairs which are biologically relevant 
in terms of ontological class or disease/drug sharing (Table L.1), but the percentage of shared 
edges which include a disease-associated or drug-interacting gene at a threshold of 100 top 
paths are lower than those in the main text (Table L.2), as the smaller edge-sets mean less 
chance to capture a relevant gene.  Interestingly, those genes that are found are also less likely 
to be associated with both diseases, suggesting that the smaller path-sets are less useful for 
capturing potential drug repurposing hypotheses. 
	
Table L.1 Biological relevance of shared edges 









In the same Disease 
Ontology top-level class 
500 threshold: 44.7% 26.3% <2.20e-16 
100 threshold: 49.1% 26.9% 3.55e-15 
In the same Disease 
Ontology sub-class 
500 threshold: 18.1% 7.2% <2.20e-16 
100 threshold: 18.1% 7.7% 1.33e-8 
Share drugs (in Phase III 
clinical trials or approved) 
500 threshold: 17.2% 8.0% 1.33e-13 
100 threshold: 20.2% 8.2% 5.20e-10 
Share disease-associated 
genes 
500 threshold: 19.2% 10.8% 5.27e-10 





Table L.2 Disease-associated and drug-interacting genes in shared edges 
	
	  All significant 
disease pairs 
Top 100 most 
significant 
disease pairs 
Percentage of significant disease pairs 
which include a disease-associated 
gene for either disease in their shared-
edge-set 
500 threshold: 41.7% 62.2% 
100 threshold: 27.5% 30.8% 
Percentage of these genes associated 
with both diseases (excluding same-
disease pairs) 
500 threshold: 6.4% 7.4% 
100 threshold: 0.9% 1.8% 
Percentage of significant disease pairs 
which include a drug-interacting gene 
for either disease in their shared-edge-
set 
500 threshold: 51.9% 74.5% 
100 threshold: 28.2% 47.7% 
Percentage of these genes associated 
with both diseases (excluding same-
disease pairs) 
500 threshold: 9.8% 15.9% 







APPENDIX M: RESULTS AT DIFFERENT FEATURE SET SIZES 
	
To test the dependence of the results on the chosen feature set size, different feature set sizes 
of 20, 50, and 200 were tested were tested for ontological, literature co-occurrence, genetic, 
and transcriptomic feature spaces (phenotypic and drug feature spaces being of fixed size).   
As expected, the proportion of links that were significantly greater than those observed in 
random maps (and therefore the number of links in each disease map) varied depending on the 
feature set size, with larger feature set sizes resulting in greater differentiation from random 
maps (Table M.1).  Related to this, the mean Jaccard overlap of drugs shared by diseases linked 
in the map increases at smaller feature set sizes, where only the highest similarity links pass 
the random significance threshold and are included in the map (Table M.1). 
Evaluating the full similarity matrices (in terms of the proportion of links which share drugs, 
and the ability to predict DO categories) produced similar results at different feature set sizes, 
with some minor variations in the performance of individual feature spaces (Figures M.1 and 
M.2).  Finally, at all feature set sizes, literature co-occurrence, phenotype, and ontological 
spaces were the most highly correlated to the fused space.   
 
Table M.1 Comparison of disease maps at different feature set sizes 
 Feature set size 
20 50 100 200 
Percentage of links in full 
similarity matrix which are 
significant (included in map) 
2.98 4.76 6.91 9.12 
Percentage of links in disease map 
classed as novel 
16.2 15.6 15.3 16.3 
Mean Jaccard overlap of drugs 
shared by diseases linked in the 
disease map, approved and Phase 
III/approved only 
0.099/0.107 0.082/0.081 0.069/0.069 0.061/0.059 
Mean Jaccard overlap of drugs 
shared by novel links in the 
disease map, approved and Phase 
III/approved only 





   
 
Figure M.1 Comparing the drug overlap (approved or in Phase III clinical trials) of links in disease networks at different thresholds of 
similarity, and different feature vector sizes. 
Similar	overall	results	are	obtained	for	feature	vector	sizes	of	20	(top	left),	50	(top	right),	100	(bottom	left),	and	200	(bottom	right),	with	some	
minor	 variation	 in	 the	 performance	 of	 individual	 spaces.	 	 In	 particular,	 at	 a	 feature	 vector	 size	 of	 20,	 literature	 space	 and	 ontological	 space	









Figure M.2 Random Forest AUROC scores for individual and fused disease similarities 












APPENDIX N RESULTS OF WEIGHTED MAP 
 







Table N.1 Comparison of balanced and weighted fused similarities 
 Balanced Weighted 
Percentage of links in full similarity matrix classed 
as significant (and therefore included in the 
resulting disease map) 
6.91 (242 links) 6.02 (211 links) 
Percentage of links in disease map classed as 
novel 
15.3 (37 links) 17.1 (36 links) 
Mean Jaccard overlap of drugs shared by diseases 






Mean Jaccard overlap of drugs shared by novel 






AUC of DO class prediction, disease of 
anatomical entity/disease of cellular proliferation 
0.924/0.985 0.891/0.979 
 
This table shows the results of adjusting the weights on the similarities so that the three 
‘traditional’ spaces which show high similarity to each other (ontological, phenotype, and 
literature-based spaces) account for only a third (instead of half) of the fused similarities, i.e. 
the contribution of the other three spaces (genetic, expression, and transcriptomic) is doubled 
(weighting scheme 1, 1, 1, 2, 2, 2).  Down-weighting these highly similar ‘traditional’ spaces 
means that they have less influence on the resulting disease map, however, the results shown 
here indicate that this down-weighting makes little difference to properties of the resulting 
disease map.  For the DO class prediction, ontological space is excluded from the fused matrix, 
meaning that phenotypic and literature spaces together account for 25% of the fused similarities 
(weighting scheme 1, 1, 2, 2, 2).  After this weighting, note that the fused space is no longer 
the best-performing space for the prediction of disease of anatomical entity (being slightly 
outperformed by phenotypic and literature co-occurrence similarities at 0.902 and 0.905 
respectively).  Note that the AUC quoted here for the balanced kernel varies slightly from that 







Figure N.2 Comparing the drug overlap of linked diseases in weighted and balanced 
spaces 
The	overlap	of	drugs	for	each	link	(mean	Jaccard	score)	is	very	similar	for	balanced	and	
weighted	spaces.		In	this	case,	drug	space	is	excluded	from	the	evaluation,	meaning	that	the	
contribution	of	the	two	remaining	non-traditional	spaces	is	tripled	so	that	the	traditional	
spaces	contribute	a	third	of	the	similarity	(weighting	scheme	1,	1,	1,	3,	3).		Note	however	that	
in	contrast	to	the	balanced	space,	the	weighted	fused	(minus	drug)	space	is	outperformed	by	
literature	space	at	the	top	5%	of	similarities. 
